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ABSTRACT OF THE DISSERTATION
The Role of Myc and AP-1 Transcription Factors in the Development and Function of the
Dendritic Cell Lineage
by
Wumesh K.C.
Doctor of Philosophy in Biology and Biomedical Sciences
(Immunology)
Washington University in St. Louis, 2015
Professor Kenneth M. Murphy, Chair
Dendritic cells (DCs) orchestrate immune responses to foreign and self proteins by
capturing, processing and presenting antigens to naïve CD4+ and CD8+ T cells in specialized
regions of lymphoid organs. Consequently, DCs function in many disparate infectious settings,
during which their activation can result in both pathogenic and protective responses. The diverse
properties of DCs manifest through the actions of a limited set of lineage-specifying DNAbinding proteins called transcription factors (TFs). The precise molecular program controlled by
these developmentally important TFs (such as Irf8 and Batf3) is largely unknown because most
studies to date have been largely descriptive. We have identified bona fide targets of BATF3
and IRF8 by comparative microarray analysis and chromatin immunoprecipitation followed by
sequencing (ChIP-Seq). These targets provided insights into the specialized processes carried
out by DCs and may also represent future pathways for manipulation during the development of
vaccines.
We characterized the stage-specific actions of BATF3 in the development of CD8a+ DCs,
a critical initiator of cellular immunity to intracellular pathogens and tumors. Batf3 induction
occurs after the expression of Irf8 in the precursor to classical DCs (pre-cDC), in which BATF3
acts subsequent to an Irf8-dependent lineage commitment step to induce the terminal maturation
xiv

and survival of CD8a+ DCs. Genomic regions bound by IRF8 and BATF3 were identified by
ChIP-Seq, and notably, the proximal promoters of CD8a+ DC-specific genes showed IRF8 and
BATF3 co-occupancy. Furthermore, we evaluated IRF8 binding in BATF3-deficient cells to
identify BATF3-independent targets. One such candidate was the Myc homolog Mycl1 (L-Myc).
Analysis by quantitative real-time PCR (qPCR) of the hematopoietic compartment revealed that
Mycl1 expression is restricted to pDCs and cDCs.
To evaluate the significance of L-Myc activity in dendritic cells, we generated a new
knock-in mouse model of the Mycl1 locus by replacing the first coding exon with an in-frame
GFP cassette. Analysis of heterozygous mice (Mycl1+/gfp) revealed that Mycl1 expression is
restricted to dendritic cells. Interestingly, induction of Mycl1 occurs at the CDP to pre-cDC
transition concurrent with the loss of Myc (c-Myc) from DCs. Although dispensable for the
development of DCs, L-Myc supports the growth and survival of dendritic cells. Moreover,
following activation of DCs with pathogen associated molecular patterns (PAMPs) or activating
cytokines, L-Myc protein levels either remained constant or increased, suggesting that growthpromoting circumstances are intricately linked to levels of L-Myc. Lastly, L-Myc deficient DCs
primed antigen-specific responses poorly and were incapable of supporting the intracellular
growth of Listeria monocytogenes.
Collectively, these findings suggest that the switch from Myc to L-Myc expression
represents a strategy of growth in the face of disparate inflammatory signals experienced during
infections. L-Myc may therefore represent a therapeutic target for selective inhibition or
augmentation of immune responses driven by dendritic cell

xv

Chapter 1 Introduction to dendritic cells
Contents of this chapter have been previously published in Seminars in Immunology.
Satpathy AT, Murphy KM, KC W. Transcription factor networks in dendritic cell development.
Semin Imm. 2011 Oct; 23(5):388-97. Epub 2011 Sep 15

1.1

Abstract
The immune system comprises a broadly distributed collection of functionally specialized

cells that must constantly recognize and remove infectious threats. Considerable progress has
been made in our understanding of immunological recognition by intensively studying
lymphocytes and their clonally distributed antigen-specific receptors. By comparison, the
"accessory" cell type(s) responsible for initiating and directing immune responses has received
less attention in several important ways despite being identified by Ralph Steinman and
colleagues as a unique cell type with "stellate" or dendritic morphology nearly 40 years ago. The
relative paucity and similarity to other myeloid lineages – such as macrophage and monocytes –
has been a major barrier to characterizing DCs at the molecular level. Though the recent
identification of lineage-restricted progenitors and cytokines and transcription factors necessary
for DC homeostasis represent major breakthroughs in the field, further insight into the molecular
mechanisms underlying DC diversity and function is needed.
In this dissertation, we have characterized and compared the stage-specific actions of the
transcription factors Irf8 and Batf3, which act in concert to regulate the terminal differentiation
and survival of CD8a+ DCs. Moreover, gene expression profiles combined with ChIP-Seq
analysis of IRF8 and BATF3 occupancy led to the identification of unstudied candidate gene
targets. We then investigated the role of one such target called Mycl1, a putative oncogene that
belongs to the Myc family of basic helix-loop-helix transcription factors. By targeting exon 1 of
the endogenous Mycl1 locus, we generated a new knock-out mouse model that also serves as a
reporter for Mycl1 promoter activity. Analysis of lymphoid and peripheral tissues revealed that
Mycl1 is exclusively expressed by immature and mature cells of the DC lineage. Interestingly,
1

neither c-Myc nor N-Myc was expressed in DC progenitors or any of the mature DC populations
surveyed. Subsequent characterization of L-Myc-deficient DCs revealed deficits in local
proliferation and survival, which magnified in response to DC activation by pathogen associated
molecular patterns (PAMPs) or live pathogens. The net consequence of L-Myc deficiency was
poorer priming of antigen-specific CD4+ and CD8+ T cells in response to challenges with
Listeria monocytogenes and vesicular stomatitis virus. Lastly, L-Myc-deficient CD8a+ DCs
captured bacteria normally but failed to support the initial burst of L. monocytogenes, thereby
making L-Myc-deficient mice highly resistant to lethal challenge. This last observation revealed
an unappreciated cell-intrinsic role for CD8a+ DCs in the dissemination of bacteria during the
initial phase of infection. In summary, our studies have clarified a critical circuit of three
transcriptional regulators that function to maintain DCs and therefore support functional
responses to intracellular pathogens.

1.2

Isolation and functional characterization of dendritic cells
DCs were discovered nearly 40 years ago by Steinman and Cohn, who identified a "large

stellate cell" population among adherent splenocytes on particular glass and plastic surfaces 1.
Beginning with a strictly descriptive analysis, these cells were defined as a distinct lineage,
separate from B and T cells as well as granulocytes and macrophages, on the basis of several
criteria. Initially, their "dendritic" morphology and clear phagocytic capacity set them apart from
lymphocytes. However, it was their profound capacity for stimulating T cells in a allogeneic and
syngeneic mixed lymphocyte reaction (MLR) that prompted the notion that these cells could play
a unique role in directing adaptive immunity 2. Subsequently, the demonstration that DCs could
support the in vitro generation of anti-trinitrophenol (TNP) cytotoxic T lymphocytes (CTL)
2

suggested that DCs represented the critical accessory cell for the in vivo development of immune
responses 3,4. Additional hallmarks emerged from flow cytometric analyses that identified a
distinct set of cell-surface markers separating DCs from macrophages and other myeloid lineages
5,6

. Subsequent studies have demonstrated that, in addition to stimulating the immune response,

DCs also possess a capacity to impose a tolerogenic state on T cells under appropriate conditions
7,8

.
The first two decades of work on DCs largely considered this cell a homogenous

population. In 1992, the first clear-cut example of subset differentiation within DCs was put
forth, based upon the expression of the murine CD8-alpha marker. Clearly distinct from
developing or re-circulating thymic T cells, this subset represented a relatively small population
within the thymus, and was thought to derive from an intrathymic lymphoid-restricted precursor
rather than from bone marrow precursors 6,9. As a byproduct of differences in identification and
separation methods, the demarcation of various subsets has since been somewhat inconsistent 10.
Currently, the field considers four major subsets of lymphoid-resident DCs. In addition to the
CD8-alpha positive DC, two other populations of conventional DCs (cDC) are defined by the
presence or absence of the cell-surface molecule CD4 11. These two populations show a high
degree of similarity with respect to function, development, and gene expression, and for
simplicity will be grouped together and further referred to as CD4+ cDCs in this review 12. A
fourth population of plasmacytoid DCs (pDC) is defined by the expression of several
distinguishing markers including B220, Siglec-H, and Bst2 13-15. Human counterparts for each of
these DC subtypes have been identified, underscoring the conservation of DC lineage
diversification across species, presumably owing to their important functional specialization 16-18.
As discussed briefly below, monocyte-derived cells sharing many features with DCs arise under
3

inflammatory rather than steady-state conditions, although little is currently known regarding the
transcriptional and molecular basis of their differentiation 19,20.

Figure 1.1: Temporal expression of genes in DCs and progenitors
The expression of key surface markers used for the identification of mature dendritic cells
(DCs) and their bone marrow precursors is depicted. In addition, the expression of important
growth factors required for the development of DC subsets is shown.

All subsets express high levels of the complement receptor CD11c, and also display a
variety of surface receptors endowing them with the properties of growth factor responsiveness,
efficient phagocytosis, and antigen presentation. Figure 1.1 outlines the expression of some of
these key surface proteins as DC subsets differentiate from hematopoietic precursors (discussed
further below). While they are convenient markers in the murine system, there is no known
function of the CD4 and CD8-alpha molecules in the execution of specific functional processes.
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In addition, these two markers are among the few that do not show conservation with subsets of
DCs in the human system.
Beyond differences in cell-surface receptors as the basis for defining distinct subsets,
non-overlapping functions for these populations are beginning to emerge. For example, pDCs
appear to be a major source of type I interferon during viral infections. Recent models in which
pDCs are selectively eliminated highlight their contributions in some, but not all, settings of
infections by pathogens 21-23. The cDC subsets appear to be primarily concerned with priming
adaptive immune responses, particularly those of T cells, although important interactions with
other immune cells, such as B cells and NK cells, have also been described 24-26.

1.2.1

The role of CD8a+ and CD103+ dendritic cells in immune responses
The immune system has evolved distinct effector modules to combat pathogens that may

reside in the intracellular or extracellular microenvironment. Consequently, the DC lineage, like
other hematopoietic lineages, comprises multiple subsets, each apparently dedicated to the
elimination of particular pathogens. The initial proposal for DC heterogeneity was in fact based
on the differential expression of CD8a on thymic and splenic DCs 6. Early observations that selftolerance to peripheral tissue antigens could be mediated by the CD8a+ DC led to the idea that
this DC subset surveyed the peripheral tissues for cellular antigens to present to naïve CD4+ and
CD8+ T cells. Furthermore, a study by den Haan and colleagues indicated that one potentially
unique function of the CD8a+ DC is its capacity to cross-present exogenous antigens on MHC
class I 27. As a result, it was hypothesized that these cells are uniquely capable of cross-priming
CD8+ T cells, a process first described in 1976 and now implicated as a critical response in viral
and anti-tumor immunity 28-30. A developmentally related DC subset (called the CD103+ DC)
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exists in all peripheral tissues and is also a critical player in initiating T cell responses to mucosal
pathogens31,32. By virtue of this unique function, these cells could provide an efficient
mechanism to induce CD8+ T cells against pathogens that fail to infect DCs directly, and
therefore evade classical mechanisms of inducing CTL (cytotoxic T lymphocyte) responses. In
support of this role, CD8+ DCs are now recognized to reside in the T cell zones of the spleen,
and are thought to traffic from areas of pathogen trapping into areas of T cell presentation 33,34.
Other studies have also proposed that these cells may provide functions independent of crosspresentation, such as the production of essential cytokines in response to various pathogens 35,36.
A definite example of an indispensable innate effector function of the CD8a+ DC was elucidated
with Batf3 deficient mice, which lack the CD8a+ DCs and thus cannot generate adequate
amounts of IL-12 necessary for defense against Toxoplasma gondii37.

1.2.2

The role of CD11b+ dendritic cells in immune responses
CD4+ cDCs for the most part have been considered poor cross-presenters in comparison

to their CD8+ counterparts. These cells are largely considered to activate CD4+ T cells, rather
than having any specialized role in the induction of CTLs 38. However, the classical paradigm of
functionally segregating cDC subsets based on the efficiency and quality of MHC class I and II
presentation is not without controversy. For example, a recent study suggests that the distinction
between CD8+ and CD4+ DCs may instead lie in the inability of the former to process antigens
for MHC class II efficiently; and when controlled for antigen dose and delivery, both subsets are
capable of efficient cross-presentation 39. In fact, under certain inflammatory conditions, the
monocyte-derived DC can present exogenous antigens more efficiently than either of the
lymphoid-tissue resident cDCs 40,41. Collectively, these seemingly conflicting observations may
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be explained by the type of antigen and the context in which it is being studied. Recently, an
innate effector function has also been ascribed to the Notch2-dependent CD11b+ DCs. In
response to attaching-and-effacing intestinal pathogens such as Citrobacter rodentium, intestinal
CD11b+ DCs are the obligate source of IL-2342,43. However, an alternative strategy for ablating
this lineage concluded that these cells were not necessary for resistance to C. rodentium44.
Additional studies comparing these two methods will be necessary to determine the reasons for
this discrepancy.

1.2.3

The role of plasmacytoid dendritic cells in immune responses
pDCs secrete large amounts of type I interferon in response to viral infection45-47.

Naturally, it was believed that these cells were critically important for controlling viral
replication and even priming antigen-specific responses. For example, a recent study using an
LCMV strain that leads to chronic infection concluded that pDCs play some role in the
accumulation of antigen-specific T cells23. Another approach to conditionally deplete pDCs with
DTR under the control of SiglecH concluded that pDCs mount responses to Listeria
monocytogenes and control tumor rejection48. However, new genetic tools have cast some doubt
on the importance of pDCs during the early phase of viral infection21. More specific genetic
tools for the proper characterization and ablation of pDCs is required to settle these
controversies.

1.3

Accurately defining the DC lineage
As discussed above, the criteria to mark the DC lineage has relied on a constantly

evolving rubric, beginning with the purely descriptive analyses of Steinman and colleagues in the
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1970's to a more functional and phenotypic characterization at present. Yet such seeming clarity
has not resolved the topic of the exact contribution of DCs during an immune response, in part
because of the shared expression of many surface markers between DCs and other myeloid cells.
In fact, some of the seminal studies over the last decade that relied on genetic or antibody-based
depletion of specific myeloid populations also affected several other cell types 49. For instance,
two independent reports have claimed that basophils, and not DCs, are critical for mediating T
helper type 2 responses (Th2) 50,51. However, these reports were disputed by another group who
demonstrated that the antibody-based depletion of basophils in the previous studies also removed
a key DC population, which actually appears to be necessary for initiating Th2 immunity 52.
More recently, a report claiming the importance of beta-catenin signaling in intestinal DCs to gut
tolerance was based upon the selective deletion of this molecule in only DCs, a specious claim
given there was also complete deletion in a sizeable fraction of macrophages 53. These
ambiguous results are the byproduct of a strict reliance on cell-surface markers to segregate
myeloid populations. Instead, when considering any lineage, especially one as heterogeneous
and plastic as DCs, more rigorous criteria need to be applied for its functional characterization in
various contexts. Some authors have suggested defining DCs based on their anatomical location,
origin from dedicated precursors, and antigen presenting properties in addition to phenotypic
markers 54. However, all of these measures can be inconsistent depending on the physiological
context or method of measurement. Therefore, we suggest that the most succinct and reliable
definition of the DC lineage is based on the expression of key lineage-specifying transcription
factors which are unequivocally required for their development in all settings. Parsing these
transcriptional networks will help resolve developmental and functional controversies that
currently exist within the field.
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1.4

The developmental origin of DCs
An issue with particular relevance to the transcriptional basis of DC development is their

derivation from bone marrow progenitors. It is now clearly established that DCs are short lived
and are continuously repopulated in the periphery, both within lymphoid and non-lymphoid
tissues, from progenitors that arise in the bone marrow 55,56. For some period of time, there was
confusion about the origin of DCs, based primarily on the initial classification of immune
lineages as broadly derived either from a common lymphoid-restricted progenitor (CLP), or from
a common myeloid-restricted progenitor (CMP) 57,58. Whereas other cells of the immune system,
such as T cells, B cells or neutrophils, are derived strictly from the CLP or from the CMP, it is
now clear that all DC subsets can be derived from either population 59-61. This unexpected
finding overturned the existing paradigm that CD8+ DCs were of lymphoid while CD4+ DCs
were of myeloid origin 6,62. Despite the ability of CLPs to generate DCs upon adoptive transfer
into irradiated hosts, the mechanisms and cell intermediates through which this occurs is unclear.
Moreover, recent lineage tracing studies by Schlenner et al. indicate that the contribution of this
pathway to the steady-state DC compartment is minimal 63. Therefore, our focus will be on the
CMP-derived pathway of DC development.
Fogg and colleagues identified the first precursor downstream of the CMP that still
retained DC potential, termed the macrophage-dendritic cell precursor (MDP) 64. As its name
would indicate, the MDP strictly has the potential to generate macrophages and DCs whereas
alternate myeloid lineages proceed through the granulocyte-macrophage precursor (GMP) 58.
Soon thereafter, two groups reported the identification of a purely DC-restricted bone marrow
progenitor called the common dendritic cell progenitor (CDP), which is efficiently able to
generate all DC subsets at a clonal level 65,66. The CDP was shown to originate from the MDP
9

following the loss of monocyte lineage potential 67. Similar to the MDP, the CDP expresses
relatively high levels of macrophage colony-stimulating factor 1 receptor (M-CSFR) and FMSlike tyrosine kinase 3-ligand receptor (Flt3), but lower levels of the stem cell factor receptor (cKit). Presently it is thought that both the MDP and the CDP derive exclusively from the CMP in
vivo, strengthening the argument that DCs are minimally derived from lymphoid precursors.
Finally, the terminal steps in diversification of DC subsets appear to begin at the CDP stage. As
outlined in Figure 1.2, CDPs seem to be the immediate precursor of both pre-pDCs and precDCs, which are cells restricted to their respective lineages but not yet fully mature 68,69. pDCs
complete their maturation in the bone marrow and circulate through the blood to secondary
lymphoid organs. In contrast, pre-cDCs seed lymphoid and non-lymphoid tissues via the blood
where-upon they complete their differentiation into either the CD8+ or CD4+ cDC subsets.
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Figure 1.2: Stages of DC development
DCs derive from BM–resident hematopoietic progenitors.
1.5

Extracellular cues supporting DC development
A number of extracellular cues induce the progression through the progenitor stages

described above, mainly by activating several cytokine receptors. The major cytokine receptors
influencing DC development are M-CSFR, granulocyte-macrophage colony-stimulating factor
receptor (GM-CSFR) and Flt3, which are all expressed variably on early hematopoietic
precursors but remain highly expressed on committed DC progenitors (Figure 1.1).
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The importance of these cytokines in the differentiation of DCs was first established by early
studies demonstrating the ability of GM-CSF, either alone or in combination with IL-4, to drive
the formation of DCs from mouse bone marrow or human peripheral monocytes 62,70. The
unique potency of these cells for antigen presentation, combined with their expression of CD11c
and MHC class II, confirmed their identity as bona fide DCs and provided a widely used model
system for in vitro studies. Therefore, it was surprising when both GM-CSF- and GM-CSFRdeficient mice showed a largely unperturbed DC compartment, leading to the conclusions that
GM-CSF is dispensable or redundant in steady-state DC development 71,72. The recent
identification of TNF-alpha- and iNOS-producing DCs under inflammatory conditions, and their
dependence on GM-CSF, points to the relevance of this cytokine in infectious settings and likely
explains its ability to induce DC development in vitro 39,73,74.
Nonetheless, these early results suggested that other cytokines were likely responsible for
the steady-state development of DCs in vivo. In 1996, McKenna and colleagues reported that the
administration of exogenous Flt3-ligand (Flt3L) potently induces the expansion of all DC subsets
in vivo 75. This cytokine was then also shown to support the development of all subsets in vitro
76

. Moreover, forced expression of Flt3 (receptor for Flt3L), or its downstream effector molecule

STAT3, in progenitors committed to alternative lineages can re-direct their development into
DCs 77. The requirement for Flt3L in vivo was confirmed by the greatly reduced numbers of
DCs in Flt3L-deficient mice and Flt3-deficient mice 78,79. Interestingly, the absence of Ftl3L
presented with a stronger DC phenotype than the absence of Flt3, suggesting that the ligand may
interact with a hitherto undefined receptor. These findings have been reinforced by subsequent
studies on STAT3-null mice, which appear to phenocopy Flt3L deficiency 80. Recent evidence
suggests that the activation of STAT3 is mediated by mTOR (mammalian target of rapamycin)
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signaling, and accordingly, chemical inhibition of mTOR with rapamycin perturbs the
development of DCs in vitro 81.
While Flt3L appears to be the dominant cytokine controlling steady state DC
development, GM-CSF may contribute, as mice deficient in both Flt3L and GM-CSF have lower
numbers of DCs than either single cytokine deficiency alone 71. The precise degree of
redundancy is still a matter of ongoing work. Much in the same manner as differential
localization within the bone marrow has been proposed to regulate B cell development through
various stages by distinct actions of cytokines and cell-surface proteins on stroma, a similar
combinatorial regulation of DCs has recently been proposed 82,83. First, as noted above, there is a
compound defect in mice deficient in both Flt3L and GM-CSF, suggesting contributions of both
cytokines to DC development. In addition, different cytokines appear to have varying effects on
the development of specific DC subsets. For instance, GM-CSF favors the development of cDCs
while inhibiting the development of pDCs, through a mechanism dependent upon activation of
STAT5 84. In contrast, culturing bone marrow cells in M-CSF in combination with Flt3L has the
opposite effect, favoring pDC development 65. It is conceivable that specific stromal niches
within the bone marrow could support distinct DC developmental outcomes through differential
cytokine production. Indirect evidence supporting this model comes from clonal studies of the
CDP, which noted that some cells within the population already appear to be biased toward
either pDCs or cDCs 66. The generation of unique, non-overlapping reporter systems for each of
the abovementioned cytokines will greatly aid in the resolution of this outstanding question of
niche-dependent effects.
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1.6

Transcription factors control DC commitment and specification
Generally, cell fate specification occurs through the actions of transcription factors which

may be induced or inhibited by initiating extracellular cues. Recently, a number of transcription
factors have been identified that control commitment, specification, and survival of DCs. In this
review, we will group these factors into two major categories. The first category consists of
transcription factors that are required for the development of early DC progenitors, which for the
most part influence all DC subsets. As one might expect with factors influencing such early
decisions, the loss of these genes often affects a number of additional immune lineages besides
DCs. The second category is comprised of more lineage-restricted transcription factors, which
regulate later stages of DC fate decisions. Deficiency of these factors usually results in more
specific defects within the DC lineage. It is worth keeping in mind that the expression of some
factors from the first category is not extinguished as the steps of commitment and specification
unfold, and therefore may influence both progenitors and mature cell types in distinct ways.
Importantly, unique developmental outcomes may emerge from transcriptional programs
initiated by broadly expressed factors of the first category through the induction and then
interaction with factors from the second.

1.6.1

Factors regulating early DC progenitor development
The landmark discovery of the indispensable role of the zinc finger transcription factor

Ikaros in the development of all lymphoid lineages also represents the initial identification of a
factor necessary for DC development. Specifically, Ikaros-null mice lack pDCs and CD4+ cDCs,
and mice harboring a dominant-negative form exhibit a complete absence of all DC subsets 85,86.
Unexpectedly, Ikaros-null mice retain a residual population of CD8+ cDCs, although the function
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or origin of these cells has not been examined. The apparent mechanism by which Ikaros
controls DC development is through its regulation of a large panel of receptors and transcription
factors. Although classically considered to be required only for the priming of lymphoid
lineages, gene expression analysis of the earliest cell stages of hematopoietic development
revealed that the loss of Ikaros affects the expression of large gene sets associated with both
lymphoid and myeloid lineages 87. For example, the expression of Flt3, IL-7 receptor, Notch1,
and the transcription factor Mef2c are all controlled by Ikaros, suggesting that it acts globally on
many aspects of lineage specification 88.
Another well-known transcription factor influencing the early development of DCs is the
ETS factor PU.1. Recently, PU.1 was unequivocally shown to be necessary for DC
development, resolving earlier studies that resulted in conflicting conclusions 89,90. Mice with a
conditional deletion of PU.1 within the hematopoietic compartment fail to develop all DC
subsets, but also show defects in other myeloid lineages including but not limited to
macrophages and neutrophils 91. Similar to Ikaros, PU.1 appears to control the induction of a
broad range of genes necessary for development of many hematopoietic lineages. In particular,
PU.1 controls the early expression of Flt3, GM-CSFR, and M-CSFR on progenitors, although
only the absence of Flt3 was confirmed on DC precursors 92,93. Notably, forced expression of
Flt3 in PU.1-deficient progenitor cells did not rescue DC development, reinforcing the notion
that PU.1 regulates other important programs aside from the signaling downstream of Flt3.
Finally, Gfi1, a known transcriptional repressor, appears to play a role in the development
of all DC subsets. Gfi1-null mice have a global reduction in lymphoid-organ DC compartments,
albeit not as severe as either Ikaros- or PU.1-deficient mice 94. Analysis of Flt3+ DC progenitors
revealed a cell-autonomous role for Gfi1 in the activation of STAT3, suggesting that it may act
15

downstream of Ikaros or PU.1. One proposed mechanism is through its ability to inhibit PIAS3
(protein inhibitor of activated STAT3), a specific inhibitor of STAT3 95. In this model, loss of
Gfi1 leads to the maintenance of PIAS3 activity and thus a reduction in transcriptional events
mediated by STAT3. Additionally, studies in human monocytes have shown that Gfi1 can bind
to a large number of myeloid gene loci such as JAK3, IL-8, and the CEBP family of transcription
factors, indicating a potential role beyond its effect on STAT3 96. Interestingly, surviving Gfi1deficient DCs closely resemble their counterparts from mice deficient in members of the NFkappaB signaling cascade, suggesting that these two factors may converge on a common
developmental pathway (see below) 97. The dependence of DC development on both PU.1 and
Gfi1 is in stark contrast to B cell ontogeny, during which these two factors act in opposition 98.
Whether Ikaros, PU.1, and Gfi1 act in concert or independently in DC development remains to
be determined.

1.6.2

Factors regulating late DC progenitor development
Whereas the factors discussed above appear to be necessary during the HSC to CDP

transition, particularly for the proper expression of key cytokine receptors, several transcription
factors exert control over developmental options after commitment to the DC lineage has already
occurred. These factors are expressed beginning in the CDP stage, and thus specify commitment
into subsets or act on survival or proliferation programs in immediate precursors. For the most
part, the factors acting in this realm of DC development have been evaluated for their actions on
lymphoid resident DCs. However, it is clear that they likely affect the development of
corresponding non-lymphoid DCs as well by mediating similar genetic programs in both
compartments (Figure 1.2) 32,99.
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The first transcription factor identified to affect a particular subset was RelB, a member
of the NF-kappaB family of transcription factors, which also consists of RelA (p65), c-Rel, p50
and p52. In contrast to RelA and c-Rel, RelB selectively forms a heterodimer with p52 or the
precursor form, p100 100. Expression of RelB is induced in the pre-cDC and then preferentially
maintained in CD4+ DCs. Consequently, mice deficient in RelB show a significant decrease in
the CD4+ population of cDCs, a defect determined to be cell intrinsic, while CD8+ cDCs and
pDCs appear to be unaffected 101,102, 1995 1 /id}.
Although studies investigating the mechanism by which RelB controls DC differentiation
are lacking, one gene suggested to be a target of RelB is interferon regulatory factor 4 (IRF4),
whose deletion also results in a large reduction in the number of CD4+ DCs 103. IRF4, one of
nine IRF family members, contains an N-terminal DNA-binding domain (DBD) and a Cterminal IRF-associated domain (IAD). IRF4 is known to interact with a number of other
transcription factors, including ETS factors and AP1 family members. In different settings, these
interactions are critical in determining the DNA-binding specificity and functional nature of the
IAD, either as an activator or repressor of transcription 104-106. However, whether these
interactions occur within the context of DCs remain to be defined, although PU.1 (ETS) and
Batf3 (AP1) are attractive candidates.
Of the IRF family members, the member most functionally related to IRF4 is IRF8. IRF8
has also been demonstrated to play a critical role in DC differentiation. IRF8 deficiency leads to
a complete loss of both CD8+ cDCs and pDCs, and mice lacking both IRF4 and IRF8 exhibit
essentially a compound phenotype, with a severe reduction in the total number of DCs and an
absence of all but a few CD4+ and double negative cDCs 107,108. This result suggests that these
factors may provide an overlapping function in certain subsets, but for most DCs, these two
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factors display essentially non-overlapping patterns of expression. It is not yet known what
signals are controlled by the IRF proteins, or what signals or transcription factors lead to the
induction of IRF4 or IRF8 in their respective subsets.
In contrast to the selective expression of IRFs within DC subsets, Batf3 is expressed in
both CD8+ and CD4+ cDCs, but loss of Batf3 leads to an abrogation in the development of only
one of these subsets, the CD8+ DC 109. Batf3 is a member of the AP1 family of transcription
factors that forms an obligate heterodimer with cJun or other Jun paralogs. However, unlike
other AP1 members, Batf3 lacks a C-terminal extension that would provide a transcriptional
activation domain, and instead consists only of a basic DNA-binding motif followed by a dimerforming leucine zipper region 110,111. Batf3 is most similar to a related factor Batf, which was
recently found to be necessary for Th17 and Tfh differentiation as well as for isotype-switching
in B cells 112,113. These recent findings reverse the earlier notion that these minimal AP1 family
members, Batf3 and Batf, were simply dominant-negative analogs of Fos, and instead suggest
that these factors form unique heterodimers with Jun that posses distinct transcriptional
activities. In the case of Batf3, this activity presumably includes the activation of genes
selectively expressed by CD8+ DCs.
Mice deficient in Batf3 have normal numbers of precursors, including CDPs and precDCs 32, and appear deficient in only the most terminal stage of CD8+ DC maturation. This final
step is defined by the induction of genes important for the function of this DC subset, including
Langerin and CD103. However, at present the immediate transcriptional targets of Batf3 are
unknown.
The factors discussed above appear to regulate terminal steps of commitment to particular
DC lineages. In contrast, two additional transcription factors appear to regulate the survival of
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terminally committed precursors or mature cell types. The transcription factor Rbp-j, a critical
mediator of the Notch signaling pathway, was recently found to be required for the survival of
CD4+ DCs in vivo 114. Mice deficient in Rbp-j lack more than 50% of their CD4+ DCs. Detailed
analysis revealed that commitment to this lineage appears to be unaffected since the population
of splenic pre-cDCs in these mice is normal. Rather, higher levels of Annexin-V staining and
BrdU incorporation in surviving CD4+ DCs suggest increased apoptosis of the terminal cell
stage.
Similarly, the zinc finger transcription factor Bcl6 appears to regulate the survival of cDC
precursors 115. Bcl6 is a BTB (bric-a-brac, tramtrack, broad) -domain containing repressor that
also has important actions in Tfh differentiation and exerts a repressive action on plasma cell
genes within germinal center B cells 116-118. In DCs, Bcl6 deficiency causes a severe reduction in
both types of cDCs. While in vitro Flt3L experiments suggest a more pronounced effect on
CD8+ DC equivalents, the in vivo results indicate a larger effect on CD4+ DC frequency. In
contrast to Rbp-j deficiency, Bcl6-null mice do appear to exhibit increased Annexin V staining in
cDC precursors and accordingly, express markers of apoptosis such as p53.

1.7

The balance between E2-2 and Id2 determines the choice between cDC and pDC

fates.
A family of transcription factors known as class I basic helix loop helix (bHLH) factors
plays an important role in the differentiation and survival of a number of lymphocyte populations
119

. Class I bHLH proteins, also referred to as E proteins, comprise a family of four members:

E12, E47, E2-2, and HEB. These proteins function either as homodimers or heterodimers
between family members, and bind to a conserved DNA motif referred to as an E-box. The
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DNA-binding activity of these heterodimers can be interrupted by formation of a complex
between E proteins and members of the inhibitor of differentiation (Id) HLH protein family,
which lack the necessary DNA-binding motif of the basic region. Of the four members of the Id
protein family, Id2 and Id3 appear to be the major inhibitors of E2 protein activity during
lymphocyte development.
The first indication of the importance of E proteins in DC development arose from the
observation that over-expression of Id2 or Id3 inhibits the development of pDCs in vitro 120.
This was extended by the finding that Id2 expression is induced in vitro in response to GM-CSF,
and that Id2 is required for in vivo development of CD8+ DCs, but not other subsets 121.
Surprisingly, the frequency of pDCs is increased in these mice suggesting that Id2 may function
to divert cDC precursors away from the pDC fate. This hypothesis is supported by the finding
that DCs developing in Id2-deficient mice also show de-repression of many genes normally
associated with B cells as well as pDCs, as they share a large common gene signature 122.
A major breakthrough in the understanding of DC subset development resulted from the
discovery that E2-2 is required for the development of pDCs in vivo 68. These findings also
helped to establish the identity of a pDC-restricted precursor: a CD11c+ Ly6C+ SiglecH- cell
termed the pre-pDC. Mechanistically, E2-2 regulates a large pDC gene program including the
direct regulation of other key transcription factors associated with pDC development, including
IRF8, Bcl11a, and Spi-B. Interestingly, E2-2 also appears to repress genes associated with cDC
subsets 123. This was shown using an inducible Cre-deletion system whereby E2-2 was deleted
in mature pDCs. Terminal deletion of E2-2 results in the induction of a number of cDCassociated genes including the re-expression of Id2. However, only a small subset of cDC genes
appears to be affected. Therefore, it is not clear whether the emergence of these genes represents
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a conversion of pDCs into bona fide cDCs, or instead into the recently reported alternative CD8+
CX3CR1+ DC lineage that appears to be more closely related to pDCs 124. In any event, derepression of Id2 caused by the loss of E2-2 expression now highlights an important regulatory
circuit that controls the switch between pDCs and cDCs. In this circuit, induction of Id2
decreases E2-2 expression, and E2-2 activity suppresses Id2 expression. This arrangement
represents a classical "flip-flop" circuit based upon mutual antagonism of alternately expressed
factors. Presently, it is unknown what signals might control the induction of alternate states of
this circuit.

1.8

Gene expression analysis of the CDP points to "pDC-priming"
Elaborating the transcriptional mechanism of T cell development was greatly aided by the

identification of distinct cellular stages through which T cells progress. For example, the fate
choice between T and NK cell lineages in the thymus was known to take place during the CLP to
pro-T cell transition and to be dependent on Notch1 125. Careful gene expression analysis of
intermediate cell stages allowed three groups to identify the downstream factor Bcl11b as a key
mediator of this specification process 126-128, 2010 4712 /id} .
In contrast to T cell development, the specific intermediate stages of DC development
have only recently been identified, as discussed above. In addition, the difficulty in identifying
and isolating these progenitors, as well as their relative paucity in the bone marrow, has made
them difficult to study. As a result, the relationships between the transcription factors that
regulate DC development and the progenitor stages at which they act are still unclear. One
plausible arrangement of the transcription factor network with respect to cellular differentiation
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is shown in Figure 1.3. In this scheme, we have diagrammed the potential relationships between
key transcription factors, some of which were suggested in the original reports.
We propose that the CDP represents the key stage at which the choice between the pDC
and cDC lineage is made. The CDP is the natural candidate for this choice, since it has
extinguished its ability to form alternate lineages, but still retains the ability to generate all DC
subsets. Recent studies, as well as unpublished studies from our lab, have provided expression
profile data for each sequential stage of DC differentiation in vivo including the CDP 129.
Strikingly, analysis of transcription factors expressed in CDPs reveals that a number of pDC
factors, including E2-2, Bcl11a, and Runx2, are already expressed at moderate levels (Figure
1.4). In contrast, factors associated with the cDC lineage, such as Id2, Batf3, and Bcl6, are
expressed either at very low levels or not at all. One interpretation of this data is that CDPs may
be set to "default" into the pDC lineage unless a trigger is received to induce Id2. Id2 becomes
highly expressed at the pre-cDC stage where-upon pDC-associated genes are lost. Such a default
pathway could be likened to the strong skewing of naïve T cells towards the Th2 phenotype,
which is mediated by an auto-activation of Gata-3 130.
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Figure 1.3: Transcription factor networks control DC development
A number of transcription factors regulate the commitment and survival of dendritic cells at
various stages of development. However, the coordinated action of these factors with respect
to one another as well as to relevant progenitor stages has not been well defined. One
plausible network of these factors is depicted alongside the cellular stage in which they likely
exert their functions. Solid arrows indicate connections that have been proven or suggested
within original reports. Dotted arrows indicate hypothesized relationships.
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Figure 1.4: CDPs are “pDC-primed”
CDPs represent the last common precursor for both cDCs and pDCs, and thus a likely stage of
specification into either lineage. This decision is dependent on a mutually antagonist balance
between the transcription factors E2-2 and Id2. Gene expression analysis of progenitor
populations reveals that CDPs express a number of pDC-specific transcription factors. Shown
is the expression of pDC factors (E2-2, Bcl11a, and Runx2) in comparison to cDC factors
(Id2, Batf3, and Bcl6). Expression of pDC factors and the lack of expression of cDC factors in
the CDP points to a "default" pDC pathway during DC differentiation. Re-direction into the
cDC lineage requires the induction of Id2 and repression of pDC factors in the pre-cDC.

1.9

Conclusions
The transcriptional networks regulating the diversification of myeloid lineages are

currently being elucidated. Arguably, DCs remain the most enigmatic and developmentally
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uncharacterized cell type within this system. However, recent studies have defined key steps in
the DC differentiation pathway by identifying restricted bone marrow precursors. We hope that
these advances will encourage the current transition of the field from a relatively descriptive state
to one in which molecular mechanisms are emphasized. This shift in approach is needed to
clarify confusion regarding the precise role of the DC lineage, and particularly specific DC
subsets, in settings of infection and tolerance. For example, our understanding of the functional
differences between pDCs and cDC subsets has greatly improved since the identification of
transcription factors which are required for their development, such as E2-2 and Batf3,
respectively. The deletion of either gene leads to a model in which the exact function of the
relevant cell can be interrogated.
Clearly, many questions regarding the transcriptional regulation of DC fate decisions still
remain unanswered. The basis for the initial commitment to the DC lineage or its split from the
monocyte pathway downstream of the MDP is unknown. Similarly, the mechanisms regulating
the transition from the cDC precursor into either the CD4+ or CD8+ subset are also unclear.
Another key issue is whether the combinatorial action of cytokines within distinct stromal niches
plays any role in influencing these fate choices. Answers to these outstanding questions will
allow for the arrangement of the current transcription factor network into a resolvable structure
that can be used for manipulation of DCs in clinical settings.
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Chapter 2 Batf3 regulates survival and maturation subsequent to an Irf8-dependent lineage
+

commitment step in the development of CD8α dendritic cells

2.1

Abstract
Classical dendritic cells (cDCs) in lymphoid tissues are composed of two major subtypes

distinguished by differential expression of CD8α. CD8α+ cDCs are important for responses to
many viruses based on their in vivo capacity for cross-presentation and priming of CD8+ T cells.
While CD8α+ cDCs require Batf3 and Irf8 for development, the cellular basis of these actions
remains unclear. Here, we analyzed the developmental stage and cellular processes controlled
by Batf3 and Irf8 in ontogeny of CD8α+ cDCs. Irf8 is highly expressed in CD8α+ cDCs and in
progenitors of mature cDCs and pDCs. In contrast, Batf3 is not expressed in early cDC
progenitors, and is induced only in the terminal stages of cDC maturation. We find that Irf8-/mice exhibit reduced numbers of common dendritic cell progenitors (CDPs) and committed cDC
precursors (pre-cDCs). Furthermore, Irf8-/- mice show a complete absence of CD24+ Sirp-αcDCs, which represent the committed progenitors of mature CD8α+ cDCs. In contrast, Batf3-/mice have normal numbers of CDPs and pre-cDCs and retain a reduced population of CD24+
Sirp-α- cDCs that express high levels of Irf8. However, Batf3-/- CD24+ Sirp-α- cDCs exhibit
decreased lifespan and reduced competitive fitness in vivo and fail to express genes characteristic
of functionally mature CD8α+ cDCs such as Xcr1, Clec9a and Tlr3. These results indicate that
Irf8 and Batf3 act at distinct stages of CD8α cDC development, with Irf8 initiating CD8α+

lineage commitment and Batf3 acting in survival and maturation of these committed progenitors.
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2.2

Introduction
Murine dendritic cells (DCs) comprise classical DCs (cDCs) involved in T cell activation

and plasmacytoid DCs (pDCs) involved in viral sensing and interferon production 1,2. cDCs in
lymphoid tissues segregate into two major subsets based on expression of the CD8α marker 3,4.
Although lacking expression of CD8α in non-lymphoid tissues, peripheral DCs segregate into
two functionally related subsets distinguished by the expression of CD103 and CD11b 2,5.
Lymphoid-resident CD8α+ cDCs and tissue-resident CD103+ cDCs are related by shared
expression of several markers, such as XCR1 and Clec9a, and by providing antigen crosspresentation in the activation of CD8+ T cells against viruses 6-9.
Adoptive transfer studies 10-12 suggest both the common lymphoid progenitor (CLP) 13
and common myeloid progenitor (CMP) 14 can generate all DC subsets. However, lineage
tracing indicates that steady-state DCs in vivo are predominantly CMP-derived 15. The CMP
generates a macrophage/dendritic cell-restricted precursor (MDP) 16,17 which then gives rise to a
common dendritic cell progenitor (CDP) 18,19. The CDP appears to be the immediate precursor
of pre-pDCs 20 and pre-cDCs 16,21, both of which are lineage- restricted but immature. While
pDCs mature in the bone marrow (BM) and circulate through the blood to secondary lymphoid
organs, pre-cDCs migrate via the blood to populate both lymphoid- and non-lymphoid tissues
where upon development into either CD8α+ cDC or CD8α- cDC is completed 16. While the
precursor-product relationship for murine dendritic cells is mostly resolved, the molecular
mechanism and stage of action for key transcription factors important in DC development is still
poorly understood.
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Some transcription factors regulate broad aspects of DC development 22,23. Ikaros (Ikzf1)
is required for the development of all lymphoid lineages 24 and for some DCs subsets. Ikzf1-/mice lack pDCs and CD8α- cDCs, and a dominant negative form of Ikaros eliminates all DCs
24,25

. Deletion of PU.1 (Sfpi1) from hematopoietic cells eliminates all DC subsets and causes

defects in macrophages, neutrophils and other myeloid lineages 26. This may relate to the
regulation by PU.1 of FMS-like tyrosine kinase 3-ligand receptor (Flt3) 27,28, a key receptor for
DC homeostasis in vivo29. Similarly, loss of Gfi1 broadly reduces the size of DC populations,
albeit not as severely as in Ikzf1-/- or Sfpi1-/- mice 30. In addition to DCs, many other myeloid and
lymphoid lineages are broadly affected by defects in Ikaros, PU.1 or Gfi1, consistent with their
relatively high expression in early hematopoietic progenitors.
In contrast, other transcription factors are expressed late in DC development and regulate
subsets of DCs. Within cDCs, Irf4 and Irf8 are expressed in CD8α+ or CD8α- DCs, respectively
31

. Irf4-/- mice reportedly have reduced numbers of CD8α- DCs 32 and also have defects in T and

B cells 33,34. Irf8-/- mice lack CD8α+ cDCs and pDCs , but also display defects in macrophages
and B cells 35-40. Despite being recognized for nearly a decade as a requirement in CD8α+ cDC
development, the cellular and molecular basis for the actions of Irf8 are not yet understood.
Finally, the AP-1 family member Batf3 is selectively required for CD8α+ 7 and peripheral
CD103+ cDC development8. In contrast to the expression of Irf4 and Irf8, Batf3 is expressed in
both DC subsets. The cellular basis for the requirement of Batf3 in CD8α+ cDC development is
currently unclear. In the present study, we characterize the cellular basis for Batf3 and Irf8 in the
development of CD8α+ cDCs.
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2.3

Results

2.3.1

Batf3 induction occurs subsequent to the expression of Irf8 in DC progenitors
The AP-1 family member basic leucine zipper transcription factor, ATF-like 3 (Batf3;

also known as JDP1 and p21SNFT) is critically required for the proper development of CD8α+
DCs in lymphoid organs and the related CD103+ DCs in peripheral tissues despite being
expressed in both subsets of DCs 7,8. Additionally, interferon regulatory factor 8 (Irf8; also
known as ICSBP) is required for the development of CD8α+ cDCs and pDCs41-43; and in the
setting of competitive bone marrow reconstitution, it is also required for the reconstitution of
CD11b+ DCs. Moreover, IRF8-deficient mice show profound changes in both lymphoid and
myeloid progenitors in the bone marrow44. Lastly, several reports have recently demonstrated a
functional interaction between AP-1 and IRF proteins on AP1-IRF composite elements (AICE).
To characterize the stage-specific actions of Batf3 and Irf8, we quantitated the relative
expression of both genes in early myeloid progenitors and mature DC populations. Irf8 is
expressed highly in DC progenitors (CDP and pre-cDC) and CD8α+ DCs, but largely absent
from CD4+ DCs. In contrast, Batf3 is induced at the progenitor stage and then highly
upregulated mature DC subsets (Figure 2.1 A-C).
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Figure 2.1: Batf3 induction occurs subsequent to the expression of Irf8 in DC progenitors
(A) Bone marrow cells from C57BL/6 wild-type mice were stained for the indicated markers and
the gated populations were isolated by cell sorting. (B) Splenocytes were stained with the
indicated markers and the DC populations were purified by cell sorting. (C) Quantitative realtime PCR (qPCR) for Batf3 and Irf8 in the indicated cell populations. The assay was performed
on two independently purified sets of each cell type, except for BM and spleen pre-cDCs, which
were only sorted a single time. Bars represent the mean and standard deviation.

2.3.2

Neither Irf8 nor Id2 rescue Batf3 deficiency in dendritic cell development
Although Irf8 expression precedes the induction of Batf3 in BM DC progenitors, we

determined whether BATF3 was necessary for the subsequent maintenance of Irf8 downstream
of the CDP and pre-cDC stages of development. Similarly, we evaluated whether the
transcription factor inhibitor of DNA binding 2 (Id2), which is also necessary for CD8α+ DC
development, is downstream of Batf3. To directly test these two hypotheses, we adapted a
previously reported in vitro system for the generation and retroviral transduction of DCs37,45;
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Ozato and colleagues have successfully used this system to rescue Irf8-deficient DCs.
Therefore, we generated retroviral constructs harboring the cDNA of either murine Irf8 or Id2
(cloned from splenic cDNA library) upstream of an internal ribosome entry site (IRES) and
green fluorescent protein (GFP). We then confirmed efficient transduction of DC precursors
generated with the cytokine FMS-like tyrosine kinase ligand (Flt3L) 46. However, neither IRF8
nor ID2 transduction rescued Batf3-deficiency in vitro (Figure 2.2 A). We obtained similarly
negative results in vivo with radiation bone marrow chimeras47 that were transplanted with
transduced hematopoietic stem cells (HSCs) (Figure 2.2 B). These data suggest that BATF3
activity is non-redundant with respect to other known transcriptional regulators of DC
development.
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Figure 2.2: Irf8 and Id2 fail to rescue Batf3 deficiency
Transduction of bone marrow DC cultures (A) or cKit enriched cells was carried out as described
in Methods. Shown are two-color histograms for the indicated markers. Numbers represent
percent of cells in the gate. cKit enriched BM cells were cultured in the presence of stem cell
factor (SCF) and thrombopoietin for 12 hours and then transplanted into conditioned mice.
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2.3.3

AP-1 complexes consisting of BATF3 are non-redundant and play a unique role in

the context of DC development
The inability of IRF8 and ID2 to restore BATF3-deficient CD8α+ DCs suggests a unique
role for BATF3-containing AP-1 complexes. Interestingly, the two components of the canonical
AP-1 complex, FOS and JUN (and their related paralogs), are thought to be widely expressed in
both hematopoietic and non-hematopoietic tissues, in which AP-1 is known to regulate gene
expression broadly 48-50. Batf3 is a member of the ATF family, which is a subgroup of a larger
family of DNA binding proteins collectively called basic leucine zipper (bZIP) transcription
factors51. These factors minimally contain a α-helical basic DNA-binding region and regularly
spaced leucine zipper motif52-54. The function of bZIP proteins as transcription factors was
described through extensive studies on two of the earliest identified family members, FOS and
JUN, which together constitute the heterodimeric transcription factor complex called activator
protein 1 (AP-1)49. AP-1 complex is thought to regulate gene expression through its transactivating domains (TAD), which mediate recruitment of chromatin remodeling complexes.
Alternatively, the AP-1 complex can directly interact with nearby transcription factors, such as
nuclear factor of activated T cells (NFAT), to modulate gene expression.
Unlike the canonical members of the AP-1 family, BATF3 contains no TAD and thus
has been proposed to inhibit gene expression through a dominant-negative mechanism. And yet
the numerous functional and developmental defects observed in Batf3-/- and Batf-/- mice suggest a
positive transcriptional activity for BATF(3)-containing AP-1 complexes 7,55. To clarify this
matter, we performed multiple sequence alignment of FOS, JUN, and ATF family members,
paying particular attention to the basic region and leucine zipper (Figure 2.3 A). The relevant
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basic residues that contact the major groove of DNA are highly conserved among all members,
agreeing with previous studies showing that BATF3 binds to the AP-1 consensus site56.
Although the dimerization-promoting leucine residues (which face inward on the heterodimer
complex) are also highly conserved, the outward facing residues show poor conservation,
especially for BATF and BATF3. Next, we tested each AP-1 member for its functional
similarity to BATF3 in DC development (Figure 2.3 B). We found that neither FOS nor JUN
family members promoted the in vitro generation of CD8α+ DCs. Given FOS and JUN contain
TAD, which might account for the observed difference, we used a naturally occurring splice
variant of Fosb that lacks the TAD (ΔFosb) and functions effectively as a dominant negative 57.
ΔFosb showed the greatest inhibitory activity during the generation of in vitro derived CD8α+
DC equivalents. This result suggests that the determinant for AP-1 activity during DC
development is either in the basic region or the leucine zipper. We also evaluated the more
closely related ATF family members, activating transcription factor 3 (ATF3) and JUN
dimerization protein 2 (JDP2), which also associate with JUN proteins to form a functional AP-1
complex. Neither ATF3 nor JDP2 were able to rescue BATF3-deficient cells, again suggesting a
unique function of BATF3-containing AP-1 complexes. The molecular basis of this differential
activity must lie within either the DNA binding domain (DBD) or the leucine zipper motif. Two
possibilities exist, then – the DBD binds to the consensus AP-1 motif but also recognizes
degenerate sequences which are distinct from those recognized by FOS-containing complexes; or
the leucine zipper mediates distinct interactions with different partner proteins58. Recently,
several reports concluded that BATFs can interact with IRF family members through the leucine
zipper region59-61. While the interaction analysis was performed on bona fide target genes for

43

lymphocytes, the studies minimally evaluated DC targets under the dual control of IRFs and
BATFs.
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Figure 2.3: BATF3 containing AP1 complexes are uniquely required for DC development
(A) Protein sequences of the indicated AP-1 factors were compared with ClustalW2 (EMBLEBI). Single-letter amino acid sequence is shown, with the basic region and leucine zipper
indicated. Within each segment, sequences that contact the DNA (basic region) or play a role in
protein dimerization (leucine zipper) are raised. (B) BM cells were cultured for 10 days in the
presence of recombinant Flt3L. Retroviral transduction of DC cultures was carried out on day 2
and cells were stained for analysis on day 10. Shown are two-color histograms for the indicated
markers. Numbers represent percent of cells in the gate. Data are representative of 2
independent experiments.

2.3.4

Batf3 induction primes progenitors toward CD8α + DC commitment
The overexpression of BATF3 in progenitors actively promoted the generation of in vitro

derived CD8α+ DCs. Yet Batf3 levels are rather low in BM DC progenitors. It has also been
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noted that the CDP is a pDC-primed state, in which pDC-related transcription factors (such as
Tcf4, Bcl11a, Runx2) are moderately expressed but cDC-related factors are poorly expressed23.
Thus, we hypothesized that Batf3 induction promotes the active commitment of early DC
progenitors away from pDC or CD11b+ DCs and toward CD8α+ DCs. One potential inducer of
Batf3 is Flt3L, as it has long been recognized for its propensity to increase CD8α+ DC numbers
dramatically after exogenous administration 29. We tested this by administering Flt3L by
intraperitoneal route and isolating pre-cDCs from the bone marrow and performed microarray
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Figure 2.4: Batf3 induction primes DC progenitors toward CD8α+ DCs
(A) WT C57BL/6 mice were treated with a single dose of 10 mg per mouse recombinant Flt3L.
Bone marrow cells were isolated two days later and DC progenitors were sorted as lineagenegative, CD11c+ cKit+. Purified RNA was converted to labeled product and microarray
analysis performed. PCA analysis was carried out in R. Top 14 genes with the highest positive
and negative loading scores are shown for PC2 and PC3.
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Next, an unbiased assessment of the treated progenitor was carried out through the use of
principal-component analysis (PCA). In PCA of multiple myeloid progenitor populations and
mature DCs, most of the variation in gene expression is captured in three principal components
(Figure 2.4). PC1 segregates cell types as either myeloid progenitors (CDP, CMP, GMP) or
immature and mature DC subsets (the most negative loadings include H2-A/E, Zbtb46, Batf3
which are all known cDC genes). When genes are ordered by their relative weights in PC3, the
most positive loadings correspond to well characterized CD8α+ DC genes such as Tlr3, Xcr1,
and CD3662,63; the most negative loadings correspond to genes such as Spib, Zeb2, Sirpa and
Csf1r, which are associated with functions in CD11b+ DCs or monocytes 64-67. This analysis
suggests that early BM DC progenitors can be induced to express Batf3, which then partly
initiates the CD8α+ DC commitment program.

2.3.5

Commitment by pre-cDCs to the CD8α cDC subset requires Irf8 but not Batf3
+

Since mature CD8α+ DCs arise from pre-cDCs through a CD24HighSirp-αLow intermediate
population 16,21, we asked whether the expression of these two markers could identify an earlier
stage of CD8α+ DC development (Figure 2.5 A). Batf3-/- mice on the 129SvEv background have
a significant reduction in spleen-resident CD8α+Dec205+ DCs, comprising 0.1% of total cDCs,
as compared to wild type (WT) mice, which have 6.3% of total cDCs (Figure 2.5 A, upper
panels). However, 129SvEv Batf3-/- mice retain a residual 2-3% population of CD24+Sirp-αcDCs, representing a 4-fold reduction relative to WT 129SvEv mice (Figure 2.5 A, lower
panels). Interestingly, Batf3-/- mice on the C57BL/6 background show a less complete loss of
CD8α+Dec205+ DCs as compared to 129SvEv mice (Figure 2.5 B, upper panels), as we
previously reported 68, but still exhibit defective CD8α+ cDC function in vivo 69,70. Notably,
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C57BL/6 Batf3-/- mice also retain a CD24+Sirp-α- cDC population that is again slightly larger
than the CD8α+Dec205+ cDC population (Figure 2.5 B, lower panels). These results suggest
that CD24+Sirp-α- cDCs are only partially dependent on Batf3.
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Figure 2.5: Development of CD24+SIRPα- DC requires Irf8 but not Batf3
(A) FACS analysis of splenocytes from indicated genotypes. Histograms of cells previously
gated as CD11c+MHCII+B220-. Numbers represent the percentage of cells in the indicated gate.
(B) WT or Batf3-/- mice (B6 Batf3-/-) and analyzed as in (A). (C) spleen (SPL), inguinal lymph
nodes (ILN), mesenteric lymph nodes (MLN), and thymus (THY) or bone marrow (BM) of WT,
Batf3-/- or Irf8-/- mice on the C57BL/6 genetic background. BM DCs (Flt3L) were generated
with Flt3 ligand in vitro as described in Methods. (D) The percentage of cells present within the
CD24+SIRPα- gate from (C) are presented for WT (black bars) and Batf3-/- mice (open bars) on
either the 129SvEv (left) or C57BL/6 (right) genetic backgrounds. At least 5 mice were
analyzed per group. Numbers represent the p value for an unpaired Student's t test.
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Since Irf8-/- mice also lack CD8α+ cDCs, we analyzed resident DCs from spleen, lymph
nodes, thymus and Flt3L-treated bone marrow (BM) cultures between C57BL/6 Irf8-/- and Batf3/-

mice (Figure 2.5 C, D, Supplementary Figure 2.1). Surprisingly, while CD24+Sirp-α- cDC

development strictly requires Irf8 in all sites, we find a variable requirement for Batf3 that differs
across anatomic locations. Specifically, we find that CD24+Sirp-α- cDCs are strongly Batf3dependent in mesenteric lymph nodes (MLN) and spleen (SPL), partially Batf3-dependent in the
thymus (THY), and nearly independent of Batf3 in inguinal (skin-draining) lymph nodes (ILN)
(Figure 2.5 C, Supplementary Figure 2.2). For example, the CD24+Sirp-α- cDCs comprise 44%
of cDCs in MLN of WT mice, but only 3.4% in Batf3-/- mice (Figure 2.5 C, D), representing a
10-fold reduction. In SPL, THY, and Flt3L-treated BM cultures, we find a 2-3 fold reduction in
CD24+ Sirp-α- cDCs between WT and Batf3-/- mice (Figure 2.5 C, D). Finally, CD24+Sirp-αcDCs represent 43% of cDCs in WT ILN, and 37% of cDCs in Batf3-/- mice (Figure 2.5 C). The
same anatomic order of Batf3-dependence is seen on the 129SvEv strain, except for ILN which
show a modest 3-fold reduction in CD24+Sirp-α- cDCs (Supplementary Figure 2.2). These data
suggest that Irf8 and Batf3 play distinct roles in CD8α+ DC development, with Irf8 being strictly
required for appearance of the early CD8α-committed, CD24+ Sirp-α- population, and Batf3
acting later in its maturation. Second, the persistence of this CD24+ Sirp-α- population may vary
with anatomic location and genetic background.
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2.3.6

Batf3-deficient CD24+ SIRPα - DCs respond poorly to Flt3L and PAMP stimulation
Several studies have demonstrated that CD8α+ DCs can develop independently of Batf3,

Id2, or Nfil3 in a high IL-12- or irradiation-induced setting59,71. This compensatory
developmental pathway requires the paralogous factors Batf and Batf2 72. Additionally, various
pathogens are also known to regulate DC numbers positively and negatively. For example,
pulmonary tuberculosis can lead to the expansion of the related lung CD103+ DC, whereas
systemic infection with plasmodium can enhance CD8α+ DC numbers in the spleen 59,73. Since
DC numbers can vary dramatically in response to many disparate stimuli, we determined
whether Batf3-deficient DCs could be rescued by other cytokines or PAMPs.
In response to Flt3L, all DC populations expand greatly with a preferential skewing
toward the CD8α+ DC lineage29. By contrast, intravenous administration of LPS is known to
cause redistribution of CD11c+ cells from the marginal zone to the T cell area of the spleen,
whereupon the cells disappear after several days74,75. Intraperitoneal administration of
recombinant Flt3L into Batf3-deficient mice resulted in poor expansion of splenic CD24+SIRPαDCs (Figure 2.6 A). Moreover, CD24+SIRPα- DCs expressed low levels of surface CD8α and
CD205, but relatively high amounts of CD11b, a marker of the CD8α- DC lineage (Figure 2.6
B). Similarly, we observed a consistent reduction of CD24+ DCs from either C57BL/6 or
129SvEv genetic backgrounds at both high and low doses of Flt3L in vitro (Supplementary
Figure 2.3). These results suggest that Flt3L is involved in the maintenance rather than the
terminal differentiation of DCs, especially with regard to the compensatory pathway. Next, we
administered agonists for TLR3 (polyinosinic:polycytidylic acid, polyI:C), TLR4
(lipopolysaccharide, LPS), and TLR9 (CpG1826, type B) and analyzed DC compartment 24
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hours later. We saw a consistent reduction of Batf3-deficient CD24+ cells in response to
inflammation (Figure 2.6 C). Lastly, we found this residual population of CD24+ DCs poorly
captured latex particles (Figure 2.6 D). Collectively, these data show Batf3 deficiency results in
an inability to respond to homeostatic cytokines, such as Flt3L, and inflammatory stimuli,
indicating a terminal maturation defect.
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Figure 2.6: Exogenous Flt3 ligand and TLR stimulation fails to rescue Batf3-/(A) Mice treated with 10 mg Flt3L (Flt3L) or PBS (CTL) and DCs analyzed on day 8. Data are
representative of 3 mice per group. (B) DC evaluated by additional surface markers. (C) Mice
treated with 50 mg of polyI:C, 20 mg of LPS, 5 nmol of CpG-B or PBS (CTL). Analysis at 42
hours. (D) Mice treated with 200 mL of 0.3% solution of Fluoresbrite Plain YG 1mm latex
beads. DCs were analyzed for bead uptake after 1 hour. Shown are the percentage of cDCs
positive for phagocytosis of latex beads as determined by fluorescence in FL1, with background
determined by fluorescence of cells from mock injections.
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2.3.7

Batf3 is not required for development of the MDP, CDP or pre-cDC
To further establish the stage-specific actions of Irf8 and Batf3, we determined the

expression pattern of various transcription factors in progenitor populations (Figure 2.7 A). Irf8
expression increases significantly from the GMP or CMP to the CDP stage, after which it is
maintained in BM pre-cDCs and CD8α+ DCs, but extinguished from CD8α- DCs. In contrast,
Batf3 expression is low in progenitors, but high in mature CD8α+ and CD8α- DCs. Conversely,
other transcription factors important for DC development, such as E2-2, Sfpi1, or Irf4, are
expressed as early as the CMP, CDP or pre-cDC, respectively. Interestingly, the expression of
RelB and Id2 is induced in mature DC subsets similarly to Batf3. The relatively late expression
of Batf3 in DC development lead us to hypothesize that defects seen in Batf3-/- mice are unlikely
to be caused by cellular changes at the CDP or pre-cDC stage.
To test this hypothesis, we quantified DC progenitors from WT, Batf3-/-, Irf4-/-, and Irf8-/mice (Fig. 2B, Fig. S3). Ifr8-/- mice and mice homozygous for the Irf8R294C mutation 35 both
show a 4-5 fold reduction in BM pre-cDCs (Figure 2.7 B), suggesting an early role in DC
development 44. In contrast, Batf3-/- and Irf4-/- mice have normal numbers of BM pre-cDCs
(Figure 2.7 B), MDPs and CDPs (Supplementary Figure 2.4), and spleen-resident pre-cDCs
(Figure 2.7 C). Batf3-/- pre-cDCs also showed normal competitive fitness in mixed chimeras
generated from WT and Batf3-/- bone marrow (Figure 2.7 D). Finally, gene expression
microarray analysis of CDPs and BM pre-cDCs from WT and Batf3-/- mice revealed few genes
where expression changed in the absence of Batf3 (Figure 2.7 E, Table 1). In summary, Batf3 is
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expressed late during cDC development and does not influence development or gene expression
in the CDP or BM pre-cDC.
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Figure 2.7: pre-cDC homeostasis is Irf8 dependent but Batf3 independent
(A) GMP, CMP, CDP, BM pre-cDC, and splenic CD8α+ and CD8α- DCs were purified as shown
in Fig. S3 and mRNA extracted. Microarray analysis performed as described in the Methods.
Shown is a heat map for the relative expression levels of various transcription factors. (B)
Shown are the numbers of pre-cDCs as a percentage of total BM cells from indicated mice. Error
bars represent standard error of the mean for at least 5 mice per group. (C) Shown are the
frequency of spleen-resident pre-cDCs. Error bars represent standard error of the mean, and p
value for unpaired Student's t test for at least 5 mice. (D) Mixed BM chimeras were generated as
described in Methods. After 8 to 12 weeks, chimerism for CD45.1 and CD45.2 was determined
in splenic pre-DCs. Shown is the percentage of CD45.2 chimerism as a percentage of total
splenic pre-cDCs. (E) Microarray analysis for CDP and BM pre-cDCs as indicated for WT and
Batf3-/- mice. Shown are M-plots from WT and Batf3-/- microarrays. Indicated are probe sets
expressed at least 3.0 fold higher (red) or lower (blue) in WT relative to Batf3-/- cells.
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2.3.8

Batf3-/- CD24+ Sirp-α - cDCs fail to develop into mature CD8α + cDCs.
Given that Irf8 expression is extinguished from the pre-cDC to the CD8α- cDC, one

explanation of a dual requirement for Irf8 and Batf3 in CD8α cDC development is that Irf8
+

expression eventually becomes dependent on Batf3. In such a model, CD8α-committed DCs
develop, but begin to lose Irf8 expression in Batf3-/- mice, possibly explaining the complete
absence of CD24+ Sirp-α- cDCs in Irf8-/- mice but only a reduction in Batf3-/- mice.
Alternatively, Batf3 may act independently of lineage commitment to regulate the survival or
maturation of CD24+ Sirp-α- cDCs into functional CD8α cDCs.
+

To distinguish these possibilities, we first measured Irf8 expression by intracellular
staining in CD8α+ and CD8α- cDCs. In WT and Batf3-/- mice, Irf8 was normally expressed in
CD8α+ cDCs, but not in CD8α- cDCs, in all lymphoid tissues (Figure 2.8 A, Supplementary
Figure 2.5 A). Furthermore, CD8α+ cDCs from WT and Batf3-/- mice expressed equivalent
levels of Irf8 mRNA (Figure 2.8 B). However, Batf3-/- CD8α+ cDCs expressed higher levels of
CD11b and lower levels of CD103 than WT CD8α+ cDCs in both spleen (Figure 2.8 C) and
lymph nodes (Supplementary Figure 2.5 B ). In contrast, no alteration in CD11b or CD103
expression was observed in Batf3-/- CD8α- cDCs (Figure 2.8 C, Supplementary Figure 2.5 C).
Interestingly, Batf3-/- CD8α+ cDCs expressed slightly higher levels of Irf4, and failed to induce
wild-type levels of key effector genes, such as Clec9a, Xcr1 and Tlr3 (Figure 2.8 D). These data
suggest that Batf3 regulates the maturation of an Irf8-positive, CD24+ Sirp-α- population into
bona fide CD8α+ cDCs.
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Figure 2.8: Batf3 regulates the terminal maturation of CD8α+ DCs
(A) Splenic DCs analyzed for Irf8 protein levels. Shown are histograms for intracellular Irf8
levels. (B) DCs from spleen purified from WT (black bars) or Batf3-/- mice (open bars). mRNA
was converted into cDNA, and Irf8 expression was measured by quantitative RT-PCR (qRTPCR). Shown is the relative Irf8 expression normalized by HPRT expression as described in the
Methods. (C) Shown are histograms for CD11b or CD103 expression for indicated DC subtypes.
(D) DCs isolated from (B) were analyzed for expression of Irf4, Clec9a, Xcr1 and Tlr3 by qRTPCR. Shown is the normalized expression of the indicated gene in WT (black bars) or Batf3-/cDCs (open bars). (E) Microarray analysis of cells from (A). Expression of the indicated
transcription factors (left panel) and growth/survival genes (right panel) is shown as a ratio of the
value in Batf3-/- CD8α+ DCs relative to WT controls. Bars represent standard error of the mean
for 3 biological replicates and a p value from an unpaired Student's t test for (B) and (D).
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Finally, gene expression microarray analysis of CD8α+ cDCs from C57BL/6 WT and
Batf3-/- mice identified a number of genes for which expression either increased or decreased by
the loss of Batf3 (Figure 2.8 E). Expression of the transcription factors Ehf and Irf4, which are
normally restricted to CD8α- cDCs, increased by 7 to 8 fold in Batf3-/- CD8α+ cDCs. Likewise,
the factor Pbx1, normally restricted to CD8α+ cDCs, was reduced several fold in Batf3-/- CD8α+
cDCs. Several genes related to cell growth or survival were also decreased in Batf3-/- CD8α+
cDCs (Figure 2.8 E, right panel), including Rasgrp3 76,77 and Plce1 78. However, we find that
CD8α+ cDCs developed normally in both Rasgrp3-/- and Plce1-/- mice (Supplementary Figure 2.6
E), indicating that these Batf3 target genes alone are dispensable for normal CD8α+ cDC
homeostasis.

2.3.9

BATF3 regulates the survival of CD8α-committed cDCs.
Our results indicate that Batf3 acts after an Irf8-dependent commitment step to promote

functional maturation. Besides regulating CD8α+ cDC-specific genes (Clec9a, Tlr3, Xr1), Batf3
also regulates genes putatively involved in the proliferation or survival of the immature CD24+
Sirp-α- progenitor cells. To test this idea, we assayed C57BL/6 WT and Batf3-/- mice for in vivo
proliferation and turnover. Surprisingly, Batf3-/- CD24+ Sirp-α cDCs showed an increased
−

fraction of non-quiescent cells relative to WT CD24+ Sirp-α cDCs as measured by Ki67 staining
−

(Figure 2.9 A, left panels, and 9 B). In agreement, Batf3-/- CD24+ Sirp-α cDCs had a 2-fold
−

increase of cells in S/G2/M phase of the cell cycle compared to WT counterparts (Figure 2.9 A,
middle panels). Analysis of in vivo BrdU labeling also revealed a 2-fold increase in the rate of
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incorporation at 4 hours by Batf3-/- CD24+ Sirp-α cDCs relative to WT CD24+ Sirp-α cDCs.
−

−

Interestingly, BrdU incorporation was similar in WT and Batf3-/- CD24+ Sirp-α cDCs when the
−

labeling pulse was extended to 24 hours (Figure 2.9 C). The increased BrdU incorporation in
Batf3-/- CD24+ Sirp-α cDCs at 4 hours argues against a role for Batf3 in cellular proliferation per
−

se. Combined with the normalization in BrdU incorporation by 24 hours, the results indirectly
suggest a role for Batf3 in regulating survival.
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Figure 2.9: Batf3 regulates survival of CD8α+ DCs
(A) Proliferation of splenic pre-cDCs from wild type (WT) or Batf3-/-. Shown are histograms of
splenocytes for expression of Ki67 (solid lines), 7-Amino-actinomycin D (7AAD) staining, or
BrdU incorporation (BrdU) as indicated and described in the Methods. Background staining for
Ki67 expression was determined using an isotype control antibody (dashed lines). For BrdU
incorporation, background was determined using cells from untreated mice. Numbers represent
the percentage cells within the indicated gates. (B) Percentage of DCs positive for Ki67+
defined by gating in (A). Bars represent the standard error of the mean for groups of at least 5
mice, and p the value for an unpaired Student's t test. (C) Percentage of DCs that are BrdU+
defined by gating in (A) for WT (closed) or Batf3-/- (open bars) mice treated with BrdU for
either 4 hr or 24 hr as indicated. Error bars represent SEM for groups of at least 5 mice, and p
the value for an unpaired Student's t test. For 24 hr treatments, mice were housed with water
supplemented with 0.8 mg/ml BrdU. (D) Mean BrdU incorporation as a percentage of BrdU+
cells for indicated populations from WT (red) and Batf3-/- mice (blue). (E) Mixed BM chimeras
as described in Methods. After 8-12 weeks, the relative contribution by CD45.1 and CD45.2
cells to the indicated DC population was analyzed. Shown is CD45.2 chimerism as a percentage
of total DCs.
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To test survival directly, we performed a BrdU pulse-chase assay to compare the in vivo
half-life of different DC populations between WT and Batf3-/- mice (Figure 2.9 D). The reported
in vivo half-life of CD8α cDCs is approximately three days 79,80. Consistent with this estimate,
+

we find that WT CD24+ Sirp-α cDCs have a half-life of approximately three days (Figure 2.9 D,
−

left panel, red line), while the half-life of Batf3-/- CD24+ Sirp-α cDCs was approximately 36
−

hours. This reduction in half-life was specific to CD24+ Sirp-α cDCs, as no difference in half−

life of CD24- Sirp-α cDCs between WT and Batf3-/- mice was observed (Figure 2.9 D, right
+

panel).
We independently tested for a fitness defect using competitive mixed-BM chimeras. We
observed that CD45.2+ Batf3-/- BM contributed to about 10-20% of the total CD24+ Sirp-α

−

cDCs, whereas CD45.2+ WT BM consistently gave rise to about 50-60% of CD24+ Sirp-α cDCs
−

in SPL, MLN, and THY (Figure 2.9 E). Notably, in the ILN, we observed a small but
statistically significant difference in chimerism for CD24+ Sirp-α cDCs between WT and Batf3-/−

BM (Figure 2.9 E). This reduction was specific for CD24+ Sirp-α cDCs, as no difference in
−

chimerism for CD24- Sirp-α cDCs between WT and Batf3-/- BM was observed in any lymphoid
+

compartment (data not shown). These results support the idea that Batf3 regulates survival after
an initial Irf8-dependent lineage commitment step.
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2.4

Discussion
The major advance of this study is to draw a clear distinction between the roles of Irf8

and Batf3 in the development of CD8α+ cDCs. We find that the CD24+ Sirp-α cDC population
−

fails to develop at all in the absence of Irf8. However, these committed progenitor cells develop
in Batf3-/- mice, although at reduced frequency and with a shortened half-life, and they fail to
induce genes characteristic of mature CD8α+ cDCs. This distinction between the actions of
these factors will be important in moving forward to define the molecular basis of their effects.
The decreased half-life and reduced population size of Batf3-/- CD24+ Sirp-α cDCs is
−

likely a consequence of the greatly reduced half-life of CD8α-commited cDCs. The increase in
labeling of Batf3-/- CD24+ Sirp-α cDCs by Ki67, 7AAD, and BrdU may at first seem
−

paradoxical. Yet in light of the shorter half-life observed for Batf3-/- CD24+ Sirp-α cDCs, we
−

conclude that the absence of Batf3 results in an Irf8-expressing, CD8α-committed population,
which remains functionally immature and undergoes rapid proliferation and turnover. Consistent
with this idea, we observe a significant reduction in the expression of CD8α+ cDC-specific
genes, such as Clec9a, Xcr1, and Tlr3, and genes involved in cell growth and survival. While
these genes are candidates for Batf3-dependent transcription, the small size of cDC populations
currently poses a technical challenge for identifying direct interactions of Batf3 with loci by
techniques such as chromatin immunoprecipitation.
In summary, we have distinguished the roles of Irf8 and Batf3 in CD8α+ cDC
development. Irf8 is strictly required for generation of immature CD24+ Sirp-α cDCs, whereas
−

Batf3 influences their survival and maturation into mature DCs. Identification of direct targets
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of Batf3 transcriptional activity will be an important next step in understanding its mechanisms.
It will also be important to understand how Batf3 promotes survival of CD8α cDCs but not
+

CD8α cDCs. Finally, it is intriguing that the Batf3-dependence of CD8α cDCs can vary with
−

+

genetic background and anatomic site. Conceivably, an alternative Batf3-independent pathway
of cell survival is operative within the skin-draining lymph nodes, which is absent in mesenteric
lymph nodes where CD8α+ cDC development is strongly Batf3-dependent. Identification of
such a Batf3-bypass pathway could provide insights to improve the effectiveness of CD8 T cell
vaccines.
Table 2.1: Batf3 is dispensable for DC progenitor gene expression
WT CDP / KO CDP
Gene symbol
Erdr1
Mid1
1700112E06Rik
Hmga2
Dntt
Ctla2a
Hmga2
Batf3
Cmah
Ets1
Ctla2a
Gimap6
Myl10
Hmga2
Gimap8
Ctla2b
Mn1
Slc35d3
Il7r
Angpt1
Ptpn22
Hlf
Hspa1b
A030001D16Rik
Lcn2
Ddit4
Per1
Pira2
Hmga2-ps1
Igl, Igl-C1, Igl-V1
Igl-V1
Camp
S100a8
S100a9
Chi3l3
Ngp
Ifi202b
Igk-V32

WT pre-cDC / KO pre-cDC
Gene symbol

Fold change
71
36
10
6.0
5.1
4.9
4.8
4.7
4.5
4.4
4.2
4.1
3.9
3.7
3.7
3.6
3.5
3.4
3.4
3.3
3.2
3.1
3.0
3.0
0.3
0.3
0.3
0.3
0.3
0.2
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.1

Fold change

Erdr1
Mid1
Hspa1b
Hspa1a
Batf3
Msn
Golph3
Zwint
Card11
S100a9
Acaa2
Ywhaz
Syne2
Slc29a1
Wdfy1
Klf9
Igh-2, Igh-VJ558
5830436I19Rik
H2-gs10, H2-Q6
Ier3
Per1
Socs3
Ptgs2
Ddit4
Rasgrf2
Socs3
Fam84b
Igk, Igk-C, Igk-J1, Igk-V28
Igh-2, Igh-VJ558
Igh-2, Igh-VJ558
2010205A11Rik
Igk, Igk-C, Igk-J1, Igk-V28
6030422H21Rik
Ifi202b

46
14
11
9.4
4.2
4.0
3.6
3.6
3.4
3.3
3.3
3.1
3.1
3.0
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.2
0.2
0.2
0.2
0.2
0.2
0.1
0.1
0.1
0.1
0.1

CDP and BM pre-cDCs from WT and Batf3-/- mice (KO) mice were purified by cell sorting, total
RNA prepared, and gene expression microarray analysis performed using Affymetrix Mouse
Genome 430 2.0 arrays. Shown are the fold change for the indicated genes as a ration of the
expression value in WT CDP to the expression value in KO CDP (WT CDP/ KO CDP) (left
column), or WT pre-cDC to the expression value in KO pre-cDC (WT pre-cDC / KO pre-cDC).
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Supplementary Figure 2.1: Gating strategy for classical DCs
(A-D) Cells were harvested from spleen (SPL) (A), inguinal lymph nodes (ILN) (B), mesenteric
lymph nodes (MLN) (C), or thymus (THY) from wild type, Batf3-/- or Irf8-/- C57BL/6 mice as
indicated and analyzed by FACS as described in the Methods.
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Supplementary Figure 2.2: Batf3-/- mice retain a residual populations of DCs that resemble
CD8α+ DCs
Cells were harvested from SPL, ILN, MLN or THY as indicated from WT or Batf3-/- 129SvEV
background mice. Shown are two parameter histograms.
B

A

129SvEv

Flt3L

p=0.002

WT

0

2

28%
10

10

3

10

4

10

5

CD24+ cDCs (%)

45%

p=0.009

10
5
0

Batf3-/-

150 ng/ml

50 ng/ml

C57BL/6
10

2

10

0.3%

Irf8

CD24

-/-

Sirp-a

3

10

4

10

50

5

CD24+ cDCs (%)

0

p<0.0001

40

p=0.003

30
20
10
0

150 ng/ml

50 ng/ml

Supplementary Figure 2.3: Flt3 ligand stimulation fails to expand CD24+SIRPα- DCs in
Batf3-/- mice
(A) BM cells from C57BL/6 and 129SvEv WT and Batf3-/- mice were harvested and cultured
at the indicated concentrations of recombinant Flt3L for 10 days. Non-adherent cells were
harvested and stained for DC analysis. BM cells from C57BL/6 Irf8-/- mice were also
included. (B) Shown is the relative quantitation of CD24+SIRPα- DCs at the indicated
concentrations of Flt3L. Numbers represent percent of cells in the cDC gate. Data are
representative of three independent experiments.
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Supplementary Figure 2.4: Pre-cDC analysis in Irf8-/- and Batf3-/- mice
BM cells were gated as Lin-CD16/32-Sca-. MDPs (R1), pre-cDCs (R2), and CDPs (R3)
are shown.
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Supplementary Figure 2.5: Batf3-/- DCs induce Irf8 but fail to repress CD11b or
induce CD103
(A) ILN and MLN were harvested from C57BL/6 WT or Batf3-/- mice and analyzed by
FACS. Histograms for IRF8 levels in DCs gated either as CD24+Sirpα- Dec205+ CD8α+
DCs (CD8α+, solid lines) or CD24-Sirpα+ Dec205-CD8α- (CD8α-, dashed lines). (B-C)
Histograms for CD11b or CD103 expression for WT (solid lines) or Batf3-/- (dashed
lines) mice.
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Supplementary Figure 2.6: Rasgrp3 and Plce1 are dispensable for CD8α+ DC
development
Splenocytes were harvested from C57BL/6 WT, Rasgrp3-/- (A) or Plce1-/- mice (B) and
analyzed by FACS. Histograms for cells previously gated as CD11c+MHCII+B220- to
identify DCs (left panels). Two color histograms for CD11b and Dec205 (right panels)
are shown for cells in the CD24+ Sirp-α- gate from the left panel. Numbers represent
the percentage of cells in the indicated gate.
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2.5

Materials and Methods

2.5.1

Mice
Wild-type 129S6/SvEv mice were purchased from Taconic. Wild-type C57BL/6 mice

and the congenic strain B6.SJL were purchased from The Jackson Laboratory. Batf3-/- mice on
either 129S6/SvEv or C57BL/6 backgrounds have been previously described 7,68. Irf8-/- mice 40
were obtained from the European Mutant Mouse Archive and maintained in our animal facility.
BXH2/TyJ mice carrying a point mutation in exon 7 of Irf8 resulting in an Arg to Cys change at
amino acid position 294 39 were purchased from The Jackson Laboratory. The mice were then
backcrossed to the C57BL/6 background for 10 generations and maintained as homozygous
mutants. Irf4 conditional (floxed) mutant mice 34 were purchased from The Jackson Laboratory
and subsequently germline deletion was generated by crossing floxed mice to transgenic CMVCre mice (B6.C-Tg(CMV-Cre)1Cgn/J) (also purchased from The Jackson Laboratory).
Generation of Rasgrp3-/- mice and Plce1-/- mice have been previously described 77,78.
Experiments were performed with sex- and age-matched mice at 6-20 weeks of age. Mice were
bred and maintained in our specific pathogen-free animal facility according to institutional
guidelines.

2.5.2

Antibodies and flow cytometry.
Staining was performed at 4°C in the presence of Fc block (clone 2.4G2, BD

Biosciences) in FACS buffer (PBS, 0.5% BSA, 2 mm EDTA) The following antibodies were
purchased from BD Biosciences: V450 and PerCP-Cy5.5 anti-NK1.1 (PK136), V450 antiLy6C/G (RB6-8C5), V450 anti-Ly6C (AL21), V500 anti-B220 (RA3-6B2), PE-Cy7 anti-CD8α
66

(53-6.7), PE-Cy7 anti-CD24 (M1/69), PerCP-Cy5.5 anti-Ly6G (1A8), FITC and APC antiCD172a/Sirpα (P84), APC anti-CD4 (RM4-5). These antibodies were purchased from
eBioscience: PE anti-NKp46 (29A1.4), PerCP-Cy5.5 anti-CD11b (M1/70), APCeFluor780 antiCD11c (N418), PE anti-CD103 (2E7), APC anti-CD317/BST2 (eBio927), eFluor450 antiMHCII (I-A/I-E) (M5/114.15.2), FITC and APC anti-CD45.2 (104), PE-Cy7 and PerCP-Cy5.5
anti-CD45.1 (A20), PerCP-Cy5.5 anti-CD16/32 (93), PE-Cy7 anti-cKit (2B8), eFluor450 antiCD105 (MJ7/18), eFluor450 anti-Ter119, PE anti-CD135 (A2F10), Alexa700 anti-Sca1 (D7),
FITC, APC and PerCP-eFluor710 anti-SiglecH (eBio440C), eFluor450 anti-Ter119 (Ter119),
biotin anti-CD115 (AFS98). These antibodies were purchased from Miltenyi: PE antiCD205/Dec205 (NLDC-145) and APC anti-CD205/Dec205 (NLDC-145). These antibodies
were purchased from Invitrogen: APC anti-F4/80 (BM8), PE anti-B220 (RA3-6B2), FITC and
APC anti-CD8α (5H10).

2.5.3

Intracellular Irf8 staining.
Cells were stained for surface markers, then fixed and permeabilized with Foxp3 Staining

Buffer Set (eBioscience) according to manufacturer's instructions. Next, samples were incubated
with unconjugated goat anti-Irf8 antibody (clone C-19, Santa Cruz Biotechnology) in 1X
Permeabilization Buffer (Foxp3 Staining Buffer Set) for 30min at 4ºC. After washing, cells were
incubated with FITC-conjugated donkey anti-goat F(ab')2 (Jackson ImmunoResearch
Laboratories, Inc.) in 1X Permeabilization buffer for 30min at 4ºC, washed and analyzed by flow
cytometry. Background staining was determined by the signal from Irf8-/- cells.
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2.5.4

DC preparation.
Lymphoid organ dendritic cells were harvested and prepared as described 8,69. Briefly,

spleens, ILNs (inguinal), MLNs, and thymus were minced and digested in 5 ml Iscove’s modified
Dulbecco’s media + 10% FCS (cIMDM) with 250 µg/ml collagenase B (Roche) and 30 U/ml DNase
I (Sigma-Aldrich) for 30 min at 37°C with stirring. Red blood cells were lysed with ACK lysis
buffer. Cells were counted on a Vi-CELL analyzer, and 5–10x106 cells were used per antibody
staining reaction.

2.5.5

Bone marrow cultures.
Bone marrow cells from femurs and tibias were collected and red blood cells were lysed

in ACK lysis buffer. Cells were cultured in cIMDM in six-well plates at 2×106 cells/ml
containing either 150 ng/ml or 50 ng/ml murine Flt3L (Peprotech). Non-adherent cells were
collected at day nine or ten for flow cytometry analysis.

2.5.6

Generation of mixed bone marrow chimeras.
BM cells from wild-type C57BL/6 mice (CD45.2), wild-type congenic B6.SJL (CD45.1),

and C57BL/6 Batf3-/- mice (CD45.2) were collected from the femur and tibia. Cells were
counted, and 5x106 cells from CD45.1 B6.SJL mice were mixed with either 5x106 cells from
wild-type CD45.2 mice or 5x106 cells from Batf3-/- CD45.2 mice. A total of 107 BM cells were
then transplanted by intravenous injection (tail vein) into B6.SJL (CD45.1) recipient mice that
received 11 Gy whole body irradiation on the previous day. Chimeras were analyzed at eight to
twelve weeks after transplant.
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2.5.7

Cell proliferation assays.
For BrdU-incorporation studies, mice were injected intraperitoneally (i.p.) with 2mg

BrdU (Sigma) in saline and then given 0.8mg/ml BrdU in sterile drinking water. Splenocytes
were harvested at 4 hours and 24 hours following BrdU administration. For BrdU-chase studies,
mice were kept on BrdU-containing drinking water (made fresh and changed daily) continuously
for 10 days and then transferred to normal drinking water for either 24, 48, or 72 hours. BrdU
staining was performed with FITC BrdU Flow Kit (BD Pharmingen) following cell-surface
staining. In all BrdU studies, background was determined by cells from untreated mice. For
detection of Ki67, cells were stained for surface markers, and then fixed and permeabilized with
the FITC BrdU Flow Kit (BD Pharmingen) according to manufacturer's instructions. Cells were
then stained with anti-Ki67 antibody (clone B56) or an isotype control from the FITC or PE
Mouse Anti-Human Ki-67 Set (BD Pharmingen). To determine cell-cycle phase, dendritic cells
were first enriched with CD11c MicroBeads (Miltenyi Biotec) and then surface markers were
stained. Cells were then fixed and permeabilized with Foxp3 Staining Buffer Set (eBioscience)
for 1hr at 4ºC. After washing, cells were incubated for 30min with 7AAD solution (BD
Pharmingen) and then analyzed on a BD FACS CANTO II (BD Biosciences). During analysis,
event rate was maintained at 300-400 events per second on the lowest flow rate to ensure doublet
exclusion.

2.5.8

Statistical Analysis.
Differences between groups were analyzed by an unpaired, two-tailed Student's t-test,

with p values less than or equal to 0.05 considered significant (GraphPad Prism, GraphPad
Software, Inc.).
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Chapter 3 BATF3-IRF8 complexes direct transcription of CD8α DC-specific genes

3.1 Abstract
Considerable progress has been made toward identifying homeostatic cytokines, defined
lineage-restricted progenitors, and developmentally important transcription factors for the
dendritic cell lineage. Yet the precise molecular mechanism underlying DC specification and
functional specialization is still poorly understood, and most studies to date remain largely
descriptive on these topics. Numerous studies across disparate cell lineages in eukaryotes have
concluded that much of the active gene expression program is dominated by a small number of
the many transcription factors expressed 1-4. Similarly, CD8α+ DC development and function is
regulated by a small set of factors, namely Irf8, Batf3, Nfil3, and Spi1 (PU.1)5-7. The molecular
activities and possible cooperative interactions of among some of these factors remain poorly
characterized, and studies focusing on these aspects of DC biology represent a major priority in
the field.
The recent identification of a genomic regulatory element that is recognized by AP-1-IRF
complexes8-10, which can direct large components of lymphocyte gene expression, led us to
hypothesize that a similar mechanism regulates lineage commitment and functional
specialization of CD8α+ DCs. Though evidence of AP-1-IRF interactions in DCs was presented,
the studies focused on in vitro GM-CSF-derived DC subsets that poorly represent actual DC
subtypes in vivo and have no reported phenotypes in the setting of Batf3 deficiency11-13.
Moreover, these examples provided few insights into the possible role of BATF3-IRF8
complexes in the regulation of bona fide CD8α+ DC gene targets. By pairing genome-wide
measurements of protein-DNA interactions with transcriptome profiling, we have determined
that BATF3-IRF8 complexes occupy the proximal promoter regions and distal conserved non77

coding sequences (CNS) of a large number of CD8α+ DC-specific genes. The loss of Batf3
impaired the CD8α+ DC-specific gene expression program, thereby suggesting that the role of
AP-1-IRF complexes is to regulate the selective gene expression program of this lineage.
Importantly, this indicates that the combination of PU.1 and IRF8 is insufficient for specifying
the totality of CD8α+ DC-specific gene expression program. This result is somewhat surprising
because PU.1 is known to bind globally to enhancers and promoters. In addition, PU.1 and Batf3
are expressed at equal levels between CD8α+ DCs and CD11b+ DCs, thereby being insufficient
to regulate specific gene expression differences between the two populations. Instead, it is the
combination of the three factors that appears to be necessary and sufficient to induce lineage
specific expression module. The relatively high expression of PU.1 in DCs and near absence in
CD4+ T cells represents an important difference and warrants further investigation.
We characterized several direct targets of AP-1-IRF complex by analyzing knockout
mice when available or performing overexpression rescue experiments on in vitro Flt3L cultures.
Since no single gene target recapitulated the Batf3-/- developmental phenotype, we suggest that it
is the combination of several genes involved in cell signaling, growth and survival that account
for the observed deficits. Our previous work identified a compensatory developmental pathway
for CD8α+ DCs that required the paralogs Batf and Batf2 during settings of type I immunity 8.
Though this pathway accounted for the reemergence of CD8α+ DCs in the skin-draining lymph
node, it failed to restore the development of peripheral tissue CD103+ DCs. These data suggest
that despite sharing many features (ontogeny, high cross-presentation capacity, requirement for
similar cytokines and transcription factors), the CD103+ DCs and CD8α+ DCs have differential
homeostatic requirements. We sought to account for this by identifying determinants that acted
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differentially between these two related populations. Interestingly, we observed occupancy of
BATF3-IRF8 complex at several well characterized microRNA clusters and found that miR-155
was important for the homeostasis of peripheral CD103+ DCs but largely dispensable for splenic
CD8α+ DCs. miR-155 is a unique microRNA that functions primarily in the hematopoietic
compartment in which it regulates many aspects of lymphocyte activation and development 14.
Although purported to affect DC function (at least in vitro derived DCs), miR155 has not been
implicated in DC development until now. We hypothesize that miR155 may also play a role in
CD8α+ DCs following activation.
Lastly, de novo motif analysis revealed that both BATF3- and IRF8-enriched regions
were near Ets (i.e., PU.1) elements, which is to be expected given that PU.1 is known to interact
with both AP-1 and IRF proteins15-17, and runt-related transcription factor 1 (Runx1) sites, which
has not been reported. The proximity of AP-1 and IRF complexes to Runx sites suggests that the
DC lineage is specified through the coordinated actions of AP-1, IRF, PU.1 and Runx proteins.
We propose to investigate the potential role of Runx proteins in regulating DC development.

3.2 Introduction
Jacob and Monod initially defined features of gene regulation nearly half a century ago
through pioneering studies of the Escherichia coli lac operon 18. This early work and subsequent
studies in higher organisms established the paradigm of DNA binding proteins (trans-factors)
recognizing specific sequences at regulatory genomic regions (cis-elements) to modulate
transcription. In higher organisms, the sequence-specific trans-factors recruit cofactors,
chromatin remodeling proteins, and elements of the general transcription apparatus to alter the
local architecture of the chromatin for productive transcription. Each step in the process is
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subject to tight control with positive and negative feedback loops operating to enforce either
activation or inhibition. In most cases, a combination of transcription factors bind to enhancer
elements and then form physical contacts with the core promoter through a process that involves
the looping of DNA 19. In some instances, the proximal promoter can be bound directly by the
very factors that also recognize enhancers 20. Collectively, these actions give rise to a cell’s
transcriptome, which comprises housekeeping genes or cell-type specific genes. The expression
of the latter set is largely regulated by a limited set of transcription factors, as evidenced by the
conversion between cell states with a relatively few factors. Therefore, understanding the
molecular basis of lineage specification in any developmental system requires the
characterization of key lineage-defining transcription factors.

3.2.1

Interferon regulatory factor (IRF) family
The interferon regulatory factor (IRF) family of transcription factors comprises nine

evolutionarily conserved members that play a critical role in host defense 21. Though the family
was initially identified in the context of type I interferon (IFN) signaling, it is now appreciated
that specific members can also influence development of myeloid and lymphoid lineages22,23.
All IRFs contain an N-terminal DNA binding domain, which forms a helix-turn-helix structure
and recognizes the IFN-stimulated response elements (ISRE, NGAAANNGAAACT) 24; and a Cterminal IRF association domain (IAD, except for IRF1 and 2) that mediates homo- and heterodimeric interactions with other transcription factors such as PU.1 and signal transducer and
activator of transcription (STAT) 25. IRF4 and IRF8 are more selectively expressed across
immune lineages and are the two members of the family that play a role in development 26-29.
IRF4 is an important mediator of lymphocyte differentiation and function 30,31. For example, it is
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required for plasma cell differentiation and class switch recombination. It is also required for the
development of helper CD4+ lineages 30,32. Although its activities are comparatively less well
known in the myeloid lineages, IRF4 is known to influence the development of CD11b+ DCs in
lymphoid and peripheral tissues 33-35. However, most studies on the actions of IRF4 in DCs have
been largely descriptive. IRF8 also plays a role in B cell differentiation and may provide
functional redundancy in the absence of IRF4 22. In the macrophages and DCs, IRF8 may
function as either an activator or repressor depending on its association with interacting partner
proteins 29,36. IRF8 deficiency in both mouse and man results in widespread immunodeficiency
and the absence of multiple dendritic cell lineages37. Both of these IRF proteins are known to
bind the ISREs weakly and instead bind to DNA through cooperative interactions with partner
proteins such as PU.1 on Ets-IRF composite elements (EICEs). However, the broad
transcriptional activities of IRF4 and IRF8 cannot be simply explained by interactions with
PU.19,10.

3.2.2

Activated protein 1 (AP-1) family
Basic leucine zipper transcription factor, ATF-like 3 (BATF3) is a member of the ATF

subfamily of transcription factors, which also includes BATF, BATF2, JDP2, and ATF3 and is
part of a larger class of basic leucine zipper (bZIP) transcription factors38-40. These proteins
contain an N-terminal DNA binding region consisting of basic residues that form an α-helix and
a C-terminal heptad repeat of leucines that form the leucine zipper motif 41-43. The BATFs are
obligate heterodimers that pair with JUN family members through extensive contacts in the
leucine zipper. In addition, the leucine zipper has been proposed to mediate interactions with
other transcription factor families to combinations of factors that can recognize additional DNA
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elements. Interestingly, unlike the other bZIP proteins that dimerize with JUN (for example,
FOS or ATF3), BATF3 and BATF contain only the basic region and leucine zipper. This
parsimony in domain structure led to the idea that BATFs function by simply acting as dominant
negative forms of FOS-like proteins.
Unlike other member of the bZIP family, Batf3 and Batf expression is largely restricted to
the immune system. Batf is an important regulator of B and T cell function. It is required for
class switch recombination, follicular helper T cell development, induction of IL-17+ CD4 T
cells 44,45. Batf3 is required for the development of lymphoid-resident CD8α+ DCs and
peripheral tissue CD103+ DCs. Early studies of these two factors made extensive use of
overexpression and concluded that they function as inhibitors of AP-1 transcription. While the
inhibitory actions may occur in certain contexts, much of its unique actions can now be
explained by positive transcriptional regulation through interactions with IRF family members 46.

3.3 Results

3.3.1

BATF3 regulates the expression of CD8α + DC-specific genes
A recent large-scale transcriptome profiling of lymphoid-resident and peripheral tissue

DCs led to the identification of signature transcription factors and cell surface markers for each
DC subtype47,48. CD8α- DCs or CD11b+ DCs expressed high levels of the phagocytic receptor
SIRPα, which was completely absent from CD8α+ DCs or CD103+ DCs. We used this marker
in combination with other known CD8α+ DCs or CD103+ DCs (such as CD24 and CD205) to reanalyze Batf3-deficient mice in vitro and in vivo. Flt3L bone marrow cultures of Batf3-deficinet
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cells from the C57BL/6 genetic background contained a population of CD24+SRIPα- DCs
(Figure 3.1 A,B), which expressed significantly lower levels of CD103.
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Figure 3.1: BATF3 regulates the expression of CD8α+ DC-specific genes
(A,B) Flt3L (A) and splenic-derived (B) DCs from WT and Batf3-/- mice. (C, D) Population
gated in (A) and (B) were purified by cell sorting, RNA extracted and microarray analysis
performed. After background correction and normalization with Robust Multi-array Average
(RMA) method, probe sets with no known gene annotation and a linear expression value less
than 16 were removed before differential gene expression analysis. Shown is an M-Plot (C)
comparing the log 2 transformed expression values of genes different by at least 2-fold between
WT (y axis, n = 3 biological replicates) and Batf3-/- (x axis, n = 3 biological replicates) CD8α+
DCs (mean expression values were averaged from in vivo and in vitro derived DCs). Show in
(D) is a heat map generated with log2 transformed expression values for genes enriched by 4fold in WT (LEFT) or KO (RIGHT).
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Recently, several groups showed that surface CD103 expression can be induced by
PAMPs or cytokines such as GM-CSF 11,49-51; and the CD103+ fraction of CD24+SRIPα- DCs
represents a state that has higher cross-presentation capacity. Using slightly different markers
for labeling CD8α+ DCs in vivo, we observed a small but measurable population of
CD24+SIRPa- DCs (Figure 3.1 B). We sorted all three populations from WT and Batf3-/- mice
and carried out microarray analysis. We observed some 397 genes differentially expressed
between WT and Batf3-deficient DCs. Notably, we saw significant reduction in key cell-type
specific effector molecules, such as Xcr1, Tlr3, and Itgae (Figure 3.1 C and D). Also cellsignaling genes such as Rasgrp3, Clnk, and Plce1 were significantly reduced. In summary, we
conclude that BATF3 is necessary for the maximal expression of CD8α+ DC-specific effector
genes, and that it regulates the survival of CD8α+ DCs by positively regulating survival
promoting genes.

3.3.2

Generation of anti-BATF3 antibody
Chromatin immunoprecipitation followed by massively parallel sequencing (ChIP-Seq) is

an important technique for describing genome-wide occupancy of DNA-binding factors. The
unbiased nature of this approach and the high base-pair resolution can help identify previously
unappreciated interactions among different transcription factors 52,53. A major determinant in the
accuracy and depth of ChIP-Seq profiles is the quality of antibody. Extensive characterization
and validation are required before performing these experiments. We generated our own antiBATF3 antibody and validated it for chromatin immunoprecipitation.
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Batf3 was PCR amplified from a splenic CD11c-enriched cDNA library and cloned into
the bacterial expression construct pET-28a(+). The resulting vector was transformed into
expression competent E. coli and protein expression induced with low concentration IPTG at
room temperature for 12 hours. Initial efforts to affinity purify recombinant full-length BATF3
was unsuccessful because of inclusion body formation. An alternative method using the
detergents sarkosyl, Triton-X 100 and CHAPS has recently been described for solubilizing
proteins from inclusion bodies 54. We adapted this method and obtained relatively pure BATF3
(Figure 3.2 A). Rabbit anti-BATF3 serum was generated commercially (Harlan Labs) and antiBATF3 antibody was affinity purified. The specificity of our antibody stock was confirmed by
Western blot analysis of whole cell extracts of CD11c-enriched dendritic cells from wild type
and Batf3-deficient mice (Figure 3.2 B).
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Figure 3.2: Generation of anti-BATF3 antibody
(A) SDS-PAGE of recombinant BATF3 purification. (B) Westernblot analysis of whole cell
extracts from CD11c-enriched cells from WT and Batf3-/- mice. Top blot was probed with rabbit
polyclonal anti-BATF3; bottom blot was probed with mouse anti-β-actin. (C) Westernblot of
immunoprecipitated extracts from 3T3 fibroblasts stably expressing FLAG-tagged BATF3. Pull
down was performed with polyclonal anti-BATF3. Blot was probed with anti-FLAG antibody.
(D) Sonicated DNA on 2% agarose gel and stained with ethidium bromide. DNA was extracted
from Flt3L-derived DCs after chromatin cross-linking was reversed.

Next, we evaluated the reactivity of our affinity-purified anti-BATF3 on cross-linked
antigen, which is a necessary step in chromatin immunoprecipitation. We generated a line of
murine 3T3 fibroblasts stably expressing FLAG-tagged BATF3. Chromatin
immunoprecipitation was performed as previously described 55 with polyclonal anti-BATF3
antibody. Immunoblot analysis of the pulled-down product with a monoclonal anti-FLAG
antibody confirmed the reactivity of the polyclonal antibody to cross-linked antigen (Figure 3.2
C). Lastly, we sonicated cross-linked DC extracts to determine the optimal shearing time for
DC chromatin (Figure 3.2 D). In summary, we have generated a polyclonal BATF3 antibody
with specific reactivity to native and cross-linked BATF3.
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3.3.3

Genome-wide profiles of BATF3 and IRF8
We carried out chromatin immunoprecipitation with anti-BATF3 and anti-IRF8

antibodies on Flt3L-derived wild-type dendritic cell chromatin followed by sequencing. Control
immunoprecipitation was performed on Batf3- and Irf8-deficient DC chromatin to serve as
specificity controls for downstream data analyses. Raw sequencing data was aligned to the
mouse genome assembly version 9 (mm9) with Novoalign, and duplicate or unmapped reads
were removed for subsequent data processing steps. Model-based analysis of ChIP-Seq
(MACS)56 is a widely used computation tool for peak calling or discovery. We identified
statistically significant BATF3 and IRF8-occupied regions or peaks – 12894 IRF8 peaks and
9471 BATF3 peaks (Figure 3.3 A). We then compared then compared the overlap between IRF8
and BATF3 peaks. This was done by first extending the summit of each peak or presumed
binding point by the computationally determined average fragment length size. Next, we
intersected the genomic coordinates for summit-extended reads and obtained 5523 peaks. In
summary, a large fraction of IRF8 and BATF3 peaks are overlapping (Figure 3.3 D).
Interestingly, when we analyzed the read density around a 4 kilobase window across promoters
of all protein-encoding genes, the greatest coverage (and therefore supposed binding of each
factor) appeared to be around the immediate transcription start site (Figure 3.3 B and C)
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Figure 3.3: Genome-wide profiles of BATF3 and IRF8 binding
(A) Annotation (performed with HOMER software package) of IRF8 and BATF3 peaks, as
determined by MACS. Also included is an annotation of peak regions common to both BATF3
and IRF8. (B,C) Coverage or read density over a 4 kilobase region centered on the transcription
start site of all protein-coding genes. IRF8 (B) and BATF3 (C). (D) Average distance from an
IRF8 peak to its nearest BATF3 peak. Peak distances have been grouped into 7 size ranges.

3.3.4

Composite Ets-IRF (EICE), composite AP-1-IRF (AICE) and Runx sites are

enriched at regions occupied by IRF8 and BATF3
Although consensus recognition elements have been described for IRF8 and BATF3, the
ISRE and AP-1 motifs, respectively, de novo motif discovery affords an opportunity to identify
novel recognition sequences that may help characterize previously unappreciated interactions.
We used the HOMER57 software package to perform de novo motif discovery on the top 500
enriched peaks for BATF3 and IRF8 (executed 3 separate instances). As anticipated, analysis of
IRF8 peaks identified EICE as the top motif. This analysis also found significant enrichment for
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the recently described composite AP-1-IRF site (AICE). Notably, IRF8 peaks were enriched for
AP-1 and Runx motifs (Figure 3.4 A). Interestingly, an almost identical list of motifs was
generated from the analysis of BATF3 peaks (Figure 3.4 B). And yet there is no known
interaction between Runx proteins and IRF or AP-1 factors. We therefore propose to extend the
conclusions derived from the recent analyses on the interaction of IRF and AP-1 proteins by
ChIP-Seq by suggesting that Runx may also be involved in the gene expression program of DCs.
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Figure 3.4: de novo motif analysis of BATF3 and IRF8 enriched peaks
(A, B) IRF8 (A) and BATF3 (B) peaks evaluated for de novo motif discovery with HOMER
software package as described in the Methods. Top 4-6 DNA motifs empirically derived along
with the closest known motif and the associated p-value from analysis.
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3.3.5

IRF8 and BATF3 co-occupy the proximal promoter region of signature CD8α + DC

genes
CD8a+ DCs are the critical initiators of CD8 T cells responses to a diverse set of
intracellular pathogens 58, but they can also mount responses to non-infectious threats such as
tumors. This highly specialized function is in part due to the expression of unique viral and host
sensors (such as Tlr3 and Clec9a) and chemokine receptors (such as Xcr1). To date, little is
known about the regulation of these important effector molecules. We identified an almost
identical binding pattern of IRF8 and BATF3 at the proximal promoter of Tlr3, Clec9a, and Xcr1
(Figure 3.5). The co-occupancy of IRF8 and BATF3 suggests that a cooperative interaction
between these two factors drives the cell-type specific expression of Tlr3, Clec9a, and Xcr1. We
also performed gene annotation analysis of IRF8 and BATF3 ChIP-Seq peaks with HOMER and
discovered the presence of a BATF3-dependent IRF8 peak in the promoter region of microRNA
155 (miR155), which mediates broad actions throughout the hematopoietic compartment. We
hypothesized miR155 plays a role in the homeostasis of DCs. In a preliminary analysis (data not
shown), we observed a 50% reduction in lung CD103+ DCs but no reduction in spleen-resident
CD8a+ DCs. Thus, miR-155 maybe differentially required between the closely related peripheral
CD103+ DCs and lymphoid-resident CD8a+ DCs. These studies are still preliminary and require
repeating with inclusion of additional tissues.
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Figure 3.5: IRF8 and BATF3 co-occupy proximal promoter of CD8α+ DC-specific genes
(A, B, C) Gene tracks for IRF8 (blue, top) and BATF3 (red, bottom) binding to the Clec9a (A),
Tlr3 (B) and Xcr1 (C) genomic regions. Window size is indicated at the top of each track. The
transcript configuration below each track is shown as depicted in the UCSC Browser. Numbers
represent number of normalized reads.
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3.4 Discussion
Genome-wide surveys of IRF4 and BATF binding revealed that a large number of
functionally important genes in lymphocytes are directly regulated by the coordinated actions of
these two factors9,10. While a similar transcriptional activity was proposed for the dendritic cell
lineage, the use of inaccurate DC surrogates and the emphasis on IRF4 and BATF rather than
IRF8 and BATF3 dramatically limited the conclusions of this study. We therefore carried out
ChIP-Seq analysis of IRF8 and BATF3 binding in dendritic cells and discovered extensive
overlap between the two factors. Moreover, signature CD8α+ DC-specific genes showed
identical binding patterns for IRF8 and BATF3 in the promoter proximal regions, confirming our
hypothesis that these genes are directly controlled by IRF8 and BATF3 cooperativity. Lastly, de
novo motif analysis revealed the presence of Runx-binding sites near both IRF8 and BATF3
peaks, which raises the interesting prospect of Runx interactions with either IRF or AP1 family
members. This latter observation requires validation by analyzing the DC compartment of Runx
knockout mice. We hypothesize that the residual transcription of Tlr3, Xcr1, and Clec9a in
Batf3-deficient DCs is mediated by Runx-IRF activity.

3.5 Materials and Methods

3.5.1

Generation of a BATF3-specific rabbit polyclonal antibody and immunoblot

analysis.
Murine full-length Batf3 cDNA was PCR amplified from splenic CD8α+ cDC cDNA library.
The resulting PCR product was ligated into the expression vector pET-28a(+) (Novagen)
downstream of the His-Tag and the final plasmid was transformed into the Escherichia coli
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expression strain BL21-CodonPlus(DE3)-RIL (Stratagene). Recombinant BATF3 was expressed
for 12 hours at room temperature and then affinity purified on Ni-NTA His·Bind® Resin
(Novagen) according to manufacturer's instructions. Purified recombinant BATF3 was used to
immunize New Zealand White Rabbits (Harlan Laboratories) according to a standard 112-day
protocol. Finally, rabbit anti-mouse BATF3 sera were collected and BATF3 -specific antibody
was affinity purified and tested by Western blot analysis.
For immunoblot analysis, either whole-cell extracts were prepared with RIPA lysis buffer
containing protease inhibitors, or nuclei were obtained after cellular lysis with buffer containing
0.2% Nonidet P40 as described59. Extracts were denatured in Laemmli sample buffer at 95°C for
10 minutes, and 5x105 to 1x106 cell equivalent of denatured extract was loaded per well of a
7.5% precast mini polyacrylamide gel (Bio-Rad). Proteins were then transferred onto a
nitrocellulose membrane using a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad) according to
manufacturer's instructions. Blots were blocked with a solution containing 5% non-fat milk and
0.05% Tween-20 for 1 hour at room temperature and then incubated with primary antibody
overnight at 4ºC. After extensive washing, blots were incubated with a goat anti-rabbit IgG
(H+L) conjugated to horseradish peroxidase (Jackson ImmunoResearch Laboratories, Inc.) for 1
hour at room temperature. Finally, blots were developed with ECL Western Blotting Substrate
(Thermo Scientific) according to manufacturer's instructions.

3.5.2

Chromatin Immunoprecipitation (ChIP).
ChIP was carried out as previously described55. In summary, 30x106 dendritic cells from

a 10-day flt3-ligand culture of bone marrow from wild-type mice, Irf8-/- mice and Batf3-/- mice
were harvested, washed twice with ice-cold 1x PBS, and re-suspended in 1x PBS. Cells were
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cross-linked for 13 minutes at room temperature by the addition of one-tenth of the volume of
11% formaldehyde solution. Following the final wash, supernatant was discarded and cell pellets
were flash frozen in liquid nitrogen for storage at -80°C. Thawed cell pellets were lysed with
lysis buffer 1, washed with lysis buffer 2, and re-suspended in lysis buffer 3 for sonication.
Chromatin was sonicated for 36 cycles of 15 seconds on and 20 seconds off per cycle with a
Misonix Sonicator XL2020 outfitted with a Microtip and operated at a power setting between 23. Sheared DNA was run on a 2% agarose gel stained with ethidium bromide and imaged to
determine the average size, which was between 200 and 300 bps. Sonicated lysates were
incubated overnight at 4°C with magnetic beads bound to anti-Irf8 antibody to enrich for DNA
fragments. Magnetic beads were prepared by blocking 50 microliter of Protein G Dynabeads
(Invitrogen) with 0.5% BSA (w/v) in PBS, followed by an overnight incubation with 5 µg of
goat anti-Irf8 (C-19, Santa Cruz) at 4°C. Beads containing DNA fragments were washed with
RIPA buffer and TE + 50mM NaCl. Bound complexes were eluted in elution buffer at 65°C for
15 minutes with vortexing every 3 minutes. Crosslinks were reversed overnight at 65°C. RNA
and protein were digested with RNase A and Proteinase K, respectively, and DNA was purified
with phenol chloroform extraction followed by ethanol precipitation.

3.5.3

ChIP-Seq data processing and analysis.
ChIP-Seq data sets were aligned using Novoalign (Novocraft Technologies) to build

version NCBI37/mm9 of the mouse genome. Alignments were carried out using the following
parameter "-o SAM -r random -l 30 -e 100 -a
AGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG -H." Aligned and raw data can be
found online under the following GEO Series ID GSE53311.
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We used Model based analysis of ChIP-Seq (MACS v1.4.2)56 peak finding algorithm to identify
genomic regions enriched for IRF8 binding. A maximum of 1 duplicate tag and a p-value cutoff
of 1x10-9 was used for all data sets. Background estimates were made using ChIP-Seq on Irf8-/DCs as the control. Annotation (mm9) of the obtained peaks was performed using
“annotatePeak.pl” function of the Homer software package57. Peaks were further analyzed for de
novo motif discovery by using the “findMotifsGenome.pl” function of the Homer software
package using default parameters except for “-size 50 -S 10.”

3.6 Author Contributions
W.K. and K.M. designed the entire study. W.K. performed all experiments and
informatics analyses with significant contributions from X.W. The text was written entire by
W.K.

95

3.7 References
1. Ng,H.H. & Surani,M.A. The transcriptional and signalling networks of pluripotency. Nat.
Cell Biol. 13, 490-496 (2011).
2. Orkin,S.H. & Hochedlinger,K. Chromatin connections to pluripotency and cellular
reprogramming. Cell 145, 835-850 (2011).
3. Graf,T. Historical origins of transdifferentiation and reprogramming. Cell Stem Cell 9,
504-516 (2011).
4. Lee,T.I. & Young,R.A. Transcriptional regulation and its misregulation in disease. Cell
152, 1237-1251 (2013).
5. Belz,G.T. & Nutt,S.L. Transcriptional programming of the dendritic cell network. Nat.
Rev. Immunol. 12, 101-113 (2012).
6. Satpathy,A.T., Wu,X., Albring,J.C. & Murphy,K.M. Re(de)fining the dendritic cell
lineage. Nat. Immunol. 13, 1145-1154 (2012).
7. Geissmann,F. et al. Development of monocytes, macrophages, and dendritic cells.
Science 327, 656-661 (2010).
8. Tussiwand,R. et al. Compensatory dendritic cell development mediated by BATF-IRF
interactions. Nature 490, 502-507 (2012).
9. Li,P. et al. BATF-JUN is critical for IRF4-mediated transcription in T cells. Nature 490,
543-546 (2012).
10. Glasmacher,E. et al. A Genomic Regulatory Element That Directs Assembly and
Function of Immune-Specific AP-1-IRF Complexes. Science 338, 975-980 (2012).
11. Edelson,B.T. et al. Batf3-dependent CD11b(low/-) peripheral dendritic cells are GMCSF-independent and are not required for Th cell priming after subcutaneous
immunization. PLoS One 6, e25660 (2011).
12. Edelson,B.T. et al. Peripheral CD103+ dendritic cells form a unified subset
developmentally related to CD8alpha+ conventional dendritic cells. J. Exp. Med. 207,
823-836 (2010).
13. Hildner,K. et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in
cytotoxic T cell immunity. Science 322, 1097-1100 (2008).
14. Vigorito,E. et al. microRNA-155 regulates the generation of immunoglobulin classswitched plasma cells. Immunity 27, 847-859 (2007).
15. Brass,A.L., Zhu,A.Q. & Singh,H. Assembly requirements of PU.1-Pip (IRF-4) activator
complexes: inhibiting function in vivo using fused dimers. EMBO J. 18, 977-991 (1999).

96

16. Brass,A.L., Kehrli,E., Eisenbeis,C.F., Storb,U. & Singh,H. Pip, a lymphoid-restricted
IRF, contains a regulatory domain that is important for autoinhibition and ternary
complex formation with the Ets factor PU.1. Genes Dev. 10, 2335-2347 (1996).
17. Eisenbeis,C.F., Singh,H. & Storb,U. Pip, a novel IRF family member, is a lymphoidspecific, PU.1-dependent transcriptional activator. Genes Dev. 9, 1377-1387 (1995).
18. JACOB,F. & MONOD,J. Genetic regulatory mechanisms in the synthesis of proteins. J.
Mol. Biol. 3, 318-356 (1961).
19. Krivega,I. & Dean,A. Enhancer and promoter interactions-long distance calls. Curr.
Opin. Genet. Dev. 22, 79-85 (2012).
20. Goodrich,J.A. & Tjian,R. Unexpected roles for core promoter recognition factors in celltype-specific transcription and gene regulation. Nat. Rev. Genet. 11, 549-558 (2010).
21. Tamura,T., Yanai,H., Savitsky,D. & Taniguchi,T. The IRF Family Transcription Factors
in Immunity and Oncogenesis. Annu. Rev Immunol 26, 535-584 (2008).
22. Wang,H. & Morse,H.C., III. IRF8 regulates myeloid and B lymphoid lineage
diversification. Immunol. Res. 43, 109-117 (2009).
23. Schiavoni,G. et al. ICSBP is essential for the development of mouse type I interferonproducing cells and for the generation and activation of CD8alpha(+) dendritic cells. J
Exp. Med. 196, 1415-1425 (2002).
24. Darnell,J.E.J., Kerr,I.M. & Stark,G.R. Jak-STAT pathways and transcriptional activation
in response to IFNs and other extracellular signaling proteins. [Review] [97 refs]. Science
264, 1415-1421 (1994).
25. Taniguchi,T., Ogasawara,K., Takaoka,A. & Tanaka,N. IRF family of transcription factors
as regulators of host defense. Annu. Rev. Immunol. 19, 623-655 (2001).
26. Sciammas,R. et al. Graded expression of interferon regulatory factor-4 coordinates
isotype switching with plasma cell differentiation. Immunity 25, 225-236 (2006).
27. Klein,U. et al. Transcription factor IRF4 controls plasma cell differentiation and classswitch recombination. Nat. Immunol. 7, 773-782 (2006).
28. Aliberti,J. et al. Essential role for ICSBP in the in vivo development of murine CD8alpha
+ dendritic cells. Blood 101, 305-310 (2003).
29. Tamura,T. & Ozato,K. ICSBP/IRF-8: its regulatory roles in the development of myeloid
cells. J Interferon Cytokine Res 22, 145-152 (2002).
30. Brustle,A. et al. The development of inflammatory T(H)-17 cells requires interferonregulatory factor 4. Nat. Immunol. 8, 958-966 (2007).
31. De Silva,N.S., Simonetti,G., Heise,N. & Klein,U. The diverse roles of IRF4 in late
germinal center B-cell differentiation. Immunol. Rev. 247, 73-92 (2012).

97

32. Bollig,N. et al. Transcription factor IRF4 determines germinal center formation through
follicular T-helper cell differentiation. Proc. Natl. Acad. Sci. U. S A 109, 8664-8669
(2012).
33. Schlitzer,A. et al. IRF4 Transcription Factor-Dependent CD11b(+) Dendritic Cells in
Human and Mouse Control Mucosal IL-17 Cytokine Responses. Immunity 38, 970-983
(2013).
34. Persson,E.K. et al. IRF4 Transcription-Factor-Dependent CD103(+)CD11b(+) Dendritic
Cells Drive Mucosal T Helper 17 Cell Differentiation. Immunity 38, 958-969 (2013).
35. Suzuki,S. et al. Critical roles of interferon regulatory factor 4 in CD11bhighCD8alphadendritic cell development. Proc. Natl. Acad. Sci U. S. A 101, 8981-8986 (2004).
36. Kanno,Y., Levi,B.Z., Tamura,T. & Ozato,K. Immune cell-specific amplification of
interferon signaling by the IRF-4/8-PU.1 complex. J. Interferon Cytokine Res. 25, 770779 (2005).
37. Hambleton,S. et al. IRF8 mutations and human dendritic-cell immunodeficiency. N.
Engl. J. Med. 365, 127-138 (2011).
38. Finn,R.D. et al. The Pfam protein families database. Nucleic Acids Res. 38, D211-D222
(2010).
39. Landschulz,W.H., Johnson,P.F. & McKnight,S.L. The leucine zipper: a hypothetical
structure common to a new class of DNA binding proteins. Science 240, 1759-1764
(1988).
40. Lee,W., Mitchell,P. & Tjian,R. Purified transcription factor AP-1 interacts with TPAinducible enhancer elements. Cell 49, 741-752 (1987).
41. Chen,L., Glover,J.N., Hogan,P.G., Rao,A. & Harrison,S.C. Structure of the DNA-binding
domains from NFAT, Fos and Jun bound specifically to DNA. Nature 392, 42-48 (1998).
42. Vinson,C., Acharya,A. & Taparowsky,E.J. Deciphering B-ZIP transcription factor
interactions in vitro and in vivo. Biochim. Biophys. Acta 1759, 4-12 (2006).
43. Vinson,C. et al. Classification of human B-ZIP proteins based on dimerization properties.
Mol. Cell Biol. 22, 6321-6335 (2002).
44. Ise,W. et al. The transcription factor BATF controls the global regulators of class-switch
recombination in both B cells and T cells. Nat. Immunol. 12, 536-543 (2011).
45. Schraml,B.U. et al. The AP-1 transcription factor Batf controls T(H)17 differentiation.
Nature 460, 405-409 (2009).
46. Murphy,T.L., Tussiwand,R. & Murphy,K.M. Specificity through cooperation: BATF-IRF
interactions control immune-regulatory networks. Nat. Rev. Immunol. 13, 499-509
(2013).
47. Miller,J.C. et al. Deciphering the transcriptional network of the dendritic cell lineage.
Nat. Immunol. 13, 888-899 (2012).
98

48. Gautier,E.L. et al. Gene-expression profiles and transcriptional regulatory pathways that
underlie the identity and diversity of mouse tissue macrophages. Nat. Immunol. 13, 11181128 (2012).
49. de Brito,C. et al. CpG promotes cross-presentation of dead cell-associated antigens by
pre-CD8alpha+ dendritic dells. J Immunol 186, 1503-1511 (2011).
50. Sathe,P. et al. The acquisition of antigen cross-presentation function by newly formed
dendritic cells. J Immunol 186, 5184-5192 (2011).
51. King,I.L., Kroenke,M.A. & Segal,B.M. GM-CSF-dependent, CD103+ dermal dendritic
cells play a critical role in Th effector cell differentiation after subcutaneous
immunization. J Exp. Med. 207, 953-961 (2010).
52. Landt,S.G. et al. ChIP-seq guidelines and practices of the ENCODE and modENCODE
consortia. Genome Res. 22, 1813-1831 (2012).
53. Kharchenko,P.V., Tolstorukov,M.Y. & Park,P.J. Design and analysis of ChIP-seq
experiments for DNA-binding proteins. Nat. Biotechnol. 26, 1351-1359 (2008).
54. Tao,H. et al. Purifying natively folded proteins from inclusion bodies using sarkosyl,
Triton X-100, and CHAPS. Biotechniques 48, 61-64 (2010).
55. Lee,T.I., Johnstone,S.E. & Young,R.A. Chromatin immunoprecipitation and microarraybased analysis of protein location. Nat. Protoc. 1, 729-748 (2006).
56. Zhang,Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137
(2008).
57. Heinz,S. et al. Simple combinations of lineage-determining transcription factors prime
cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576589 (2010).
58. Shortman,K. & Heath,W.R. The CD8+ dendritic cell subset. Immunol Rev 234, 18-31
(2010).
59. Dignam,J.D., Lebovitz,R.M. & Roeder,R.G. Accurate transcription initiation by RNA
polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res.
11, 1475-1489 (1983).

99

Chapter 4 L-Myc is selectively expressed by dendritic cells and required for T-cell priming
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4.1 Abstract
The proto-oncogenes Myc and Mycn encode transcription factors that regulate cellular
growth in normal and pathologic settings1,2, and their genetic ablation causes early embryonic
lethality3,4. A third paralog, Mycl1, is dispensable for normal development5 and its biological
activity remains undefined6. We found that Mycl1 was expressed selectively in the immune
system by dendritic cells (DCs), which were in cell cycle but lacked expression of c-Myc and NMyc. Using a newly targeted Mycl1gfp allele, we found that L-Myc expression was controlled by
IRF8 in multiple DC lineages and was initiated during development at the common DC
progenitor (CDP) stage concurrent with loss of c-Myc expression. In mature DCs, L-Myc
protein persisted in the presence of inflammatory signals, such as GM-CSF, and was necessary
for normal proliferation and survival at steady state. L-Myc deficiency caused variable
reductions in DC populations with the greatest effect on splenic CD8α+ DCs and lung CD103+
DCs, which revealed the differential homeostatic requirements for the DC lineage based on
tissue site. Notably, L-Myc-deficient DCs were considerably smaller after ex vivo activation,
which was caused in part by a significant reduction in the expression of eukaryotic translation
initiation factor 1 (eif1) and the mitochondrial respiratory chain complex I subunit NADH
dehydrogenase(ubiquinone) Fe-S protein 5 (Ndufs5).
In addition, loss of L-Myc modestly impaired expansion of CD8α+ classical DCs (cDCs)
after infection by Listeria monocytogenes7,8 and significantly decreased in vivo T-cell priming to
bacterial and viral infections by a T-cell extrinsic mechanism. Lastly, L-Myc-deficient mice
were highly resistant to lethal Listeria challenge by intravenous route because of an impaired
cell-intrinsic capacity of CD8α+ DC to support viable growth of the bugs. However, ciritical
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innate functions of DCs (such as IL-12 production in response to Toxoplasma gondii and IL-23
production to Citrobacter rodentium) were intact in L-Myc deficient mice. Thus, the switch
from c-Myc to L-Myc in DCs may represent a strategy to preserve Myc activity in the setting of
inflammation required for eliciting maximal T-cell responses9. Our study of the physiologic
activities of L-Myc suggests that it functions comparably and affects similar cellular processes as
c-Myc and N-Myc.

4.2 Introduction

4.2.1

Dendritic cells closely resemble other myeloid lineages in terms of anatomical

location, surface phenotype, and cellular origin.
Distinguishing DCs from other myeloid and lymphoid lineages has been a constant
problem in the field and has led to inaccurate conclusions about the specific activities of DC
subsets 10-12. This is due in part to the heavy reliance of sensitive but not specific surface
markers, such as the CD11c (also known as αX integrin) and major histocompatibility complex,
class II, (MHCII). Unlike T cells and B cells, DCs do not uniquely express a single receptor that
is absolutely required for their development and can further be used for unequivocal
identification. Although adequate genetic tools exist for tracking and deleting DCs, many of
these mouse models manifest nonspecific or off target effects that greatly complicate any
conclusions derived from their use. Until recently, most genetic tools to study DC populations
exploited cell surface markers (Cd11c, CD11b, Lysm, Csf1r, and Cx3cr1)13-15, which likely
explains their lack of selectivity. Recently several large-scale transcriptome analyses of DCs and
the closely related monocytes and macrophages have identified signature transcription factors for
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each lineage, leading to a recommendation that transcription factors be used to carefully
segregate DCs from macrophages16,17. As proof of concept, the BTB-ZF family member Zbtb46
was shown to specifically mark DCs in both lymphoid and peripheral tissues18. While Zbtb46
represents an important tool, other mouse models are still needed to expand on this work and
validate the conclusions made from these initial studies. Our own comparative microarray
analysis has revealed the highly specific expression of Mycl1 in the DC lineage.

4.2.2

Myc family of proto-oncogenes
The Myc family of proto-oncogenes (c-Myc, N-Myc, L-Myc) regulates many basic

cellular processes such as proliferation, growth, metabolism, and death in both normal and
pathologic settings1,2,19. Myc’s capacity to affect broad cellular programs is a consequence of its
occupancy of many genomic loci and subsequent activity in releasing paused RNA polymerase II
complexes from proximal promoters20. This activity is quite distinct from most specific
transcription factors, which function instead to regulate transcriptional initation rather than
elongation. Thus, the Myc gene family is indispensable in all tissues undergoing rapid cellular
growth and renewal. Moreover, the importance of this gene family is clearly evidenced by the
frequent rate of mutations (insertions, translocations, amplifications) discovered among Myc
family members in a diverse set of cancers; moreover, ablations of either c-Myc or N-Myc lead
to early embryonic lethality (E9.5 or E10.5) because of multi-organ hypoplasia3,4. Surprisingly,
the deletion of L-Myc revealed no gross abnormality or phenotype, which was presumed to be a
consequence of compensation by the other Myc family members. Indeed, some investigators
have even proposed that L-Myc represents an evolutionary dead-end among the Myc family
members. However, the idea of L-Myc as a bona fide Myc factor has received renewed attention
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with the demonstration that L-Myc reprograms fibroblasts into induced pluripotent stem cells
more efficiently than c-Myc and L-Myc may play a role in β-cell dedifferentiation. In
physiologic and malignant hematopoietic settings, FLT3 signaling leads to c-Myc induction via
STAT-dependent pathways21,22. Therefore, the selective expression of L-Myc and concomitant
absence of c-Myc in DCs is unexpected and requires further investigation.

4.2.3

Dendritic cells are short lived and require constant replenishment from bone

marrow progenitors
A simple model of development posits that cellular intermediates or progenitors
progressively lose the capacity to proliferate as undergo terminal differentiation. Yet this
appears to be an oversimplification in the DC lineage, as a large fraction of DCs is actively
dividing 23-25. Almost all cDCs and pDCs turnover within 7-10 days; and the CD8α+ DC has the
shortest half-life of 3 days whereas pDCs are the longest lived. The relatively high capacity of
DCs to proliferate in situ is one proposed mechanism by which homeostatic renewal is thought to
occur. Although these early kinetic studies (i.e., BrdU labeling and parabiosis) provided
descriptive insight into DC turnover, the downstream effector molecules controlling growth and
survival were largely undefined. Elucidating the transcription factors affecting DC turnover will
provide a more complete picture of the pathways controlling immune responses. For example,
artificially extending the half-life of DCs leads to autoimmunity26. We therefore hypothesized
that the rapid turnover and growth of DCs is in part controlled by some Myc factor.
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4.3 Results

4.3.1

Mycl1 is selectively expressed in cDCs, pDCs and committed DC progenitors
To identify DC-specific transcription factors (i.e., expressed in cDCs and pDCs), we

purified several myeloid precursors (GMP and CMP/MDP) and the earliest committed DCprogenitor (CDP) (Figure 4.1 A), and performed microarray analysis in a manner similar to the
approach previously used to identify the cDC-specific factor Zbtb46 18. Using a pared down list
of Pfam27 annotated transcription factors with a linear expression of at least 100 in the CDP, we
compared CDPs versus CMP/MDP and all DCs with an extensive panel of hematopoietic and
non-hematopoietic cell types28. Interestingly, this approach identified several well-known DC
transcriptional regulators such as Irf8, Id2, and Klf429-32 and a poorly characterized Myc paralog
called Mycl1(Figure 4.1 B). To date, Mycl1 expression has been reported in the central nervous
system and small cell lung cancer33-36. We quantitated Mycl1 expression by qPCR from splenic
lymphoid and myeloid populations and observed detectable amounts in only DC subsets (Figure
4.1 C).
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Figure 4.1: Mycl1 is selectively expressed in DCs
(A) WT BM cells stained with the indicated markers. (B) Microarray analysis of indicated
populations. For each transcription factor, fold change was obtained and plotted based on the two
comparisons indicated. Each dot indicates an individual probe set. (C) Relative amount of
Mycl1 mRNA was determined by qPCR. Shown is a graph of Mycl1 values normalized to Hprt
values (bar, SD; n=3 biological replicates per cell type).

4.3.2

c-Myc and N-Myc are not expressed in mature DC subsets
c-Myc and N-Myc are expressed in the hematopoietic compartment and play growth

promoting roles in early progenitors and mature myeloid and lymphoid populations 37-42.
Laurenti and colleagues previously reported that Mycl1expression is absent in hematopoietic
lineages; however, this study failed to include DC progenitors or DCs in the analysis. We
therefore determined the expression pattern of all three Myc factors in progenitors and mature
DC subsets. Myc was highly expressed by early hematopoietic progenitors but was significantly
reduced in mature DCs (Figure 4.2 A, left panel). Like Myc, Mycn was highly expressed in
hematopoietic stem cells (HSCs), multipotent progenitors (MPPs) and common lymphoid
progenitors (CLPs), but was absent from DC progenitors and mature DCs (Figure 4.2 A, middle
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panel). In contrast, we observed that Mycl1 was expressed by CDPs, by committed precursors to
cDCs43,44 (pre-cDCs) and by mature splenic DCs (Figure 4.2 A, right panel). Interestingly, we
observed a similarly conserved expression pattern of Myc factors in human hematopoietic
lineages45,46(Figure 4.2 B, left panel).
The absence of c-Myc from DCs caused us to evaluate the local proliferation of DCs47
relative to other c-Myc-positive lineages. First, we used a 4-hour in vivo 5'-bromo-2'deoxyuridine (BrdU) labeling assay to evaluate mature DC proliferation in relation to other
myeloid and lymphoid populations (Figure 4.2 C). In contrast to B cells, monocytes and
neutrophils, which showed ~1% BrdU uptake, splenic cDC subsets showed 4-8% BrdU uptake
(Figure 4.2 C), in agreement with previous reports25,47. In addition, 4-7% of cDCs were in
S/G2/M phase as determined by DAPI staining and between 17-34% of cDCs were in cell cycle
as deteremined by Ki67 staining (Figure 4.2 D). Although splenic pDCs had little proliferative
capacity (Figure 4.2 B), consistent with published findings25, we observed a significant
proportion of bone marrow (BM) pDCs in S/G2/M phase by DAPI staining (Figure 4.2 E),
suggesting that tissue microenvironment can influence the proliferation state of DCs.
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Figure 4.2: c-Myc and N-Myc are not expressed in mature DCs
(A) Shown are mean expression values for Myc, Mycn, and Mycl1 for the indicated populations
(bars, SD; n = 2-4 microarrays from biological replicates, one-way ANOVA Tukey’s post hoc
test). (B) Shown is the mean expression value of Mycl1 mRNA in the indicated cell types
purified from humans and mice. (C) The indicated lineages were stained for intracellular BrdU
incorporation as described in Methods. Shown is the percent of BrdU+ cells within each
indicated lineage from individual mice. Data are from 2 independent experiments (bars, SD; n =
9 mice per group, one-way analysis of variance (ANOVA) Tukey’s post hoc test). (D) DC
populations stained for DNA content with DAPI and Ki67 expression. Dotted lines represent
isotype control staining. Numbers represent percent of cells in the indicated gate. Data are
representative of 3 independent experiments. (E) BM pDCs (gated as CD11c+SiglecH+B220+)
were separated into MHCII- (A) and MHCII+ (B) fractions by cell sorting. Both A and B were
then stained for DNA content with DAPI.
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4.3.3

Mycl1gfp expression is coincident with the loss of c-Myc transcript and protein
Mycl1 encodes 368 amino acids, and the protein contains an N-terminal trans-activating

domain (TAD) and a C-terminal DNA binding domain (basic-helix-loop-helix structure). 35,48,49.
The genomic context comprises two exons (Supplementary Figure 4.1 A) with exon 1 encoding
the 5' untranslated region (UTR) and 165 amino acids of the TAD. Our targeting strategy
replaces the coding sequence immediately downstream of the 5' UTR with an enhanced GFP
reporter cassette followed by a SV40 poly-adenylation sequence. The newly targeted genomic
configuration, Mycl1gfp, contains an inactive Mycl1 but preserves promoter activity, allowing for
detection of its expression (Supplementary Figure 4.1 B-D).
These above observations suggested that the induction of L-Myc expression was
coincident with the loss of c-Myc and N-Myc (see previous section). To characterize the
transition from c-Myc to L-Myc expression in the DC lineage with single-cell resolution, we
examined mice carrying a Mycgfp reporter allele encoding a GFP-c-Myc N-terminal fusion
protein50 and mice harboring our newly targeted Mycl1gfp allele. We found that c-Myc protein
was highly expressed in Flt3+ common myeloid progenitors51 (CMPs), nearly extinguished in
CDPs and pre-cDCs (Figure 4.3 A and B) and undetectable in mature splenic DCs (Figure 4.3 C
and D). In contrast, Mycl1gfp expression was absent in CMPs, became detectible in CDPs and
increased in pre-cDCs (Figure 4.3 A and B). Mycl1gfp was highly expressed in all mature splenic
DC subsets (CD8α+ cDCs, CD8α- cDCs, and pDCs) but was undetectable in neutrophils,
monocytes, red pulp macrophages, NK cells and T and B cells (Figure 4.3 C-E), consistent with
endogenous Mycl1 mRNA measurements (Figure 4.1 C). All DC subsets developed in
Mycl1gfp/gfp (L-Myc-deficient) mice without compensatory induction of Myc expression (Figure
4.3 E, Supplementary Figure 4.1 E, right panel). In vitro, Mycl1gfp expression was observed in
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Flt3 ligand (Flt3L)-treated BM cultures (Supplementary Figure 4.2 A and B). Overexpression of
c-Myc in Flt3+ CMPs significantly reduced the proportion of cDCs and pDCs in Flt3-ligand
(FLT3L) cultures, whereas overexpression of L-Myc produced no apparent defects
(Supplementary Figure 4.2 C and D). These results suggest that L-Myc does not regulate the
differentiation of mature DCs per se but may instead serve a non-redundant homeostatic role.
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Figure 4.3: Mycl1 expression is coincident with loss of c-Myc expression
Histogram of GFP expression for Flt3+ progenitors from the indicated mice. Numbers represent
percent of cells in the indicated gate. (B) CMP (left panel), CDP (middle panel), Pre-cDC (right
panel). Numbers represent mean fluorescent intensities. (C-D) Cells from indicated mice were
stained to identify CD8α+ DCs, CD4+ DCs, and pDCs. Histograms of GFP expression. (E)
Mycl1+/gfp (solid green line) splenocytes were stained for myeloid (left panel) and lymphoid
(right panel) populations. Histograms of GFP expression for DCs, neutrophils (PMN),
monocytes (mono), red pulp macrophages (RPM), NK cells (NK cell), CD8 T cells (CD8 T),
CD4 T cells (CD4 T) and B cells. (F) Histogram showing frequency of pDCs, CD8α+ DCs, and
CD8α- DCs. Data are representative of at least 5 independent experiments.

109

4.3.4

Mycl1gfp expression marks the DC lineage in lymphoid and peripheral tissues
The tissue microenvironment and genetic background can be an important determinant of

DC homeostasis7,52,53. Thus, we extended our comparison between Mycgfp and Mycl1gfp
expression across numerous lymphoid and peripheral tissues. In tissues other than spleen, we
observed a similar pattern of Mycl1gfp expression even though DCs are known to incorporate
BrdU at different rates54. In inguinal and mesenteric lymph nodes, Mycl1gfp, but not Mycgfp, was
expressed by pDCs and by migratory and resident cDCs (Figure 4.4 A, Supplementary Figure
4.3 A and B). In the lung, liver, and dermis, Mycl1gfp was expressed predominantly by CD11bcDCs, but, in the small intestine, Mycl1gfp was expressed by CD11b+ and CD11b- cDCs (Figure
4.4 B). Mycl1gfp expression was absent in tissue macrophages, which can renew locally and
proliferate in response to signals such as IL-455,56, suggesting that L-Myc expression can be used
to distinguish DCs from closely related macrophage populations (Supplementary Figure 4.3 C).
To obtain a more complete profile of Myclgfp expression, we characterized the distribution
and anatomical location of GFP-positive DCs in lymphoid and peripheral tissues. By histology,
Mycl1gfp was found in stellate cells within T-cell zones in spleen and lymph nodes and in
scattered cells within B cell follicles and the splenic red pulp (Figure 4.4 C, Supplementary
Figure 4.4a-e). Mycl1gfp-expressing cells were sparsely present within the sub-capsular sinus of
inguinal lymph nodes where Zbtb46+ cDCs are known to reside18 (Figure 4.4 B, Supplementary
Figure 4.4 B). In addition, Mycl1gfp was expressed by CD4-B220- cells in small intestinal lamina
propria, inside villi and within Peyer's patches (Figure 4.4 C, Supplementary Figure 4.4 D).
Mycl1gfp expression was not apparent in stromal cells such as fibroblasts, and unlike Zbtb46, was
undetected in vascular endothelium (Supplementary Figure 4.4 E, F). Thus, Myclgfp expression
uniquely identifies DCs in both lymphoid and non-lymphoid peripheral tissues.
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Figure 4.4: Mycl1 expression is restricted to DCs in lymphoid and peripheral tissues and is
regulated by IRF8 and GM-CSF
(A) Spleen, inguinal lymph node (ILN), and mesenteric lymph node (MLN) cells of Mycl1+/gfp
mice were stained for analysis. GFP+ cells are further gated as pDCs, resident DCs, or migratory
DCs. Numbers represent percent of cells in the indicated gate. (B) Cells from lung, liver,
dermis, and small intestine (intestine) of WT and Mycl1+/gfp mice were stained. Histograms of
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CD11b and GFP expression for indicated cells is shown. (C) Tissue sections from Mycl1+/gfp
mice were prepared for analysis by fluorescence microscopy. The stain for each tissue is
indicated above the picture. (D) BM cells and splenocytes from indicated mice were stained for
analysis. Histograms of GFP expression for lineage-negative Flt3+ progenitors and splenic
pDCs. (E) BM monocytes were isolated from indicated mice and differentiated for 4 days with
either GM-CSF (left panel) or GM-CSF and IL-4 (right panel). Histograms of GFP expression.
(F) BM cells from indicated mice were cultured for 9 days in Flt3 ligand (Flt3L) and treated with
media, anti-CD40 antibody (a-CD40), interferon gamma (IFN-g), granulocyte-macrophage
colony-stimulating factor (GM-CSF), interferon beta (IFN-b), heat-killed Listeria
monocytogenes EGD (HKLM), or interleukin 4 (IL-4) for 24 hours. Whole-cell extracts were
prepared and Western blot analysis was performed. Shown are immunoblots for L-MYC (top)
and PLC-g2 (bottom) from the indicated treatments. (G) BM cells from indicated mice were
cultured for 9 days in Flt3L and treated with media or GM-CSF for 24 hours. Nuclear extracts
were prepared and Western blot analysis was performed. Shown are immunoblots for L-MYC
(top) and HDAC1 (bottom). (h-i) Gene tracks for IRF8 binding to the Mycl1(h) and Myc (i)
genomic regions (20-kb window) in Flt3L-derived DCs from WT (top panel) or Batf3-/- (bottom
panel) mice. The transcript configuration below each track is shown as depicted in the UCSC
Browser. Numbers represent number of normalized reads. FACS data are representative of at
least 5 independent experiments
4.3.5

IRF8 induces Mycl1 expression in multiple DC subtypes and GM-CSF stabilizes L-

Myc protein
In common myeloid progenitors (CMPs) and all-lymphoid progenitors (ALPs), which
give rise to DCs, loss of the transcription factor IRF8 results in a decreased abundance of Mycl1
transcript57. We found that Mycl1gfp expression was absent in DC progenitors and significantly
reduced in pDCs isolated from Irf8R294C mice58, which harbor a point mutation that abrogates
IRF8 interactions with the transcription factor PU.1 (Figure 4.4 D, Supplementary Figure 4.5 A).
Moreover, DCs differentiated from Ly6Chi monocytes in the presence of IL-4 and GMCSF18,59,60 also induced Mycl1gfp expression in WT cultures but not in Irf8R294C cultures (Figure
4.4 E, Supplementary Figure 4.5 B). Using an L-Myc-specific antibody (Supplementary Figure
4.5 C), we found that L-Myc protein was maintained in cDCs under various inflammatory
conditions, which included treatment with IFN-β or IFN-γ (Figure 4.4 F). In addition, L-Myc
protein was increased by treatment with GM-CSF (Figure 4.4 F and G). ChIP-Seq analysis
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identified several genomic regions enriched for IRF8 binding across the Mycl1 and Myc loci.
These binding occurrences did not require IRF8 interactions with the transcription factor BATF3
(Figure 4.4 H and I). Together, these results support a role for IRF8–PU.1 interactions, as
opposed to IRF8–BATF3 interactions61, in the direct regulation of Mycl1 transcription; and
indicate that L-Myc protein levels vary in response to activating signals, which is analogous to
the regulation of c-Myc protein62-64.

4.3.6

L-Myc regulates the growth and survival of CD8α + cDCs and pDCs
Next, we characterized the effect of L-Myc deficiency on DC homeostasis at steady state.

In lymphoid and peripheral tissues, loss of L-Myc decreased the total number and relative
frequency of DCs, and based on the analysis of competitive mixed BM chimeras, we found that
these defects were due to cell-intrinsic mechanisms (Figure 4.5 A-C, Supplementary Figure
4.6A-G). The largest defect was observed in CD103+CD11b- cDCs in the lung, an organ rich in
GM-CSF65. A recent report concluded that GM-CSF is important for the survival of lung
CD103+ DCs 66. In WT mice, CD103+CD11b- cDCs in the lung showed higher expression of
Mycl1 and greater proliferative capacity as measured by Ki67 as compared to migratory
CD103+CD11b- cDCs from draining lymph nodes (Supplementary Figure 4.6 H and I). Using
Gene Set Enrichment Analysis (GSEA)67, a computational method for determining whether an a
priori set of genes shows a statistically significant difference between two populations, we
observed significant enrichment for cell-cycle–related transcripts in lung CD103+CD11b- cDCs
as compared to migratory CD103+CD11b- cDCs from draining lymph nodes (Supplementary
Figure 4.6 J). Thus, variations in the abundance of cell-extrinsic factors such as GM-CSF in the
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local tissue microenvironment result in different homeostatic requirements for resident DCs that
are revealed by the loss of L-Myc.
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Figure 4.5: L-Myc regulates the growth and survival of DCs
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(A) Mixed BM chimeras were generated as described in Methods. Splenocytes and peripheral
blood cells were analyzed for relative donor contribution 8-10 weeks following lethal irradiation
and transplant. Shown is the contribution of CD45.2+ WT BM or CD45.2+ Mycl1gpf/gfp BM to
the indicated DC subset as a ratio of peripheral blood neutrophils (PMN) from the same animal
(% CD45.2+ contribution in DC / % CD45.2+ in PMN). Data are representative of 3 independent
experiments (bar, SD; n=9, Mann-Whitney U test). (B) CD103+CD11b- DCs from lung, liver,
and small intestine were quantitated as a percentage of live CD45.2+ hematopoietic cells. Data
are representative of 3-4 independent experiments (bar, SD; n=5-7, two-way ANOVA HolmSidak post hoc test). (C) Shown is the contribution of CD45.2+ WT BM or CD45.2+ Mycl1gpf/gfp
BM to CD103+CD11b- DCs in the indicated peripheral tissues as a ratio of peripheral blood
neutrophils from the same animal. Data are representative of 3 independent experiments (bar,
mean; n=5-9, Mann-Whitney U test). (D) Splenocytes were harvested 1 hour after BrdU
injection. BrdU+ cells within each indicated lineage from individual mice is shown. (bar, SD; n
= 5 mice per group, Student’s t-test). (E) Sorted pDCs were cultured in imiquimod for 24 hours
(24 h, left panel) and 48 hours (48 h, right panel). Cells stained with 7AAD and AnnexinV to
assess viability. Histograms depicting live cells (7AAD-AnnexinV-), early apoptotic cells
(7AAD-AnnexinV+), and late apoptotic or necrotic cells (7AAD+AnnexinV+). (F) Quantitation
of live pDCs from (E) (bar, SD; n = 7 biological replicates, Student's t-test). (G) Shown is a twocolor histogram of side scatter (SSC-A) and forward scatter (FSC-A) for pre-gated live pDCs
(7AAD-AnnexinV-) from media treated or imiquimod treated wells (24 h and 48 h). (H) Sorted
CD8α+ DCs were cultured in GM-CSF for the indicated time points. Histogram of FSC-A for
live cells. (I) BM CDPs, pre-cDCs, MHCII- pDCs cultured in Flt3L for 24 h. Wells were pulsed
with 10mM BrdU for the last 4 hours of culture. Shown is the percent of cells in S phase. Data
are representative of 2-3 experiments (bar, SD; n = 5, Student’s t-test). (J) BM cells from WT
mice were cultured in Flt3L and infected on day 4 with a retrovirus expressing ERT2 or the LMYC-ERT2 fusion protein and then cultured for an additional 6 days. Cells were harvested and
purified into subsets as CD11c+ MHCII+ CD24+Sirp-a- (CD8a+ DC, left panel) or CD11cint
SiglecH+ (pDC, right panel) by cell sorting. Infected and uninfected (control) cells were treated
with vehicle (DMSO) or 100 nM 4-hydroxytamoxifen (4-OHT) for 24 hours in 100 ng/ml Flt3L,
pulsed with BrdU for the last 4 hours and stained for intracellular BrdU incorporation. Shown is
the percent of cells in S phase (bar, SD; n=4 independent retroviral transductions, two-way
ANOVA Holm-Sidak post hoc test). *, p<0.05, **, p<0.01, ***, p<0.001, ns, p>0.05.

4.3.7

L-Myc regulates growth-related genes in CD8α + DCs and pDCs
Using gene expression microarrays, we found that L-Myc deficiency produced changes in

gene expression that were distinct among pDCs, CD8α+ cDCs, and CD8α- cDCs (Supplementary
Figure 4.7 A and B) at steady sate. In BM pDCs and splenic CD8α+ cDCs, we observed target
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genes associated with cellular proliferation and apoptosis (Supplementary Figure 4.7 C). Thus,
we analyzed local DC proliferation in vivo and assayed survival after ex vivo activation of DCs.
BrdU labeling in vivo showed a 50% decrease in local proliferation of splenic CD8α+ cDCs in LMyc-deficient mice relative to WT mice (Figure 4.5 D). Loss of L-Myc also decreased the size
of splenic CD8α+ cDCs and pDCs following GM-CSF treatment and toll-like receptor 7 (TLR7)
activation, respectively (Figure 4.5 E-H). In the BM, L-Myc-deficient pDCs and pre-cDCs
proliferated less in response to Flt3L than WT populations, as measured by the proportion of
cells in S phase (Figure 4.5 I). However, L-Myc deficiency had no effect on CDP proliferation
(Figure 4.5 I, Supplementary Figure 4.8 A). Using a tamoxifen-activated form of L-Myc (LMYC-ERT2 fusion protein), we found that activation markedly and specifically increased the
proliferation of CD8α+ cDCs and pDCs expressing L-MYC-ERT2 (Figure 4.5 J, Supplementary
Figure 4.8 B and C). Thus, in the absence of c-Myc or N-Myc, L-Myc can regulate DC
proliferation and survival following activation.
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Figure 4.6: Gene expression analysis of L-Myc deficient CD8α+ DCs and pDCs following
activation
DCs were sorted from WT and Mycl1-/- mice treated with Flt3L and then cultured in vitro. RNA
was purified and microarray analysis performed as described in Methods. M-Plots comparing the
log2 transformed expression values of 409 GM-CSF inducible genes between WT (y axis, n = 3
biological replicates) and Mycl1-/- (x axis, n = 3 biological replicates) CD8α+ DCs (left and
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middle panels); and of all genes between WT (y axis, n = 3 biological replicates) and Mycl1-/- (x
axis, n = 3 biological replicates) pDCs treated with imiquimod (right panel).
Recently, several reports have demonstrated that Myc influences the transcription of
many genomic loci by mediating the release of paused RNA pol II complexes68-70. We asked
whether the induction of 409 genes following GM-CSF was impaired in L-Myc deficient mice.
We observed most inducible genes to be more highly enriched in WT vs KO, which was specific
to treatment as this set showed no difference when compared with media treated DCs (Figure 4.6
A and B). Interestingly, some genes remained different between WT and KO despite showing
no increase with GM-CSF. This list included Eif1, Rpl13a, and Ndufs5. Eukaryotic translation
initiation factor 1 facilitates tRNA binding to the ribosome by stabilizing a conformation change
in the small (40S) ribosomal subunit that opens the mRNA binding channel71. We also observed
a similar reduction in Eif1 and Ndufs5 in pDCs activated with imiquimod; although in pDCs Eif1
levels increased following treatment (Figure 4.6 C). These data suggest that L-Myc can regulate
the expression of many genomic loci and also modulate the expression of genes involved in
controlling protein synthesis similar to c-Myc 72.

4.3.8

Mycl1 is dispensable for the innate effector functions of DCs to Toxoplasma gondii

and Citrobacter rodentium
Initially recognized for the superior capacity to prime adaptive immune responses, DCs
are now known to mediate several key innate effector responses. For example, the CD8α+ DC
and the related CD103+ DC sense infection by Toxoplasma gondii and are the critical source of
IL-12 necessary for early host resistance73. Conversely, the Notch2-dependent intestinal CD11b+
cDCs are the obligate source of IL-23 required for survival after infection with C. rodentium, a
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model for attaching-and-effacing bacterial infections74. Interestingly, the only perihperal site
where CD11b+ DCs express detectible amounts of Mycl1 is the small intestine lamina propria.
We asked whether L-Myc played a role in these innate effector responses.
I.P. infection by tachyzoites of the type II avirulent Prugniaud (Pru) strain of T. gondii led
to complete lethality of Batf3−/− mice relative to WT and Mycl1-/- mice (Figure 4.7 A). We also
observed no difference in parasite burden at three different time points (Figure 4.7 B). These
data confirm that L-Myc-deficient CD8α+ DCs sense and respond appropriately to T. gondii
infection. Next, we infected mice with C. rodentium and monitored mice for weight loss and
survival. As expected, conditional deletion of Notch2 led to rapid weight loss and complete
lethality by 10 days. L-Myc-deficient mice displayed no weight loss and survived the infection
for the duration of the experiment (Figure 4.7 C and D). These data suggest that L-Myc is
dispensable for the innate effector functions of DCs.
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Figure 4.7: L-Myc is dispensable for the innate effector functions of DCs
(A) WT, Mycl1−/−, and Batf3−/− mice were infected with an avirulent strain of Toxoplasma
gondii as described in the Methods. (B) Infected mice underwent whole-body in vivo imaging
throughout the course of infection to measure bioluminescence. Data shown are combined
parasite burden from infected 129S6/SvEV mice from two independent experiments. (C) Weight
loss (C) and survival (D) of the indicated mice given oral inoculation of C. rodentium (2 × 109
colony-forming units).
4.3.9

Mycl1 is required for priming of CD8+ T cells following bacterial and viral infection
Finally, we assessed whether L-Myc expression was required for T cell priming and other

functions attributed to DCs75,76. In WT mice, CD8α+ cDCs increased markedly from days 2 to 5
following infection with L. monocytogenes, consistent with previous reports 7. However, CD8α+
cDC expansion in L-Myc-deficient mice was significantly impaired relative to WT mice (Figure
4.8 A, Supplementary Figure 4.8 D). We then measured antigen-specific CD8 and CD4 T cell
responses after infection with L. monocytogenes expressing soluble ovalbumin (LM-OVA).
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Loss of L-Myc significantly decreased the total number and relative frequency of IFN-γproducing OVA-specific CD8 and CD4 T cells (Figure 4.8 B and C, Supplementary Figure
4.9a-d). To demonstrate that these effects were not the result of a requirement for L-Myc in T
cells, we adoptively transferred congenically marked L-Myc-sufficient OT-I CD8 T cells into
WT and L-Myc-deficient mice. After infection with LM-OVA, OT-I CD8 T cell expansion was
dramatically reduced in L-Myc-deficient mice as compared to WT mice (Figure 4.8 D and E,
Supplementary Figure 4.9 E and F). Likewise, after infection with LM-OVA, congenically
marked L-Myc-sufficient listeriolysin O (LLO)-specific CD4 T cells (LLO118) adoptive
transferred into L-Myc-deficient mice were decreased in frequency as compared to WT mice
(Supplementary Figure 9 G). L-Myc-deficient mice also showed impaired CD8 T cell priming
after infection with vesicular stomatitis virus expressing ovalbumin (VSV-OVA) (Figure 4.8 F,
Supplementary Figure 4.9 H).
These priming defects were attributable to the action of L-Myc in CD8α+ cDCs, as
depletion of pDCs77 or Notch2-dependent CD11b+ cDCs78 had no impact on CD8 T cell priming
after infection with LM-OVA (Supplementary Figure 4.10 A-C). We found no cell-intrinsic
defect in the antigen processing and presentation capacity of any subset of L-Myc-deficient DCs
(Supplementary Figure 4.9 D and E ) in vitro. In addition, L-Myc deficient DCs cross-presented
and cross-primed T cells in vivo to syngeneic tumor grafts, which requires the actions of the
CD8α+ DC76,79. These data suggest that L-Myc deficiency in the CD8α+ DC is the cause of
impaired priming, but the mechanism probably does not entail antigen processing or presentation
per se. Supporting this conclusion is a large body of literature describing the critical role this cell
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type plays in capturing and spreading the initial Listeria infection as well as performing the
initial presentation of antigen to T cells 80-83.
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Figure 4.8: L-Myc deficiency results in abnormal T cell priming and resistance to Listeria
monocytogenes
(A) Splenocytes from mice infected with LM-OVA were harvested at the indicated time points
and stained for analysis. Total number of CD8α+ DCs was determined for each indicated day
following infection. Data are from 2 independent experiments (bar, SD; n=8 biological
replicates, two-way ANOVA Holm-Sidak post hoc test). (B) Splenocytes were harvested 7 days
after infection with LM-OVA, re-stimulated with SIINFEKL peptide in vitro for 5 hours and
stained for analysis. Histogram of TNF-a and IFN-g expression for cells pre-gated gated as
Thy1.2+CD8α+. Numbers represent the percent of cells in the indicated gate. Data are from 2
independent experiments. (C) Shown is the total number of SIINFEKL-specific CD8+ T cells
determined for infections described in (B). Data are from 2 independent experiments (bar, SD;
n=12 infected biological replicates, Student's t-test). (D) Expansion of transferred WT OT-I
CD8+ T cells was determined 7 days after infection. Numbers represent the percent of donor OTI CD8+ T cells. (E) Shown is the total number of OT-I CD8+ T cells determined for the infection
described in (D). Data are from 2 independent experiments (bar, SD; n=8 infected biological
replicates, Student's t-test). (F) WT (black dots) or Mycl1gfp/gfp (green dots) mice were infected
intravenously with 5x106 PFU VSV-OVA. Splenocytes were harvested 7 days after infection
and re-stimulated as in (B). Shown is the total number of SIINFEKL-specific CD8+ T cells.
Data are from 2 independent experiments (bar, SD; n=11 biological replicates, Student's t-test).
(G) WT (black dots) and Mycl1gfp/gfp (green dots) mice were infected intravenously with 100,000
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Listeria monocytogenes (wild-type strain EGD) and followed daily for survival. Data are from 3
independent experiments (n=15 mice per group, Log-rank Mantel-Cox test). *, p<0.001, ns,
p>0.05

We also assessed the capacity of CD8α+ cDCs to capture and promote infection by L.
monocytogenes in the absence of L-Myc. CD8α+ cDCs are the initial cellular target for
intracellular L. monocytogenes infection82, and Batf3-/- mice, which lack CD8α+ cDCs, are
resistant to lethal infection by L. monocytogenes80. We observed that L-Myc-deficient mice
were also resistant to infection by L. monocytogenes as compared to WT mice (Figure 4.8 G).
Since the CD8α+ DCs are modestly reduced in the spleen of L-Myc-deficient mice, we
hypothesized that the resistance phenotype was caused by either impaired bug capture or poor
initial spreading and proliferation of bugs within this DC compartment82. Although previously
thought to infect predominantly splenic macrophages 84,85, Busch and colleagues showed that the
initial viable burden is heaviest among CD8α+ DCs, and any impairment of bug growth and
spreading in these cells dramatically attenuates overall infection and T cell priming.
We performed similar sorting experiments on different splenic populations from WT
mice and confirmed the selective presence of viable L. monocytogenes within CD8α+ DCs for 24
hours following infection(data not shown). The initial capture of L. monocytogenes by L-Myc
deficient CD8α+ DCs was equal to WT DCs (Figure 4.9 A, right panel)and comparable to
published values81,82. However, we observed a significant reduction in viable L. monocytogenes
within L-Myc deficient CD8α+ DCs as compared to WT (Figure 4.9 A, left panel) by 24 hours.
This defect was cell-intrinsic as sorted L-Myc deficient CD8α+ DCs poorly supported L.
monocytogenes growth. Consequently, the reported spread to other myeloid lineages, including
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CD8α- DCs, was greatly diminished in L-Myc-deficient mice. Lastly, the decreased pathogen
burden seen in Mycl1−/− mice was reflected in substantially reduced histological lesions in spleen
and liver compared to WT mice. The WT mice had characteristically large lesions in the PALS,
which represent apoptotic death of lymphocytes86, but L-Myc-deficient mice had a large number
of unaffected PALS (Figure 4.9D). In summary, L-Myc-deficient CD8α+ DCs inefficiently
support the initial L. monocytogenes infection, thereby limiting pathogen spread but also
attenuating T cell responses.

Figure 4.9: L-Myc-deficient CD8α+ DCs capture but do not support growth of L.
monocytogenes
(A) Mice were infected with LM-EGD and the indicated DC subsets were sorted after
either 2 hours (2 h) or 24 hours (24 h) according to the Methods. CFU burden for DC subsets
was determined as described in Methods. (B) Mice were infected with
123

50x106 CFU LM-EGD and DCs were isolated 2 h post-infection. Sorted CD8α+ DCs were
cultured in the presence of the indicated antibiotics. Cells were harvested after 10 hours of
growth at 37ºC and bug burden was determined as in (A). (C) Mice were infected as in (A)
and the indicated myeloid populations were purified after 60 hours and bug burden determined.
(D) Mice were infected with 105 CFU LM-EGD and histopathology (H&E) of spleen (top
panels) and liver (bottom panels) was carried out. Scale bars for spleen represent 400 µm; bars
for liver represent 160 µm.

Supplementary Figure 4.1: Generation of Mycl1gfp/gfp mice by homologous recombination
(A) Genomic context of Mycl1, the targeting vector, and targeted allele are shown. Restriction
enzyme digestion with NcoI of the wild-type locus generates a 12.5 kb fragment detectable by
either 5' or 3' probes. NcoI digestion of the targeted locus generates a 3.3 kb fragment (detected
by 5' probe), a 2.3 kb fragment containing most of the GFP-Neo cassette, and a 9.3kb fragment
(detected by 3' probe). (B) Southern blot analysis of NcoI-digested total DNA with the 5' probe.
(C) Southern blot analysis of NcoI-digested genomic DNA with the 3' probe. (D) Genotyping
PCR of indicated mice. The wild-type genomic allele yields a 337 bp band and the mutant allele
yields a 525 bp band. (E) The relative amount of Mycl1 and Myc mRNA was determined by
qPCR for indicated genotypes. Shown is a graph of Mycl1and Myc values normalized to Hprt
values (bar, SD; n=3 biological replicates per cell type).
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Supplementary Figure 4.2: In vitro derived DCs express Mycl1
(A) Histograms of GFP expression for the indicated cells derived from WT, Mycl1+/gfp, and
Mycl1gfp/gfp BM cultured in Flt3L for 10 days. Numbers represent GFP+ cells as a percent of live
cells. Data are representative of 3 independent experiments. (B) Histograms of CD24 and SIRPα expression for Flt3L DCs as described in (A). Flt3L DCs from BM of Mycl1+/gfp mice were
pre-gated either as GFP+ or GFP-. (C) BM cells from WT mice were harvested and Flt3+ CMPs
were purified by cell sorting. CMPs were cultured in Flt3L for 12 hours before being transduced
with control (Empty), Irf8, Mycl1, or Myc expressing retrovirus. Cells were cultured an
additional 5 days and then stained for analysis. Numbers represent the percent of cells in the
quadrant gate. (D) Shown is the quantitation of undifferentiated (non-DC or non-pDC) cells
from (c). Data are from 4 independent transductions per retrovirus (bar, SD; n=4, one-way
ANOVA Tukey's post hoc test). *, p<0.01; ns, p>0.05.
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Supplementary Figure 4.3: Mycl1 expression is restricted to DCs in secondary lymphoid
tissues
(A) Spleen (left panel), inguinal lymph node (ILN, middle panel), and mesenteric lymph node
(MLN, right panel) stained for analysis. Histograms of auto-fluorescent negative cells. Numbers
represent percent of cells in the indicated gate. Data are representative of at least 5 independent
experiments. (B) Historgrams of GFP expression for resident DCs and migratory DCs from
MLN and ILN of WT (grey lines) and Mycl1+/gfp mice (green lines). (C) Cells from the brain,
spleen, peritoneum, kidney, and liver stained for analysis. Histograms of F4/80 and GFP
expression for microglia (CD45intCD11b+), splenic red pulp macrophages
(F4/80+autofluorescenthigh, RPM), peritoneum macrophages (F4/80+CD11b+, Peritoneum), liver
and kidney macrophages (F4/80+CD11bint, liver, kidney), and liver DCs (CD11c+MHCII+). Live
hematopoietic cells were pre-gated in all non-lymphoid tissues as CD45+/int7AAD-. Numbers
represent percent of cells in the indicated gate. Data are representative of 2-3 independent
experiments.
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Supplementary Figure 4.4: Mycl1 expression is restricted to DCs by microscopy
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(A) Sections of spleen from Mycl1+/gfp mice were analyzed by fluorescence microscopy for B220
(blue), F4/80 (red) and GFP (green). (B) Inguinal lymph node from Mycl1+/gfp mice was
analyzed by fluorescence microscopy for B220 (blue), CD169 (red) and GFP (green). (C)
Mesenteric lymph node from Mycl1+/gfp mice was analyzed by fluorescence microscopy for B220
(blue), CD169 (red) and GFP (green). (D) Sections of small intestine from Mycl1+/gfp mice were
analyzed by fluorescence microscopy for CD4 (blue), β-catenin (red) and GFP (green). (E)
Mesenteric lymph node from Mycl1+/gfp mice was analyzed by fluorescence microscopy for B220
(blue), MAdCAM-1 (red) and GFP (green). (F) Mesenteric lymph node from Zbtb46+/gfp mice
was analyzed by fluorescence microscopy for B220 (blue), MAdCAM-1 (red) and GFP (green).
Scale bars, 200 µM (Inguinal lymph node, small intestine), 100 µM (Spleen, Mesenteric lymph
node).
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Supplementary Figure 4.5: IRF8 regulates Mycl1 expression
(A) Splenocytes indicated mice were stained for analysis. Histograms of CD11c and SiglecH
expression (left panels), and CD11b and CD205 expression (right panels). Numbers represent
the percent of cells in the indicated gates. Data are representative of 2 independent experiments.
b, BM Ly6C+ monocytes were purified by cell sorting. Monocytes were cultured in either GMCSF or GM-CSF and IL-4 for 4 days and stained for analysis. Histograms of MHCII and CD11c
expression for differentiated monocytes. c, Phoenix E cells were transfected with Murine Stem
Cell Virus (MSCV) retroviral plasmids expressing the mutant human estrogen receptor (ERT2),
murine Myc (c-MYC), murine Mycl1 (L-MYC), and a fusion between Mycl1 and the mutant
human estrogen receptor (L-MYC-ERT2). Whole-cell extracts were prepared 2 days after
transfection and Western blot analysis was performed. Shown are immunoblots for L-MYC
(left) and c-MYC (right) on the indicated transfections. Blots were stripped and re-probed for
GFP (bottom).
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Supplementary Figure 4.6: L-Myc regulates DC homeostasis
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(A) Shown is the quantitation of splenic DC subsets as gated in (Figure 3 F) from WT (black
dots) and Mycl1gfp/gfp (green dots) mice on the C57BL/6 (A) and 129SvEv (B) genetic
backgrounds. Total number of the indicated DC subset per spleen (right panels) and DC subset
as a percent of all splenocytes (left panels) was determined for each genetic background. Data
are from 3 independent experiments (bar, SD: n=7 biological replicates for C57BL/6
background and 10 biological replicates for 129SvEv background, Student’s t-test). (C-E) Cells
were harvested from liver (C), lung (D), and small intestine (E) of WT and Mycl1gfp/gfp mice on
the C57BL/6 genetic background and stained for analysis. Shown are two-color histograms for
indicated markers. (F) Shown is the quantitation of CD103-CD11b+ DCs from the lung, liver and
small intestine as gated in (C-E) as a percent of all live hematopoietic cells. Data are from 3-4
independent experiments (bar, SD, n=6-7 biological replicates, two-way ANOVA Holm-Sidak
post hoc test). (G) Cells were harvested from the lung, liver and small intestine of the mixed BM
chimeras described in (Figure 5 A,C) and analyzed for relative donor contribution. Shown is the
contribution of CD45.2+ WT BM or CD45.2+ Mycl1gpf/gfp BM to CD103-CD11b+ DCs in the
indicated peripheral tissues as a ratio of peripheral blood neutrophils from the same animal. Data
are representative of 3 independent experiments (bar, SD; n=5-10, Mann-Whitney U test). (H)
Shown is the relative expression of Mycl1 from gene expression microarrays of lung-resident
CD103+CD11b- DCs and migratory CD103+CD11b- DCs from mediastinal lymph nodes (MLN)
(bar, SD; n=3 biological replicate arrays, Student’s t-test). (I) Cells were harvested from lung and
MLN of WT mice and stained for analysis. Shown is a two-color histogram of CD103 and
isotype expression, or CD103 and Ki67 expression for pre-gated CD103+CD11b- DCs from the
lung and MLN. (J) Shown is Gene Set Enrichment Analysis (GSEA) plot comparing gene
expression microarrays from lung-resident CD103+CD11b- DCs (Lung, red) and migratory
CD103+CD11b- DCs (Lymph node, blue) using “KEGG_Cell_Cycle” list of genes (Signal-tonoise calculation , n=3 biological replicate arrays per group). *, p<0.05; **, p<0.01, ***,
p<0.001; ns, p>0.05;

131

B
CD8a+ DC CD8a- DC

KO CD8a- DC

WT CD8a- DC

KO CD8a+ DC

WT CD8a+ DC

KO BM pDC

WT BM pDC

A

Stat4
2810417H13Rik
Top2a
Mki67
Cd63
Hspa1a, Hspa1b
Gm3579
Slc12a2
Art2a-ps
Ifitm1, Gm7676
Cxcl16
Pttg1
Kif11
2810417H13Rik
Snhg1
Kcnn4
Slc24a1
Anxa1
Ear2, BC151093
Ctnnd2
Gng5
Mir680-2
Jun
Hist1h2bg
Ndufs5
Snord32a, Rpl13a
Mid1
G530011O06Rik
Rnu3a
Snord118
Mycl1
Ddit4
Fkbp5
Hist1h4f
Hba-a1, Hba-a2
Ccng2
Mir103-2
Xlr4a, Xlr4b, Xlr4c
4930518I15Rik
Mras
LOC641050
Slfn8
Lcn2
Ngp
Camp
I730030J21Rik
Bex6
Emr4
Clec4a3
Pla2g7
Sirpb1a, Sirpb1b
Clec4a1
Rnf217
Ms4a1
Gp2
Ccl7
Socs2
Hist1h2ab
Neil3
Hist1h4c
Ccnb1
Ndc80
E2f8
Ccnb1
Gm889
Dock6
Gm7120
Vaultrc5
Gm10786
Klra5
Tnip3
Gm4964
Art2b
Snord15a
Clec4n
Etv1
Mcpt8
Gnai1
D17H6S56E-5
Hbb-b1, Hbb-b2
Snord14c, Snord14d, Hspa8
Snord14e
Stmn1
Ifitm2
Bcl2a1a, Bcl2a1d, Bcl2a1b, Bcl2a1c
ND3

9

15
0

20

1

0

41
pDC

C

3

Expression (log2)

Gene symbol

GO_biological_process

Top2a

DNA metabolic process

Mki67

Cell proliferation

Pttg1

Cell cycle

Ccng2

Cell cycle

Ccnb1

Cell cycle

Bcl2a1a

Apoptosis

E2F8

Cell cycle

Rpl13a

Ribosome biogenesis

Ndufs5

Electron transport chain

12

Supplementary Figure 4.7: Gene expression analysis of L-Myc deficient DCs
(A) Indicated DC subsets were sorted and microarray analysis performed. A 2-fold difference in
linear expression value between WT and KO DCs was used as the threshold for further analysis.
Shown is a heat map of log2-transformed linear expression values for genes determined to be
differentially expressed. Representative genes were distributed based on hierarchical clustering
of gene expression data from the indicated WT and KO DCs. Gene names have been color
coded according to their distribution within the Venn diagram described in (B). (B) Shown is a
Venn diagram of genes satisfying a 2-fold cutoff for all three indicated DC populations. The
total number of genes unique to a particular DC subset or common to any two or all three DC
subsets is indicated within the respective zones of the diagram. c, Shown is a table containing
growth-related genes from the heat map in (A). The gene symbol as well as the putative
"GO_biological_process" has been noted.
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Supplementary Figure 4.8: L-Myc regulates DC proliferation
(A) BM CDPs, pre-cDCs, and pDCs were cultured in Flt3L for 24 h. Wells were pulsed with
10µM BrdU for the last 4 h of culture. Histogram of BrdU and DAPI for the indicated pre-gated
cells. Data are representative of 2-3 experiments. (B,C) BM cells from WT mice were cultured
in Flt3L and infected on day 4 with a retrovirus expressing ERT2 or the L-MYC-ERT2 fusion
protein and then cultured for an additional 6 days. Cells were harvested and purified into subsets
as CD11cint SiglecH+ (pDC, B) or CD11c+ MHCII+ CD24+Sirp-α- (CD8α+ DC, C) by cell
sorting. Infected cells and uninfected control cells were treated with vehicle (DMSO) or 4hydroxytamoxifen (4-OHT) for 24 h in 100 ng/ml Flt3L, pulsed with 10 µM BrdU for the last 4
h and stained for BrdU incorporation. Shown is the percent of cells in S phase. (D) WT (black
dots) or Mycl1gfp/gfp (green dots) mice were infected intravenously with 3x103 Listeria
monocytogenes expressing ovalbumin (LM-OVA). Splenocytes were harvested at the indicated
time points and stained for analysis. Percent of CD8α+ DCs was determined for each indicated
day following infection. Data are from 2 independent experiments (bar, SD; n=8 biological
replicates, two-way ANOVA Holm-Sidak post hoc test). *, p<0.001; ns p>0.05.
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Supplementary Figure 4.9: Mycl1 is necessary for optimal T cell priming by DCs
(A-D) WT (black dots) and Mycl1gfp/gfp (green dots) mice infected with 3x103 LM-OVA were
analyzed 7 days later by re-stimulation with SIINFEKL(A) or LLO190-210 (B-D) peptide in vitro.
Shown is the quantitation of IFN-γ+ cells. Data are from 2 independent experiments (bar, SD;
n=12 biological replicates, Student's t-test). (E) Shown is the frequency of OT-I CD8+ T cells
(gated as CD45.1+CD8α+) as a percent of all splenocytes for the experiment described in (Figure
8 D). Data are from 2 independent experiments (bar, SD; n=8 biological replicates, Student's ttest). (F) Shown is the absolute number of donor OT-I CD8+ T cells from mice infected with 300
LM-OVA and analyzed as in (Figure 8 D). Data are from 2 independent experiments (bar, SD;
n=6 biological replicates, Student's t-test). (G) 1000 CD45.1+ LLO118 CD4+ T cells were
transferred intravenously into CD45.2+ WT or CD45.2+ Mycl1gfp/gfp recipients 1 day before
infection with LM-OVA. Expansion of donor LLO118 CD4+ T cells was determined 7 days
after infection. Shown is the frequency of LLO118 CD4+ T cells (gated as CD45.1+CD4+) as a
percent of all splenocytes. Data are from 2 independent experiments (bar, SD; n=7 biological
replicates, Student's t-test). (H) WT (top panels) or Mycl1gfp/gfp (bottom panels) mice were
infected intravenously with 5x106 PFU VSV-OVA. T cell restimulation was performed as in
(A). Shown is a two-color histogram of TNF-α and IFN-γ expression for cells pre-gated gated as
Thy1.2+CD8α+. Numbers represent the percent of cells in the indicated gate. Data are
representative of 2 independent experiments. (I) Shown is the quantitation of IFN-γ+ cells as a
percent of CD8+ T cells (gated as Thy1.2+ CD8α+). Data are from 2 independent experiments
(bar, SD; n=11 biological replicates, Student's t-test). i, *, p<0.05; **, p<0.01; ***, p<0.001; ns,
p>0.05.
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Supplementary Figure 4.10: pDCs and Notch2-dependent CD11b+ DCs are dispensable for
T cell priming
(A) WT and BDCA2-DTR transgenic mice were treated with 125 ng diphtheria toxin (DT) per
mouse one day before infection with LM-OVA. Shown is the quantitation of pDCs as a percent
of all splenocytes to confirm efficiency of deletion (bar, SD; n=4 biological replicates per group,
Student's t-test). (B) Shown is the quantitation of IFN-γ+ cells as a percent of CD8+ T cells
following re-stimulation of infection from (A) (gated as Thy1.2+ CD8α+). (bar, SD; n=4
biological replicates, Student's t-test). (C) Peripheral blood CD8+ T cells from indicated mice
were stained with H-2Kb-SIINFEKL tetramer on day 7 of infection with LM-OVA. Shown is
the frequency of tetramer+ cells as a percent of CD8+ T cells. (bar, SD; n=4 biological replicates,
Student's t-test). (D,E) DCs, OT-I CD8+ T cells, and OT-II CD4+ T cells were isolated by cell
sorting and T cells labeled with CFSE. DCs were pulsed with whole ovalbumin protein (Ova)
for 2 h at 37ºC and then washed extensively before either OT-I CD8+ T cells (D) or OT-II CD4+
T cells (E) were plated. Cells were collected 3 days later and stained for analysis. Shown are
single-color histograms of CFSE levles for pre-gated T cells. (F,G) d42m1 or H31m1
fibrosarcoma cells were injected subcutaneously and tumor diameter (± SD) (n=10) was
measured. Mice were treated with antibodies to deplete CD8 T cells, CD4 T cells and IFN-γ.
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4.4 Discussion
In the hematopoietic compartment, c-Myc and N-Myc act in many cell types and regulate
broad cellular processes, including B cell proliferation, T cell metabolism, and maintenance of
progenitor populations37,38,42,87. Distinct thresholds of c-Myc expression result in cellular
proliferation or apoptosis, suggesting that the cellular abundance of this protein is stringently
regulated88. Recent findings indicate that c-Myc acts as a global amplifier of transcription by
direct interactions with RNA polymerases I, II and III20,68-70,89, thus providing a mechanism that
accounts for its regulation of disparate and context-dependent target loci across cell types90. For
L-Myc, a third Myc family member, a direct role in proliferation and apoptosis has been
questioned because of its weaker ability to promote cellular growth, apoptosis or transformation
as compared to c-Myc or N-Myc91,92. Although L-Myc reprograms fibroblasts into induced
pluripotent stem cells more efficiently than c-Myc93, a unique physiologic function in vivo for LMyc has not yet been established5.
Among hematopoietic lineages, DCs are uniquely specialized in priming antigen-specific
immune responses based on their ability to process and to present antigens to T cells94. Mature
DC populations show a significant rate of proliferation in vivo25,47, and the receptor FMS-like
tyrosine kinase 3 (FLT3) regulates cDC homeostasis by promoting the division of these cells in
situ24. In other physiologic and malignant settings, FLT3 signaling leads to c-Myc induction via
STAT-dependent pathways21,22. However, in DCs, proliferation and expansion7,8 occurs in the
presence of inflammatory cytokines such as type I interferons (IFN) that suppress Myc
transcription through STAT1 interactions at GAS elements in the promoter region95-97. To
further examine the homeostatic mechanisms that regulate the frequency of DCs at steady state
and during inflammation, we studied the expression of c-Myc and its paralogs and investigated
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whether L-Myc plays a non-redundant role in supporting continued proliferation and expansion
in these cells. We determined that L-Myc regulates many of the same cellular processes as cMyc or N-Myc. For example, cell size and growth were dramatically affected by L-Myc
deficiency, suggesting possible functional equivalence in certain contexts. Moreover, L-Myc
also regulated many inducible genes following activation. Through our cellular studies of LMyc deficient mice, we characterized a critical cell-intrinsic role for CD8α+ DCs in supporting
the initial growth of L. monocytogenes, which is also necessary for establishing optimal priming
of CD8 and CD4 T cell responses. This latter observation may help explain why early antibiotic
treatment of mice dramatically blunts antigen-specific responses98-100.
Although L-Myc is a functional member of the Myc family34,101, its function and
relationship to other Myc factors has remained uncertain5,6. L-Myc is selectively expressed in
DCs, maintained in the presence of inflammation, and regulates proliferation and survival
required for normal DC-mediated T cell priming to bacterial and viral infections. Since c-Myc is
repressed by interferons95-97, the switch from c-Myc to L-Myc expression in DCs may be a
strategy to maintain DC function in the setting of inflammation required for driving optimal Tcell responses. L-Myc may therefore represent a therapeutic target for selective inhibition or
augmentation of immune responses during autoimmunity or vaccination.

4.5 Materials and Methods

4.5.1

Mice.

Wild-type (WT) 129S6/SvEv mice were purchased from Taconic. WT C57BL/6 mice, Csf2rb-/mice and the congenic strain B6.SJL-Ptprca Pepcb/BoyJ (B6.SJL) were purchased from The
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Jackson Laboratory. Mice were bred and maintained in our specific pathogen-free animal facility
according to institutional guidelines. The generation of GFP-c-Myc (c-Mycgfp/gfp), Zbtb46DTR/DTR,
and BXH2 (Irf8R294C) mice has been described previously50,58,102. Irf8R294C mice were
backcrossed to the C57BL/6 background for 11 generations. Experiments were performed with
sex- and age-matched mice at 6-16 weeks of age. All pathogen infections were performed on
mice of the 129S6/SvEv genetic background unless otherwise indicated.

4.5.2

Generation of Mycl1gfp mice.

The Mycl1-gfp targeting construct was assembled using MultiSite Gateway Technology
(Invitrogen). The pENTR-lox-GFP.Neo plasmid was constructed as published18. The 5′
homology arm (1584 bp) was amplified by PCR from EDJ22 ESC genomic DNA
(129S6/SvEvTac background) using the following oligonucleotides, which contain attB4 and
attB1 sites: 5′- GGGGACAACTTTGTATAGAAAAGTTGGTAGCCTGTTTATGATAACACA
-3′ and 5′-GGGGACTGCTTTTTTGTACAAACTTGGTCCGCTCCCTGCGGGAGGG-3′. The
BP recombination reaction between the attB4 and attB1-flanked PCR product and pDONR P4P1R (Invitrogen) resulted in the pENTR-Mycl1-5HA plasmid. The 3′ homology arm (3497 bp)
was amplified by PCR from EDJ22 ESC genomic DNA using the following oligonucleotides,
which contain attB2 and attB3 sites: 5′GGGGACAGCTTTCTTGTACAAAGTGGGTAAGGACCACCCGGGGGCT-3′ and 5′GGGGACAACTTTGTATAATAAAGTTGTTAGTAGCCACTGAGGTACG-3′. The BP
recombination reaction between the attB2 and attB3-flanked PCR product and pDONR P2R-P3
(Invitrogen) resulted in the pENTR-Mycl1-3HA plasmid. A LR recombination reaction was
performed using pENTR-Mycl1-5HA, pENTR-lox-GFP.Neo, pENTR-Mycl1-3HA, and pDEST
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DTA-MLS103 to generate the final targeting construct. The SwaI linearized vector was
electroporated into EDJ22 embryonic stem cells (129SvEv background), and targeted clones
were identified by Southern blot analysis. Probes were amplified from genomic DNA using the
following primers: Mycl1_ProbeA_Fwd, TGCATGCCTGACAACAAGAC;
Mycl1_ProbeA_Rev, CCAATTCATCTAGAATCCTACA; Mycl1_ProbeB_Fwd,
ATGCTATTCTGAGGCCATTTG; and Mycl1_ProbeB_Rev, GCCCCTTGATGTGTGCATAC.
Blastocyst injections were performed and resulting male chimeras were bred to female
129S6/SvEvTac mice. Genotyping was conducted by PCR to confirm germline transmission and
to determine the genotype of progeny mice using primers Mycl15UTR_Fwd
(TGAACTCGCTCCCCTCAG), Mycl1Exon1_Rev (GCACCAGCTCGAATTTCTTC), and
Mycl1GFP_Rev (AAGTCGTGCTGCTTCATGTG) which resulted in WT band of 337 bp and
KO band of 525 bp. For indicated experiments Mycl1gfp mice were backcrossed to C57BL/6J for
at least seven generations. The loxP-flanked neo resistance cassette was removed from the
germline by crossing to B6.C-Tg(CMV-cre)1Cgn/J (The Jackson Laboratory) at F4 and loss of
the CMV-cre transgene in subsequent generations was confirmed by PCR.

4.5.3

Generation of L-MYC-specific rabbit polyclonal antibody and immunoblot analysis.

Murine full-length Mycl1 cDNA was PCR amplified from splenic CD8α+ cDC cDNA library.
The resulting PCR product was ligated into the expression vector pET-28a(+) (Novagen)
downstream of the His-Tag and the final plasmid was transformed into the Escherichia coli
expression strain BL21-CodonPlus(DE3)-RIL (Stratagene). Recombinant L-MYC was expressed
for 12 hours at room temperature and then affinity purified on Ni-NTA His·Bind® Resin
(Novagen) according to manufacturer's instructions. Purified recombinant L-MYC was used to
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immunize New Zealand White Rabbits (Harlan Laboratories) according to a standard 112-day
protocol. Finally, rabbit anti-mouse L-MYC sera were collected and L-MYC-specific antibody
was affinity purified and tested by Western blot analysis.
For immunoblot analysis, either whole-cell extracts were prepared with RIPA lysis buffer
containing protease inhibitors, or nuclei were obtained after cellular lysis with buffer containing
0.2% Nonidet P40 as described104. Extracts were denatured in Laemmli sample buffer at 95°C
for 10 minutes, and 5x105 to 1x106 cell equivalent of denatured extract was loaded per well of a
7.5% precast mini polyacrylamide gel (Bio-Rad). Proteins were then transferred onto a
nitrocellulose membrane using a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad) according to
manufacturer's instructions. Blots were blocked with a solution containing 5% non-fat milk and
0.05% Tween-20 for 1 hour at room temperature and then incubated with primary antibody
overnight at 4ºC. After extensive washing, blots were incubated with a goat anti-rabbit IgG
(H+L) conjugated to horseradish peroxidase (Jackson ImmunoResearch Laboratories, Inc.) for 1
hour at room temperature. Finally, blots were developed with ECL Western Blotting Substrate
(Thermo Scientific) according to manufacturer's instructions.
c-MYC Western blot analysis was performed similarly to the abovementioned protocol except a
commercial rabbit anti-c-Myc antibody (Y69) was used (Abcam). Rabbit anti-GFP antibody (sc8334, Santa Cruz Biotechnology, Inc.) and Rabbit anti-HDAC1 (Abcam) were used to determine
equivalent loading across blots.
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4.5.4

BrdU incorporation and cell-cycle analysis.

For in vivo BrdU-incorporation studies, mice of the C57BL/6 genetic background were injected
intraperitoneally (i.p.) with 2 mg BrdU (Sigma) or intravenously (i.v.) with 1 mg BrdU in
pyrogen-free saline. Splenocytes were harvested after 4 hours for i.p. injected and 1 hour for i.v.
injected mice. Intracellular BrdU staining was performed with APC BrdU Flow Kit (BD
Pharmingen) according to manufacturer's instructions following cell-surface staining. In vitro
BrdU-incorporation studies to determine the frequency of cells in S phase of cell cycle were
performed on sorted populations, which were then cultured for 24 hours in 100 ng/ml Flt3 ligand
(Flt3L). To detect cells in S phase of cell cycle, 10 µM BrdU was added for the last 4 hours of
culture, after which cells were fixed, permeablized, and stained according to APC BrdU Flow
Kit instructions. Analysis was performed on a BD FACS CANTO II (BD Biosciences) and the
event rate was maintained below 300 events per second on the lowest flow rate to ensure doublet
exclusion. Total frequency of cells in S/G2/M phase of cell cycle was determined by DAPI
staining of isolated populations as described previously105.

4.5.5

Pathogen infections.

Listeria monocytogenes expressing a secreted form of OVA (LM-OVA106) was a gift from Dr. H.
Shen (University of Pennsylvania School of Medicine, Philadelphia, PA). LM-OVA was stored
as glycerol stocks at −80ºC and diluted into pyrogen-free saline for i.v. injection into mice. Mice
were infected with 3x103 LM-OVA and sacrificed 7 days later for T cell analysis unless
otherwise indicated. Vesicular stomatitis virus encoding full-length ovalbumin (VSV-OVA) was
a gift from Dr. L. Lefrancois (University of Connecticut Health Center, Farmington, CT)107.
VSV-OVA stocks were stored in PBS at -80ºC and diluted into pyrogen-free PBS prior to
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injections into mice. Mice were infected i.v. with 5x106 PFU of virus and sacrificed 7 days later
for T cell analysis unless otherwise indicated.
For lethal infectious challenge, the wild-type L. monocytogenes strain EGD was used in this
study80. Listeria was stored as glycerol stocks at -80°C and diluted into pyrogen-free saline for
i.v. injection into mice. A dose of 100,000 CFU diluted from concentrated frozen stocks was
determined to be 80-90% lethal for 8-week-old wild-type male mice on the C57BL/6 genetic
background. Mycl1gpf/gfp mice on the 129SvEv genetic background were backcrossed for 10
generations with mice on the C57BL/6 genetic background to establish Mycl1gfp/gfp mice on
C57BL/6 background for lethal Listeria challenge.
Toxoplasma gondii:

The type II Prugniaud strain of T. gondii expressing a firefly luciferase

and GFP transgene (PRU-FLuc-GFP) (provided by J. Boothroyd, Stanford University, Palo Alto,
CA) was used in all tachyzoite experiments. The parasites were grown in culture in human
foreskin fibroblasts as previously described108. For infections, freshly egressed parasites were
filtered, counted, and injected intraperitoneally into mice. C57BL/6, 129S6/SvEv, and BALB/c
mice were infected with 100, 200, and 1,000 tachyzoites, respectively, for most experiments.
BALB/c mice used for tetramer studies were infected with 5,000 tachyzoites. BALB/c bone
marrow chimeras and controls were infected with 100 tachyzoites.
Citrobacter rodentium: Mice were infected by intraoral inoculation of 2 × 109 colony-forming
units of C. rodentium, strain DBS100 (American Type Culture Collection) as described109.
Survival and weight loss were monitored for 30–45 d. Survival studies were done in accordance
with institutional guidelines and with protocols approved by the Animal Studies Committee at
Washington University in St. Louis.
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4.5.6

Sorting of pathogen infected tissue.

Mice were infected with 5x105 CFU LM-EGD (2 hour time point), 1x105 CFU LM-EGD (24
hour time point), or 8x104 CFU LM-EGD (60 hour time point) as previously described82. Single
cell suspensions were prepared with collagenase B and DNAse I in the presence of 5 µg/ml
gentamicin. After ACK lysis of red blood cells, splenocytes were switched to MACS buffer for
enrichment of CD11c-expressing cells (following manufacturers guidelines). Samples were then
stained and sorted on an ARIA II directly into MACS buffer. Samples were then spun down at
400xg for 5min, buffer was removed and cell lysed in PBS + 0.05% Triton-X 100. Lysates were
plated on BHI agar plates and colon forming units were quantitated 24 hours later.

4.5.7

In vitro T cell restimulation after LM-OVA or VSV-OVA infection.

7 days after infection, spleens were mechanically disrupted, red blood cells were lysed with ACK
lysis buffer, and single cell suspensions were counted on a Vi-CELL (Beckman Coulter). 2×106
splenocytes were restimulated for 5 hours in the presence of 1 µg/mL Brefeldin A and 5µM of
either OVA peptide (257-264) or LLO peptide (190-201) (Anaspec) to activate either CD8 T
cells or CD4 T cells, respectively. After restimulation, splenocytes were surface stained with
antibodies to identify T cell populations, fixed in paraformaldehyde and stained for intracellular
IFN-γ and TNF-α in a saponin-based buffer. Dead cells were excluded with LIVE/DEAD®
Fixable Aqua Dead Cell Stain Kit (Invitrogen) according to manufacturer's instructions and
analysis was performed on a BD FACS CANTO II.
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4.5.8

Quantitative RT-PCR.

Wild-type myeloid and lymphoid cells from spleens of C57BL/6 mice were sorted to greater than
95% purity on a BD FACSAria II (BD Biosciences). DNase-treated total RNA was prepared
with RNeasy Micro Kit (Qiagen) and first-strand cDNA synthesis was performed with
SuperScript III Reverse Transcriptase (Invitrogen) using Oligo(dT)20 Primer (Invitrogen).
Relative quantitation of gene expression was performed on a StepOnePlus Real-Time PCR
System (Applied Biosystems) according to the Relative Standard Curve method and using
HotStart-IT SYBR Green qPCR Master Mix (Affymetrix/USB). PCR conditions were 10 min at
95°C, followed by 40 two-step cycles consisting of 15 sec at 95°C and 1 min at 60°C. Primers
used for L-Myc (Mycl1) and Hprt expression were as follows: Mycl1_qPCR_ Fwd,
CCCCAGCGATTCTGAAGGT; Mycl1_qPCR_ Rev, TGTCCAGAGATCGCCTCTTCTC;
Hprt-F, TCAGTCAACGGGGGACATAAA; and Hprt-R, GGGGCTGTACTGCTTAACCAG.

4.5.9

Expression microarray analysis.

Bone marrow (BM) pDCs (gated as CD11c+SiglecH+B220+MHCII+) from wild type (WT) and
Mycl1gfp/gfp mice of the 129SvEv genetic background were sorted to greater than 95% purity on a
BD FACSAria II (BD Biosciences). Splenic CD8α+ cDC (gated as
CD11c+MHCII+CD205+CD8α+CD11b-B220-) and CD8α- cDC (gated as
CD11c+MHCII+CD11b+ CD205-CD8α-B220-) from WT and Mycl1gfp/gfp mice of the C57BL/6
genetic background were similarly sorted. DNase-treated total RNA was isolated from cells
using the Ambion RNAqueous-Micro Kit. For Mouse Gene 1.0 ST Arrays, RNA was amplified
with the Ovation Pico WTA System (NuGEN), and then fragmentation and labeling was
performed with Encore Biotin Module (NuGEN). Background-corrected expression values were
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normalized using RMA quantile normalization and expression values were modeled using
ArrayStar software (DNASTAR). All original microarray data have been deposited in NCBI's
Gene Expression Omnibus (GEO) and are accessible through GEO: Myc family expression
values were determined from the following published microarray datasets: hematopoietic
progenitors (GSE14833, GSE20244), dendritic cell (DC) progenitors (GSE37030), mature DC
subsets (GSE9810). Gene Set Enrichment Analysis (GSEA)67 tool (Broad Institute, MIT) was
used to compare lung and lymph node dendritic cell gene expression profiles. We used the
"KEGG_Cell_Cycle" list under C2 (curated gene sets). Since 3 biological replicates were
available per tissue, enrichment was assessed through the use of gene-set permutations (x1000)
and log2 ratio of classes as metric for ranking genes. Lung and mediastinal lymph node CD103+
DC microarrays were obtained from the Immunological Genome Project dataset (GSE15907).
Microarray data of wild-type and L-Myc-deficient dendritic cells have been deposited in GEO as
GSE53312.

4.5.10 Immunofluorescence microscopy.
Spleens and lymph nodes were fixed in 2% methanol-free paraformaldehyde (Electron
Microscopy Sciences) for 12 hours followed by incubation in 30% sucrose/H2O overnight,
embedded in OCT compound, and cryosectioned at 7 microns. Staining of sections, image
acquisition and processing were performed as published18. Briefly, sections were blocked/stained
in CAS Block (Invitrogen) supplemented with 0.2% TritonX-100 and mounted with ProLong
Gold Antifade reagent containing DAPI (Invitrogen). Monochrome images were acquired with
either 10X or 20X objective and exported into ImageJ software for subsequent color balancing
and overlaying.
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4.5.11 Dendritic cell and macrophage preparation.
Dendritic cells from lymphoid organs and non-lymphoid organs were harvested and prepared as
described110. Briefly, spleens and lymph nodes were minced and digested in 5 ml Iscove’s
modified Dulbecco’s media + 10% FCS (cIMDM) with 250 µg/ml collagenase B (Roche) and 30
U/ml DNase I (Sigma-Aldrich) for 30 min at 37°C with stirring. Cells were passed through a 70µm strainer before red blood cell (RBC) lysis. Cells were then counted on a Vi-CELL analyzer,
and 5–10 × 106 cells were used per antibody staining reaction. Lung, liver, and kidney cell
suspensions were prepared after perfusion with 10 ml Dulbeccos PBS. Dissected and minced
tissues were digested in 5ml cIMDM with 4mg/ml collagenase D (Roche) for 1 h at 37°C with
stirring. Digested tissues were filtered and RBCs lysed as above. Cells from the peritoneal
cavity were collected by flushing with 10 ml PBS+5%FCS and 2mM EDTA. Epidermal and
dermal cell suspensions were prepared as described previously111. Microglia were isolated as
described previously 105. Lastly, small intestine lamina propria cells were isolated as described
previously112.

4.5.12 In vitro BM-derived dendritic cells.
Femurs and tibias were manually flushed to collect BM cells, and then RBCs were lysed in ACK
lysis buffer. To obtain Flt3-ligand derived pDC and cDC equivalents, BM cells were cultured in
complete IMDM at a density of 2×106 cells/ml containing 150 ng/ml murine Flt3L (Peprotech)
for 9 or 10 days. Alternatively, GM-CSF DCs were obtained by culturing BM cells in complete
IMDM at a density of 6x105 cells/ml containing 20ng/ml murine GM-CSF (Peprotech) for 8
days. Non-adherent cells were collected for FACS analysis or sorting. Sorted progenitors were
cultured at a density of 50x104 cells/ml for either 24 hours or 4 days in 100 ng/ml Flt3L.
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4.5.13 Plasmids and retroviral infection of DCs.
cDNA for Mycl1 was generated by PCR from cDNA of CD8α+ DCs. We used the previously
described method for generating a functional Myc-ER fusion protein88, which placed a segment
of the estrogen receptor (ER) at the C-terminus of the Myc protein. Specifically, the cDNA for
ERT2 was obtained by PCR from the p-Cre-ERT2 vector (a gift from Dr. T. Egawa, Washington
University School of Medicine, St. Louis, MO) and cloned into the retroviral plasmid MSCVIRES-GFP, creating the construct ERT2-MSCV-IRES-GFP. After removing the stop codon,
Mycl1 cDNA was cloned upstream of the ERT2 sequence derived from Cre-ERT2 (ref 113,114),
creating the plasmid L-Myc-ERT2-MSCV-IRES-GFP. Retroviral plasmids were transfected into
Phoenix E packaging cells as described previously115, and Flt3-ligand cultures were infected as
described previously7 except infections were performed on day 4. cDNA for murine Irf8 and
Myc were generated by PCR from cDNA of splenocytes of C57BL/6 mice, sequenced to confirm
identity, and cloned into the MSCV-IRES-GFP retroviral plasmid.
For transduction of macrophage-dendritic cell progenitors (MDP), we isolated MDPs from the
bone marrow (BM) of 6-week-old C57BL/6 mice and cultured them for 12 h in Flt3-ligand
before transduction. Transduced MDPs were allowed to differentiate for an additional 5 days
before analysis.

4.5.14 Antibodies and flow cytometry.
Staining was performed at 4°C in the presence of Fc block (clone 2.4G2, BD Biosciences) in
FACS buffer (PBS, 0.5% BSA, 2 mm EDTA). The following antibodies were purchased from
BD Biosciences: V450 and PerCP-Cy5.5 anti-NK1.1 (PK136), V450 anti-Ly6C/G (RB6-8C5),
V450 anti-Ly6C (AL21), V500 anti-B220 (RA3-6B2), PE and PE-Cy7 anti-CD8α (53-6.7), PE147

Cy7 and APC anti-CD4 (RM4-5), PE-Cy7 anti-CD24 (M1/69), PerCP-Cy5.5 anti-Ly6G (1A8),
FITC and APC anti-CD172a/Sirpα (P84). These antibodies were purchased from eBioscience:
PE anti-NKp46 (29A1.4), PerCP-Cy5.5 and AlexaFluor700 anti-CD11b (M1/70),
APCeFluor780 anti-CD11c (N418), PE anti-CD103 (2E7), APC anti-CD317/BST2 (eBio927),
eFluor450 anti-MHCII (I-A/I-E) (M5/114.15.2), FITC and APC anti-CD45.2 (104), PE-Cy7 and
PerCP-Cy5.5 anti-CD45.1 (A20), PerCP-Cy5.5 anti-CD16/32 (93), PE-Cy7 anti-cKit (2B8),
eFluor450 anti-CD105 (MJ7/18), eFluor450 and Biotin anti-Ter119, PE anti-CD135 (A2F10),
AlexaFluor700 and PerCP-Cy5.5 anti-Sca1 (D7), FITC, APC and PerCP-eFluor710 anti-SiglecH
(eBio440C), Biotin and APC anti-CD115 (AFS98). These antibodies were purchased from
Miltenyi: PE anti-CD205/Dec205 (NLDC-145) and APC anti-CD205/Dec205 (NLDC-145).
These antibodies were purchased from Invitrogen: APC anti-F4/80 (BM8), PE anti-B220 (RA36B2), FITC and APC anti-CD8α (5H10). These antibodies were purchased from Biolegend: PE
and APC anti-SiglecH (551), Biotin anti-Ly6G (1A8), Biotin anti-MHCII (M5/114.15.2).

4.5.15 Luciferase Imaging
Imaging was done as previously described 116. In brief, mice were given intraperitoneal
injections of D-Luciferin (Biosynth AG, Switzerland) at 150 mg/kg and allowed to remain active
for 5 min. Animals were then anesthetized with 2% isoflurane for 5 min and then imaged with a
Xenogen IVIS 200 machine (Caliper Life Sciences). Data were analyzed with the Living Image
software (Caliper Life Sciences).
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4.5.16 Statistical analysis.
Analysis of all data was done with Prism 6 (GraphPad Software, Inc.). P values were calculated
with Student’s t test, Mann-Whitney test, or analysis of variance (ANOVA) with appropriate
post hoc test as specified in figure legends. Statistical analysis of mouse survival was determined
using log-rank test. P values less than 0.05 were considered significant.

4.6 Author Contributions
W.K. and K.M. designed the study. W.K. performed all experiments and analysis of
Mycl1gfp mice with contributions from individual co-authors. W.K. generated Mycl1gfp mice with
gene-targeting assistance from J.A. and A.S. A.S. contributed to generating DC progenitor
microarrays (with guidance from D.B.), monocyte culture experiments and immunofluorescence
experiments. B.E., X.W., C.B., N.K. contributed to experiments related to L. monocytogenes
infection. A.R. performed VSV infections. X.W. provided assistance with the manuscript.
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5.1

Abstract	
  
Bcl11a is a transcription factor known to regulate lymphoid and erythroid development.

Recent bioinformatic analysis of global gene expression patterns has suggested a role for Bcl11a
in the development of dendritic cell (DC) lineages. We tested this hypothesis by analyzing the
development of DC and other lineages in Bcl11a−/− mice. We found that Bcl11a was required for
expression of IL-7 receptor (IL-7R) and Flt3 in early hematopoietic progenitor cells. In addition,
we found severely decreased numbers of plasmacytoid dendritic cells (pDCs) in Bcl11a−/− fetal
livers and in the bone marrow of Bcl11a−/− fetal liver chimeras. Moreover, Bcl11a−/− cells
showed severely impaired in vitro development of Flt3L-derived pDCs and classical DCs
(cDCs). In contrast, we found normal in vitro development of DCs from Bcl11a−/− fetal liver
cells treated with GM-CSF. These results suggest that the persistent cDC development observed
in Bcl11a−/− fetal liver chimeras reflects derivation from a Bcl11a- and Flt3-independent pathway
in vivo.

5.2

Introduction
Dendritic cells (DCs), comprising classical DCs (cDCs) and plasmacytoid DCs (pDCs),

develop from a common DC progenitor (CDP) residing in the bone marrow (BM); unlike
myeloid progenitors at earlier stages of development, CDPs have excluded monocyte and
macrophage potential but give rise to all DC subsets at the clonal level 1-4. Several transcription
factors that act broadly in hematopoiesis are known to regulate the development of all DCs,
including Ikaros 5,6, PU.1 7,8, and Gfi1 9. Transcription factors that regulate specific subsets of
DCs have also been reported. For example, E2-2 is required for development of pDCs 10, Batf3
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for CD8+ cDCs 11, Irf8 for pDCs and CD8+ cDCs 12,13, and the NF-κB family member RelB for
CD4+ cDCs 5,14,15.
A bioinformatic analysis of global gene expression patterns has identified groups of
transcription factors that may be involved in fate decisions along the DC lineage 16. Among
genes that increase in expression from the macrophage–DC progenitor (MDP) to the CDP, those
that do not increase in expression from the MDP to the monocyte were labeled in that analysis as
possible promoters of DC commitment. Transcription factors identified by these criteria include
some previously associated only with pDC development, including E2-2 and Spi-B 17,18, and
some previously associated only with cDCs, including Zbtb46 19,20. Other factors identified in
this analysis include Irf8, Bcl11a, and Runx2. Recently, it has been demonstrated in the setting
of competitive BM reconstitution that Irf8 promotes the development of all DC subsets 21, even
though Irf8−/− mice in other settings do not show defects in CD4+ cDC development 12,13. We
wondered, therefore, whether a similar early role in DC development could be identified for
another factor such as Bcl11a.
Bcl11a was first described as a gene located at a common proviral integration site in
BXH2 myeloid leukemias, and its human ortholog was found to be a recurrent target of
translocations in B cell malignancies 22,23. This gene encodes a Krüppel-like zinc finger
transcription factor expressed in neural and lymphoid tissues that is essential for the development
of B cells and for thymocyte maturation 24. In the erythroid lineage, BCL11A acts in trans to
silence the fetal hemoglobin locus in cooperation with the transcription factor SOX6 25,26.
Indeed, differences in stage-specific expression between human BCL11A and mouse Bcl11a
account at least in part for interspecies differences in fetal hemoglobin expression patterns 25.
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Although Bcl11a has been recognized as a useful marker of pDCs 27,28, its actual role in
DC development remains unreported. Thus, we sought to examine DC development in the
setting of Bcl11a deficiency in vivo and in vitro. We found that Bcl11a was required for normal
expression of IL-7 receptor (IL-7R) as well as Flt3 in early hematopoietic progenitors. In
addition, we observed a strict requirement for Bcl11a in pDC development and found evidence
for a Bcl11a-independent pathway of cDC development in vivo.

5.3

Results

5.3.1

Bcl11a is required for development of CLPs and CDPs
During hematopoiesis, Bcl11a is expressed at similar levels in the hematopoietic stem

cell (HSC), multipotent progenitor (MPP), common lymphoid progenitor (CLP), common
myeloid progenitor (CMP), and megakaryocyte–erythroid progenitor (MEP) 16. To study the
function of Bcl11a in hematopoietic progenitors, we used mice targeted for deletion of the first
exon of Bcl11a 24. Since Bcl11a−/− mice die in utero or perinatally, we compared hematopoietic
progenitor populations present in wild type (WT) and Bcl11a−/− fetal livers at embryonic day
14.5. First, we analyzed development of Lin−Sca-1+c-Kit+ (LSK), CLP, granulocyte-macrophage
progenitor (GMP), MEP, and CDP populations (Figure 5.1). WT and Bcl11a−/− fetal livers
showed comparable frequencies of GMPs and MEPs. However, Bcl11a−/− fetal livers showed a
greater than twofold decrease in the frequency of LSK cells and more marked decreases in
frequencies of IL-7R+ CLPs and Flt3+ CDPs relative to WT fetal livers (Figure 5.1A, B); within
the LSK fraction, Bcl11a−/− fetal livers showed defects in both CD150 (Slamf1)+ and CD150–
populations (Figure 5.1C). One study has demonstrated that a Sca-1loc-Kit+Flt3+CD150–
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population with granulocyte and macrophage potential (SL-GMP) can be identified which
excludes mast cell potential 29; GMPs in the Bcl11a−/− fetal liver, however, lacked Flt3
expression (data not shown) and no SL-GMP population could be identified (Figure 5.1D). Next,
we analyzed hematopoietic development in chimeras produced by transferring WT or Bcl11a−/−
fetal liver cells into lethally irradiated congenic recipient mice (Figure 5.2). Four to six weeks
after transfer, donor-derived Bcl11a−/− BM showed decreased frequencies of LSK cells, CLPs,
and CDPs but comparable frequencies of GMPs and MEPs relative to donor-derived WT BM
(Figure 5.2A, B); within the LSK fraction, donor-derived Bcl11a−/− BM showed a greater
proportion of CD150+ cells than did donor-derived WT BM, corresponding to a decrease in the
overall frequency of the more differentiated CD150– population (Figure 5.2C). As in Bcl11a−/−
fetal livers, no SL-GMP population could be identified in donor-derived Bcl11a−/− BM (Figure
5.2D). In summary, the loss of Bcl11a in hematopoietic progenitors resulted in impaired
development of LSK cells as well as a selective loss of CLPs and CDPs; these effects were
observed both in the fetal stage and in the adult chimera, demonstrating that this factor is
required in fetal and adult hematopoiesis.
Conceivably, the absence of IL-7R+ CLPs and Flt3+ CDPs in Bcl11a−/− fetal livers and
BM could result from a requirement for Bcl11a in the development of the CLP and CDP or from
a more restricted requirement for Bcl11a in the expression of IL-7R and Flt3, the surface markers
that identify these populations. In either case, however, the loss of Bcl11a should result in DC
defects because Flt3 ligand (Flt3L) signaling is essential for DC development in the steady state
30-32
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Figure 5.1:Bcl11a is required for development of lymphoid and DC progenitors in the fetus
(A) Flow cytometry analysis of progenitor populations in WT and Bcl11a−/− fetal livers dissected
at embryonic day 14.5 (E14.5). Populations are gated as indicated; numbers represent the
percentage of cells within the histogram that lie in the indicated gate. Data are representative of
two mice per group. (B) Progenitor populations in WT and Bcl11a−/− fetal livers at E14.5,
analyzed by flow cytometry as in (A) and presented as a percentage of total fetal liver cells. Bars
represent the mean (± SEM) of two mice per group. (C) CD150 (Slamf1) expression within the
LSK fraction in WT and Bcl11a−/− fetal livers at E14.5. (D) SL-GMPs in WT and Bcl11a−/− fetal
livers at E14.5
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Figure 5.2: Bcl11a is required for development of lymphoid and DC progenitors in the
adult
(A) Flow cytometry analysis of progenitor populations in lethally irradiated congenic mice
reconstituted with WT or Bcl11a−/− fetal liver cells, analyzed four weeks after transplant. Data
are representative of three mice per group. (B) Progenitor populations in WT and Bcl11a−/− fetal
liver chimeras at four weeks after transplant, analyzed by flow cytometry as in (A) and presented
as a percentage of total BM cells. Bars represent the mean (± SEM) of three mice per group. (C)
CD150 (Slamf1) expression within the donor-derived LSK fraction in WT and Bcl11a−/− fetal
liver chimeras at four weeks after transplant. (D) SL-GMPs in WT and Bcl11a−/− fetal liver
chimeras at four weeks after transplant.
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5.3.2

Bcl11a regulates expression of Il7r and Flt3
To identify Bcl11a target genes that explain its role in hematopoietic progenitors, we

compared global gene expression by microarray for donor-derived WT and Bcl11a−/−
populations isolated from chimeric BM (Figure 5.3). Since we observed that IL-7R- and Flt3expressing populations were affected by the loss of Bcl11a, we avoided the use of these surface
markers in order to allow for comparison of equivalent populations across genotypes. Thus, we
isolated multipotent progenitors (MPPs) as identified by the lack of CD150 expression within the
LSK fraction 33-35. We also isolated GMPs from the same BM, since the size of this population
was unaffected by loss of Bcl11a.
We found that WT and Bcl11a−/− GMPs were more similar to each other in gene
expression than WT and Bcl11a−/− MPPs were to each other (Figure 5.3A). One hundred and
thirty-four probe sets showed a greater than twofold change in expression between WT and
Bcl11a−/− GMPs. In contrast, 1020 probe sets showed a greater than twofold change in
expression between WT and Bcl11a−/− MPPs; of these, only 38 also show a greater than twofold
change between WT and Bcl11a−/− GMPs (Figure 5.3B). These data suggest that GMP
population size is unaffected by loss of Bcl11a because this transcription factor regulates
relatively few genes in GMPs.
Since the loss of Bcl11a impaired development of CDPs but not GMPs, we examined
Bcl11a target genes which showed expression patterns that distinguish DCs from monocytes and
macrophages. Thus, we compared the ratio of gene expression in CDPs relative to monocytes
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against the ratio of gene expression in Bcl11a−/− MPPs relative to WT MPPs (Figure 5.3C). Of
genes most highly expressed in CDPs relative to monocytes, those most affected by loss of
Bcl11a included Flt3, Cnn3 (encoding calponin 3), Dntt (encoding the template-independent
DNA polymerase TdT), Il7r, and Blnk (encoding B-cell linker protein, which links components
of B-cell receptor signaling). We also compared changes in gene expression between WT and
Bcl11a−/− MPPs for members of the core cDC transcriptional signature identified in a published
bioinformatic analysis 16 (Figure 5.3D). Within this core signature, we found only three genes—
Ass1, Amica1, and Flt3—that showed a greater than twofold decrease in expression in Bcl11a−/−
MPPs relative to WT MPPs. Taken together, the decreased expression of Flt3 and Il7r in
Bcl11a−/− MPPs suggests that Bcl11a may be specifically required for the expression of these
genes.
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Figure 5.3: Bcl11a regulates the expression of Flt3 and Il7r
(A) Microarray analysis of sorted GMPs (left) and MPPs (right) from WT and Bcl11a−/− fetal
liver chimeras. (B) Shown is a Venn diagram of probe sets (excluding normalization controls)
with a greater than twofold change in expression between WT and Bcl11a−/− MPPs. (C) Shown
are log2-transformed ratios of gene expression in Bcl11a−/− MPPs relative to WT MPPs (x-axis)
plotted against log2-transformed ratios of gene expression in WT CDPs relative to WT
monocytes (ImmGen; y-axis). For clarity, probe sets with less than twofold changes in
expression (log2-transformed ratios between −1 and 1) along either dimension are omitted (gray).
(D) Shown is a heat map of log2-transformed gene expression in WT and Bcl11a−/− GMPs and
MPPs for probe sets that constitute an ImmGen core cDC signature. Highlighted are genes that
show a greater than twofold change in expression between WT and Bcl11a−/− GMPs (red) or
between WT and Bcl11a−/− MPPs (green).
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5.3.3

Bcl11a is required for pDC but not cDC development in vivo
Next, we examined the development of mature hematopoietic subsets in WT and

Bcl11a−/− fetal liver chimeras (Figure 5.4). In accordance with previous reports 24, we observed
atrophic thymi in Bcl11a−/− chimeras (data not shown). In the BM, the size of the donor-derived
compartment was comparable in WT and Bcl11a−/− chimeras; in the spleen and skin-draining
lymph nodes, Bcl11a−/− cells were somewhat impaired in their competition against the residual
host population (Figure 5.4A). Within the donor-derived compartment of the spleen, a profound
defect in pDC development was apparent in Bcl11a−/− chimeras relative to WT chimeras (Figure
5.4B). In contrast, donor-derived cDCs were present in Bcl11a−/− chimeras with no significant
decrease relative to WT chimeras (Figure 5.4C).
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Figure 5.4: Bcl11a is required in vivo for development of pDCs but not cDCs
(A) Donor-derived (CD45.2+) chimerism in the BM, spleen, and skin-draining lymph node
(SLN) of WT and Bcl11a−/− fetal liver chimeras. Bars represent the mean (± SEM) of three mice
per group. (B) Flow cytometry analysis of donor-derived pDCs in the spleen. Data are
representative of three mice per group. (C) Flow cytometry analysis of donor-derived cDCs in
the spleen. Data are representative of three mice per group.

Among lymphoid subsets, donor-derived B cells, CD4 T cells, CD8 T cells, and γδ T
cells were decreased in frequency by at least tenfold in the spleens of Bcl11a−/− chimeras as
compared to WT chimeras, consistent with previous reports 24, while NK cells were decreased by
slightly more than threefold (Figure 5.5A). Among myeloid subsets other than pDCs, donorderived CD8− cDCs showed a modest threefold decrease in the spleens of Bcl11a−/− chimeras as
compared to WT chimeras; other myeloid populations examined, including CD8+ cDCs, were
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not decreased in frequency (Figure 5.5B). Thus, Bcl11a was strictly required for the development
of pDCs but not cDCs in vivo.
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Figure 5.5: Bcl11a deficiency in vivo impairs development of lymphoid and myeloid
populations
(A) Donor-derived lymphoid populations in the spleen of WT and Bcl11a−/− fetal liver chimeras,
analyzed by flow cytometry. Bars represent the mean (± SEM) of three mice per group. (B)
Donor-derived myeloid populations in the spleen of WT and Bcl11a−/− fetal liver chimeras,
analyzed by flow cytometry as in Fig. 4. Bars represent the mean (± SEM) of three mice per
group.

5.3.4

Flt3-dependent, but not GM-CSF–dependent, DC development requires Bcl11a in

vitro
We compared the development of WT and Bcl11a−/− cells in vitro in response to
treatment with Flt3L or granulocyte macrophage colony-stimulating factor (GM-CSF) (Figure
5.6). The observation that Flt3−/− mice retain DC development 36 suggests an alternative receptor
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for Flt3L or a Flt3L-independent pathway for DC development. Thus, we supplied excess Flt3L
or GM-CSF to distinguish between these possibilities in the context of Bcl11a deficiency. As
expected, pDCs developed from WT fetal liver cells (Figure 5.6A) and from the donor-derived
BM cells of WT chimeras (Figure 5.6B) in response to Flt3L treatment. In contrast, pDCs
developed in markedly decreased numbers from Bcl11a−/− fetal liver cells and completely failed
to develop from the donor-derived BM cells of Bcl11a−/− chimeras under these conditions
(Figure 5.6A, B), demonstrating that Bcl11a is required for pDC development in response to
Flt3L both in vivo and in vitro. We also examined cDC development from WT and Bcl11a−/−
fetal liver cells in vitro in response to treatment with Flt3L or GM-CSF. Flt3L-derived cDCs
were markedly reduced in cultures of Bcl11a−/− fetal liver cells relative to cultures of WT fetal
liver cells (Figure 5.6C, E). However, GM-CSF–derived DCs developed in normal numbers
from cultures of Bcl11a−/− fetal liver cells relative to cultures of WT fetal liver cells (Figure
5.6D, F). These results suggest that Flt3L cannot signal through an alternative receptor to rescue
cDC development in Bcl11a−/− cells, but that an alternative pathway of DC development may be
mediated by GM-CSF.
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Figure 5.6: Bcl11a is required in vitro for development of Flt3L-derived pDCs and cDCs
but not GM-CSF-derived cDCs
(A) Flow cytometry analysis of pDCs in Flt3L cultures of fetal liver cells. Data are representative
of three to four replicates over two experiments. (B) Flow cytometry analysis of pDCs in Flt3L
cultures of BM cells derived from fetal liver chimeras. Data are representative of three replicates.
(C, D) Flow cytometry analysis of Flt3L-derived cDCs (C) or GM-CSF-derived DCs (D) in
cultures of fetal liver cells. Data are representative of three to four replicates over two
experiments. (E, F) Counts of total cells and indicated subsets in Flt3L cultures (E) or GM-CSF
cultures (F) of fetal liver cells, analyzed by flow cytometry as in (C) or (D), respectively. Bars
represent the mean (± SEM) of three to four replicates per group pooled from two experiments.
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5.3.5

Loss of Flt3L results in lineage-specific defects in pDC development
Next, we examined the development of splenic pDCs in the context of IL-7R or Flt3L

deficiency. A previous study has demonstrated that splenic pDCs in Il7r−/− mice or Il7−/− mice
are decreased in absolute number when compared to WT controls 37. We found that splenic pDCs
in Il7r−/− mice were not decreased in proportion to total splenocytes when compared to WT
controls matched for strain, age, and sex (Figure 5.7A). This result suggests that the
hematopoietic defects in these mice may have relatively few lineage-specific consequences for
pDC development.
Previously, it has been found that Flt3−/− mice and Flt3l−/− mice show defects in the
development of pDCs 36,38. Accordingly, and in contrast to our observations in Il7r−/− mice, we
found that Flt3l−/− mice showed a greater than fourfold reduction in splenic pDC frequency as
compared to WT littermate controls (Figure 5.7B), in addition to reductions in absolute spleen
size (data not shown).
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(A) Flow cytometry analysis of pDCs in WT and Il7r−/− spleens. Data are representative of four
mice per group over two experiments. (B) Flow cytometry analysis of pDCs in WT and Flt3l−/−
spleens. Data are representative of three mice per group over two experiments. (C) Flow
cytometry analysis of donor-derived cDCs in the spleen of WT and Bcl11a−/− fetal liver
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group. (D) Bcl11a binding in the Flt3 genomic locus assayed by ChIP-qPCR. Data are
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5.3.6

Bcl11a is required for Flt3 expression in cDCs and binds the Flt3 genomic locus
Because we observed cDC development in Bcl11a−/− chimeras, we assessed whether

these cells might express Flt3 in a Bcl11a-independent manner; however, unlike WT cDCs in the
BM, Bcl11a−/− cDCs in the same compartment showed no discernible Flt3 expression by flow
cytometry (Figure 5.7C), again suggesting that a Flt3-independent pathway is instead responsible
for their development. Finally, to assay Bcl11a binding at the Flt3 locus, we performed
chromatin immunoprecipitation (ChIP) using mouse pro-B cells. By quantitative real-time
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polymerase chain reaction (qPCR), we detected an approximately threefold enrichment at a
region in the first intron of the Flt3 locus in DNA precipitated using anti-Bcl11a antibody as
compared to isotype control (Figure 5.7D).
In summary, our results document a strict requirement for Bcl11a in pDC development
both in vivo and in vitro; further, the requirement for Bcl11a in cDC development may differ
based on the cytokine stimulus to which progenitors are exposed. The actions of Bcl11a include
regulation of Flt3 expression by direct binding to the Flt3 locus, and Bcl11a is required for Flt3
expression in DCs and their progenitors.

5.4

Discussion
This study extends the known actions of Bcl1la in immune lineage development and

provides a mechanism for its effects. Although Bcl11a has been recognized as a factor required
for normal lymphoid development 24, the basis for this requirement has been unclear. It has been
shown that Bcl11a acts upstream of the B cell factors Ebf1 and Pax5 and that Il7r mRNA is not
expressed in Bcl11a−/− fetal livers 24. Lack of IL-7Rα or the cytokine receptor common γ chain
(γc, encoded by Il2rg) severely impairs T and B cell development 39-43. In T cell development,
IL-7R signaling is thought to promote thymocyte survival, since Bcl-2 rescues impaired T cell
development in Il7r−/− or Il2rg−/− mice 44-48. In B cell development, Bcl-2 does not rescue
development in the absence of IL-7R or γc 44-47,49, and IL-7R signaling is thought to induce
expression of the transcription factor Ebf in the CLP 50-52.
Here, we demonstrate that Bcl11a is required for normal expression of IL-7R as early as
the CLP and we add the novel observation that Bcl11a promotes the development of Flt3174

dependent lineages. Together, these actions provide a more complete account for previously
observed defects in lymphocyte development in Bcl11a−/− mice, since T cell potential is
preserved in IL-7–deficient CLPs in a Flt3L-dependent manner 53,54. The mechanisms by which
Bcl11a deficiency impairs T and B cell development, however, still remain incompletely
explored. Consistent with a previous report 24, we confirmed the presence of residual T and B
cells in the spleen of chimeras reconstituted with Bcl11a−/− fetal liver cells. By contrast,
tamoxifen-induced deletion of Bcl11a in chimeras that have been reconstituted with Rosa26CreERT2;Bcl11aflox/flox BM cells results in a more profound loss of T and B cells 55. Thus,
synchronous deletion of Bcl11a within a previously intact hematopoietic compartment produces
a different outcome than does sustained deficiency throughout hematopoiesis. These results may
point to a crucial lymphopoietic role for cells in which Bcl11a is dispensable for survival but
necessary for development or maturation, or vice versa; these cells could include HSCs, mature
T and B cells, or even residual CLPs undetectable due to a lack of IL-7R and Flt3 expression.
In line with a previous finding that E2-2 regulates Bcl11a expression 18, we also
document a strict requirement for Bcl11a in the development of pDCs. The development of
pDCs in vivo was lost in Bcl11a−/− fetal liver chimeras. In agreement, Flt3L cultures of BM
derived from these Bcl11a−/− chimeras showed a complete loss of pDC development in vitro.
Because mature pDCs are short-lived, non-proliferative, and continuously replenished from
progenitor populations 56,57, the nearly complete loss of this population is most attributable to a
developmental defect and not merely to cell survival defects in mature pDCs. This interpretation
would be consistent with a finding that rescue of Bcl11a-deficient progenitors from increased
apoptosis by p53 deficiency is unable to restore lymphoid potential 55.
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Notably, however, in vitro development of cDCs was eliminated in Flt3L cultures of
Bcl11a−/− fetal liver cells but was maintained in GM-CSF cultures of Bcl11a−/− fetal liver cells.
Flt3L and GM-CSF have distinct, non-redundant actions in supporting cDC development 58,59.
The combined loss of Flt3L and GM-CSF causes a more severe cDC deficiency than loss of
Flt3L alone; indeed, Flt3L-deficient mice retain an appreciable population of Flt3-expressing
progenitors 38. The maintenance of cDCs in Bcl11a−/− fetal liver chimeras suggests that these
cells may rely on a Bcl11a- and Flt3-independent pathway for their development, survival, or
expansion. Conditional knockout models would clarify which of these alternatives underlie the
observed phenotype in Bcl11a−/− mice. Since DCs developed normally in vitro from Bcl11a−/−
progenitors treated with GM-CSF, it is possible that Bcl11a−/− cDCs in vivo indeed represent
development from GM-CSF–dependent progenitors, related perhaps to monocyte-derived
dendritic cell lineages 60.

5.5

Materials and Methods

5.5.1

Mice.
C57BL/6, B6.SJL, Il7−/−, and Il7r−/− mice were purchased from The Jackson Laboratory.

Flt3l−/− and Rag2−/− mice were purchased from Taconic Farms. Flt3l−/− mice were subsequently
crossed to Zbtb46gfp/gfp mice generated previously 19; F2 offspring were studied in the present
experiments, with Zbtb46+/gfp;Flt3l+/+ or Zbtb46gfp/gfp;Flt3l+/+ mice used as WT littermate
controls. Bcl11a−/− mice were obtained from Dr. Pentao Liu 24. Mice were bred and maintained
in our specific pathogen free animal facility at Washington University in St. Louis. Mice were
sacrificed by CO2 overdose followed by cervical dislocation.
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5.5.2

Single-cell suspensions of fetal liver.
At embryonic day 14.5, fetal livers were mechanically dissociated with a syringe plunger

and sterile 70-µm cell strainer (Fisher) into IMDM + 10% (v/v) FCS (I10F). For subsequent cell
culture or flow cytometry, red blood cells were lysed in ACK lysing buffer before counting by
Vi-CELL (Beckman Coulter).

5.5.3

Antibodies.
The following antibodies were purchased from BD Biosciences: FITC anti-CD3e (145-

2C11), APC anti-CD4 (RM4-5), V450 anti-CD4 (RM4-5), PerCP-Cy5.5 anti-CD8a (53-6.7),
PerCP-Cy5.5 anti-CD11b (M1/70), APC anti-CD11c (HL3), APC anti-CD19 (1D3), PE-Cy7
anti-CD24 (M1/69), APC anti-CD25 (PC61), FITC anti-CD45 (30-F11), APC anti-CD45.2
(104), APC-Cy7 anti-CD45.2 (104), PE anti-CD135 (A2F10.1), APC anti-CD172a (P84), FITC
anti-B220 (RA3-6B2), V500 anti-B220 (RA3-6B2), PE anti-Gr-1 (RB6-8C5), V450 anti-Gr-1
(RB6-8C5), PerCP-Cy5.5 anti-IgM (R6-60.2), PE-Cy7 anti-Ly-6A/E (Sca-1) (D7), FITC antiLy-6C (AL-21), V450 anti-Ly-6C (AL-21), PE anti-Ly-6G (1A8), PE anti-MHC II (I-A/I-E)
(M5/114.15.2), PE anti-TCRγδ (GL3). The following antibodies were purchased from
eBioscience: APC-eFluor 780 anti-CD11c (N418), eFluor 450 anti-CD11c (N418), PerCP-Cy5.5
anti-CD16/32 (93), APC-eFluor 780 anti-CD44 (IM7), biotin anti-CD45.1 (A20), PerCP-Cy5.5
anti-CD45.1 (A20), Alexa Fluor 700 anti-CD45.2 (104), PE-Cy7 anti-CD49b (DX5), PE antiCD103 (2E7), APC-eFluor 780 anti-CD117 (ACK2), PE-Cy7 anti-CD117 (2B8), FITC antiCD127 (A7R34), APC anti-CD150 (mShad150), eFluor 450 anti-B220 (RA3-6B2), PE-Cy7 antiB220 (RA3-6B2), APC anti-BST2 (eBio927), eFluor 450 anti-BST2 (eBio927), FITC anti-F4/80
(BM8), PE anti-IgD (41239), eFluor 450 anti-MHC II (I-A/I-E) (M5/114.15.2), eFluor 450 anti177

NKp46 (29A1.4), FITC anti-Siglec-H (eBio440C). The following antibodies were purchased
from Caltag: FITC anti-CD8a (5H10), PE anti-B220 (RA3-6B2). Qdot 605 streptavidin was
purchased from Invitrogen and V500 streptavidin was purchased from BD Biosciences.

5.5.4

Flow cytometry and sorting.
Staining was performed at 4°C in the presence of Fc block (clone 2.4G2, BD Biosciences

or BioXCell) in FACS buffer (DPBS + 0.5% BSA + 2 mM EDTA). Cells were analyzed using a
FACSCanto II (BD Biosciences) or sorted using a FACSAria (BD Biosciences); data were
visualized using FlowJo software (TreeStar).

5.5.5

Cell cultures.
Cells were diluted to 2×106 cells/ml in I10F + 20 ng/ml Flt3L or GM-CSF, cultured in

12-well plates for 10 d (Flt3L) or 7 d (GM-CSF), then analyzed by flow cytometry.

5.5.6

Chimeras.
B6.SJL mice were lethally irradiated (1200 rad) and injected intraorbitally with 4×106

fetal liver cells isolated from WT or Bcl11a−/− fetuses. After 4 or 6 weeks, BM was isolated by
grinding and Histopaque-1119 (Sigma-Aldrich) centrifugation and either sorted by flow
cytometry or cultured. From these mice, thymi were minced and digested in 250 µg/ml
collagenase B (Roche) and 30 U/ml DNase I (Sigma-Aldrich) and analyzed by flow cytometry.

5.5.7

Microarray analysis.
MPP and GMP populations were sorted from fetal liver chimeras and pooled by donor

genotype. RNA was isolated using an RNAqueous-Micro Kit (Ambion) and submitted for
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amplification, labeling and hybridization. Expression values were analyzed after RMA quantile
normalization using ArrayStar software (DNASTAR). Data were deposited in the Gene
Expression Omnibus (GEO) repository under accession no. GSE46270.

5.5.8

ChIP-qPCR.
Pro-B cell cultures were established using Rag2−/− BM isolated by flushing and

resuspended in I10F + 5 ng/ml IL-7. Chromatin was prepared from 1×107 cultured pro-B cells
sonicated using a Bioruptor (Diagenode), immunoprecipitation was performed with a rabbit
polyclonal anti-Bcl11a antibody (NB600-261, Novus Biologicals) or control rabbit IgG, and
qPCR analysis was carried out using SYBR Green-based detection and the following previously
published primers 61: Flt3 control forward, 5′-TTTGCACTCGTAGCAAATGG-3′; Flt3 control
reverse, 5′-GTTCAGCTGCCAAAGAGAGG-3′; Flt3 promoter forward, 5′GTTCAGCTGCCAAAGAGAGG-3′; Flt3 promoter reverse, 5′CGTCACTGACCACAGATTCC-3′; Flt3 intron forward, 5′AAAAGAGGAACTATTGGTATTTCG-3′; Flt3 intron reverse, 5′TGACAGTAGTGAAAACACACACACA-3′.

5.5.9

Statistics.
Statistical differences were identified using Prism 6 (GraphPad) by multiple unpaired

Student’s t tests, controlling the false discovery rate (Q) by the method of Benjamini and
Hochberg. *, Q = 0.05; **, Q = 0.01.
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